index	id1	id2	is_in_same_sent	min_sents_window	sentence	in_neighbors	label
31940483	14810	D003072	True	0	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and @DiseaseTgt$ and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing @GeneSrc$ function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of GluN2A-subunit-containing NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . GluN2A-subunit-containing @GeneSrc$ enhancers may have therapeutic benefits in brain disorders with network @DiseaseTgt$ .	6 6 3 6 3 6 6 6 6 8 8 8|11 11 16 13 16 11 6 19 23 21 19 21 23 25 23 28 28 23 23 31 23 33 31 33 33 33 23 57 57 43 43 41 57 43 46 43 49 49 46 51 49 54 54 43 57 57 57 57 60 60 64 64 62 60 66 64 66 71 71 69 64 74 74 71 74 78 78 71 78 81 78 84 84 71 87 87 84 89 87 89 87 94 92 87 96 94 96 60 102 102 102 102 106 106 106 102 102 102 110 111 108 115 115 115 108 117 115 122 122 121 119 124 122 115 102 133 133 133 128 132 132 128 133 137 137 137 133 141 141 141 137 144 144 141 133 147 148 148 151 151 148 151 154 151 148 148 158 156 160 158 160 163 164 160 148 168 168 170 170 170 172 170 175 175 170 178 178 170|178 170	0
31940483	14811	D003072	True	0	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and @DiseaseTgt$ and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of @GeneSrc$ NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . @GeneSrc$ NMDAR enhancers may have therapeutic benefits in brain disorders with network @DiseaseTgt$ .	6 6 3 6 3 6 6 6 6 8 8 8|11 11 16 13 16 11 6 19 23 21 19 21 23 25 23 28 28 23 23 31 23 33 31 33 33 33 23 57 57 43 43 41 57 43 46 43 49 49 46 51 49 54 54 43 57 57 57 57 60 60 64 64 62 60 66 64 66 71 71 69 64 74 74 71 74 78 78 71 78 81 78 84 84 71 87 87 84 89 87 89 87 94 92 87 96 94 96 60 102 102 102 102 106 106 106 102 102 102 110 111 108 115 115 115 108 117 115 122 122 121 119 124 122 115 102 133 133 133 128 132 132 128 133 137 137 137 133 141 141 141 137 144 144 141 133 147 148 148 151 151 148 151 154 151 148 148 158 156 160 158 160 163 164 160 148 168 168 170 170 170 172 170 175 175 170 178 178 170|178 170	0
31940483	14811	D019636	False	2	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and @DiseaseTgt$ . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of @GeneSrc$ NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . @GeneSrc$ NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 27 60 60 46 46 44 60 46 49 46 52 52 49 54 52 57 57 46 60 60 60 60 63 63 67 67 65 63 69 67 69 74 74 72 67 77 77 74 77 81 81 74 81 84 81 87 87 74 90 90 87 92 90 92 90 97 95 90 99 97 99 63 105 105 105 105 109 109 109 105 105 105 113 114 111 118 118 118 111 120 118 125 125 124 122 127 125 118 105 136 136 136 131 135 135 131 136 140 140 140 136 144 144 144 140 147 147 144 136 150 151 151 154 154 151 154 157 154 151 151 161 159 163 161 163 166 167 163 151 171 171 173 173 173 175 173 178 178 173 181 181 173 181 184 181 173	0
31940483	14810	D019636	False	1	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and @DiseaseTgt$ . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing @GeneSrc$ function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of GluN2A-subunit-containing NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . GluN2A-subunit-containing @GeneSrc$ enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 27 60 60 46 46 44 60 46 49 46 52 52 49 54 52 57 57 46 60 60 60 60 63 63 67 67 65 63 69 67 69 74 74 72 67 77 77 74 77 81 81 74 81 84 81 87 87 74 90 90 87 92 90 92 90 97 95 90 99 97 99 63 105 105 105 105 109 109 109 105 105 105 113 114 111 118 118 118 111 120 118 125 125 124 122 127 125 118 105 136 136 136 131 135 135 131 136 140 140 140 136 144 144 144 140 147 147 144 136 150 151 151 154 154 151 154 157 154 151 151 161 159 163 161 163 166 167 163 151 171 171 173 173 173 175 173 178 178 173 181 181 173 181 184 181 173	0
31940483	14811	D000544	True	0	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and @DiseaseTgt$ Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of @GeneSrc$ NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and @DiseaseTgt$ mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and @DiseaseTgt$ mouse models . @GeneSrc$ NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 17|18 15 6 21 25 23 21 23 25 27 25 30 30 25 25 33 25 35 33 35 35 35 25 59 59 45 45 43 59 45 48 45 51 51 48 53 51 56 56 45 59 59 59 59 62 62 66 66 64 62 68 66 68 73 73 71 66 76 76 73 76 80 80 73 80 83 80 86 86 73 89 89 86 91 89 91 89 94|89 96 94 96 62 102 102 102 102 106 106 106 102 102 102 110 111 108 115 115 115 108 117 115 122 122 121 119 124 122 115 102 133 133 133 128 132 132 128 133 137 137 137 133 141 141 141 137 144 144 141 133 147 148 148 151 151 148 151 154 151 148 148 158 156 160 158 160 163 164 160 148 168 168 170 170 170 172 170 175 175 170 178 178 170 178 181 178 170	0
31940483	14810	D000544	False	1	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and @DiseaseTgt$ Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing @GeneSrc$ function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of GluN2A-subunit-containing NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and @DiseaseTgt$ mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and @DiseaseTgt$ mouse models . GluN2A-subunit-containing @GeneSrc$ enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 17|18 15 6 21 25 23 21 23 25 27 25 30 30 25 25 33 25 35 33 35 35 35 25 59 59 45 45 43 59 45 48 45 51 51 48 53 51 56 56 45 59 59 59 59 62 62 66 66 64 62 68 66 68 73 73 71 66 76 76 73 76 80 80 73 80 83 80 86 86 73 89 89 86 91 89 91 89 94|89 96 94 96 62 102 102 102 102 106 106 106 102 102 102 110 111 108 115 115 115 108 117 115 122 122 121 119 124 122 115 102 133 133 133 128 132 132 128 133 137 137 137 133 141 141 141 137 144 144 141 133 147 148 148 151 151 148 151 154 151 148 148 158 156 160 158 160 163 164 160 148 168 168 170 170 170 172 170 175 175 170 178 178 170 178 181 178 170	0
31940483	14810	D019522	False	1	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing @GeneSrc$ function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of GluN2A-subunit-containing NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and @DiseaseTgt$ and improves cognitive functions in DS and AD mouse models . GluN2A-subunit-containing @GeneSrc$ enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 37 27 61 61 47 47 45 61 47 50 47 53 53 50 55 53 58 58 47 61 61 61 61 64 64 68 68 66 64 70 68 70 75 75 73 68 78 78 75 78 82 82 75 82 85 82 88 88 75 91 91 88 93 91 93 91 98 96 91 100 98 100 64 106 106 106 106 110 110 110 106 106 106 114 115 112 119 119 119 112 121 119 126 126 125 123 128 126 119 106 137 137 137 132 136 136 132 137 141 141 141 137 145 145 145 141 148 148 145 137 151 152 152 155 155 152 155 155|157 152 152 161 159 163 161 163 166 167 163 152 171 171 173 173 173 175 173 178 178 173 181 181 173 181 184 181 173	0
31940483	14811	D019522	False	1	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of @GeneSrc$ NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and @DiseaseTgt$ and improves cognitive functions in DS and AD mouse models . @GeneSrc$ NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 37 27 61 61 47 47 45 61 47 50 47 53 53 50 55 53 58 58 47 61 61 61 61 64 64 68 68 66 64 70 68 70 75 75 73 68 78 78 75 78 82 82 75 82 85 82 88 88 75 91 91 88 93 91 93 91 98 96 91 100 98 100 64 106 106 106 106 110 110 110 106 106 106 114 115 112 119 119 119 112 121 119 126 126 125 123 128 126 119 106 137 137 137 132 136 136 132 137 141 141 141 137 145 145 145 141 148 148 145 137 151 152 152 155 155 152 155 155|157 152 152 161 159 163 161 163 166 167 163 152 171 171 173 173 173 175 173 178 178 173 181 181 173 181 184 181 173	0
31940483	14811	D001927	True	0	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of @GeneSrc$ NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . @GeneSrc$ NMDAR enhancers may have therapeutic benefits in @DiseaseTgt$ with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 37 27 61 61 47 47 45 61 47 50 47 53 53 50 55 53 58 58 47 61 61 61 61 64 64 68 68 66 64 70 68 70 75 75 73 68 78 78 75 78 82 82 75 82 85 82 88 88 75 91 91 88 93 91 93 91 98 96 91 100 98 100 64 106 106 106 106 110 110 110 106 106 106 114 115 112 119 119 119 112 121 119 126 126 125 123 128 126 119 106 137 137 137 132 136 136 132 137 141 141 141 137 145 145 145 141 148 148 145 137 151 152 152 155 155 152 155 158 155 152 152 162 160 164 162 164 167 168 164 152 172 172 174 174 174 176 174 178 178|174 181 181 174 181 184 181 174	0
31940483	14810	D001927	True	0	GluN2A NMDA Receptor Enhancement Improves Brain Oscillations , Synchrony , and Cognitive Functions in Dravet Syndrome and Alzheimer 's Disease Models . NMDA receptors ( NMDARs ) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders . However , the in vivo consequences and therapeutic potential of pharmacologically enhancing @GeneSrc$ function via allosteric modulation are largely unknown . We examine the in vivo effects of GNE-0723 , a positive allosteric modulator of GluN2A-subunit-containing NMDARs , on brain network and cognitive functions in mouse models of Dravet syndrome ( DS ) and Alzheimer 's disease ( AD ) . GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency ( 12 - 20 Hz ) oscillations . Interestingly , DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony . GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models . GluN2A-subunit-containing @GeneSrc$ enhancers may have therapeutic benefits in @DiseaseTgt$ with network hypersynchrony and cognitive impairments .	6 6 3 6 3 6 6 6 6 8 8 8 8 15 15 12 15 20 17 20 15 6 23 27 25 23 25 27 29 27 32 32 27 27 35 27 37 35 37 37 37 27 61 61 47 47 45 61 47 50 47 53 53 50 55 53 58 58 47 61 61 61 61 64 64 68 68 66 64 70 68 70 75 75 73 68 78 78 75 78 82 82 75 82 85 82 88 88 75 91 91 88 93 91 93 91 98 96 91 100 98 100 64 106 106 106 106 110 110 110 106 106 106 114 115 112 119 119 119 112 121 119 126 126 125 123 128 126 119 106 137 137 137 132 136 136 132 137 141 141 141 137 145 145 145 141 148 148 145 137 151 152 152 155 155 152 155 158 155 152 152 162 160 164 162 164 167 168 164 152 172 172 174 174 174 176 174 178 178|174 181 181 174 181 184 181 174	0
31899933	1080	D003550	False	2	@DiseaseTgt$ in the year 2020 : A disease with a new face . The @DiseaseTgt$ ( CF ) was once untreatable and deadly in childhood , but now most patients survive to adulthood . Many countries have instituted CF newborn screening because early diagnosis improves outcome . CF research has greatly intensified following the discovery of the @GeneSrc$ ( @GeneSrc$ ) gene , which has more than 2000 different mutations . For patients with common mutations like F508del , @GeneSrc$ modulators are life transforming and may even prevent major complications if started early in childhood . For some patients with rare @GeneSrc$ mutations , a treatment path still needs to be developed . Conclusion : This review provides a general update on CF , including screening and current and future treatment .	0 3 3 0 3 0 7 0 11 11 11 7 7 14 14|20 16 14 16 20 20 20 20 20 24 22 20 20 30 29 30 20 32 30 30 35 37 37 37 40 40 37 44 43 44 37 44 37 48 51 51 51 51 54 54 51 61 61 61 61 61 61 54 61 64 61 67 67 69 69 64 51 72 83 75 75 72 77 75 83 80 83 83 83 83 83 87 87 83 89 87 91 87 91 94 91 83 98 98 108 102 102 102 98 108 106 106 108 108 108 111 111 108 108 117 117 116 117 117 120 120 117 122 120 122 125 117 125 130 127 127 125 117	0
31899933	1080	D003141	False	3	Cystic fibrosis in the year 2020 : @DiseaseTgt$ with a new face . The autosomal recessive disease cystic fibrosis ( CF ) was once untreatable and deadly in childhood , but now most patients survive to adulthood . Many countries have instituted CF newborn screening because early diagnosis improves outcome . CF research has greatly intensified following the discovery of the @GeneSrc$ ( @GeneSrc$ ) gene , which has more than 2000 different mutations . For patients with common mutations like F508del , @GeneSrc$ modulators are life transforming and may even prevent major complications if started early in childhood . For some patients with rare @GeneSrc$ mutations , a treatment path still needs to be developed . Conclusion : This review provides a general update on CF , including screening and current and future treatment .	1 1 4 4 1 4 1 1|7 11 11 11 7 7 18 18 18 18 18 24 20 18 20 24 24 24 24 24 28 26 24 24 34 33 34 24 36 34 34 39 41 41 41 44 44 41 48 47 48 41 48 41 52 55 55 55 55 58 58 55 65 65 65 65 65 65 58 65 68 65 71 71 73 73 68 55 76 87 79 79 76 81 79 87 84 87 87 87 87 87 91 91 87 93 91 95 91 95 98 95 87 102 102 112 106 106 106 102 112 110 110 112 112 112 115 115 112 112 121 121 120 121 121 124 124 121 126 124 126 129 121 129 134 131 131 129 121	0
29750581	1080	D008171	False	1	@GeneSrc$ dysfunction in cystic fibrosis and chronic obstructive pulmonary disease . INTRODUCTION : Obstructive @DiseaseTgt$ such as cystic fibrosis ( CF ) and chronic obstructive pulmonary disease ( COPD ) are causes of high morbidity and mortality worldwide . CF is a multiorgan genetic disease caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive chronic obstructive lung disease . Most cases of COPD are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of CF and COPD differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in COPD . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the CF and COPD airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both respiratory diseases . Expert commentary : Drugs developed for people with CF to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with COPD . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 4 4 1 4 9 9 9 4 1 31 11 14 14|31 18 15 18 14 20 18 20 18 26 26 26 18 28 26 28 31 31 34 34 31 34 34 31 31 44 44 44 44 44 44 44 47 45 50 50 50|54 54 54 54 47 44 57 44 63 63 63 63 63 57 44 66 71 68 66 71 71 71 74 74 71 74 78 78 71 78 83 83 83 78 71 86 86 86 97 90 97 90 90 94 90 94 94 101 101 101 101 86 104 104 101 101 109 106 109 111 111 101 113 111 115 113 117 115 117 117 119 123 123 120 123 126 123 126 129 127 86 132 139 132 132 132 132 132 139 139 145 143 143 145 145 139 149 149 149 145 149 152 149 139 155 156 156 158 156 161 161 158 164 164 161 167 167 164 171 171 171 156 156 174 177 174 177 177 179 177 181 179 183 177 186 186 183 183 183 192 192 192 188 196 196 196 177 198 196 200 198 177 203 207 206 206 203 207 207 210 207 207 213 207 215 207 218 218 215 218 218 207 223 207 223 227 227 224 207	0
29750581	1080	D003550	True	0	@GeneSrc$ dysfunction in @DiseaseTgt$ and chronic obstructive pulmonary disease . INTRODUCTION : Obstructive lung diseases such as @DiseaseTgt$ ( @DiseaseTgt$ ) and chronic obstructive pulmonary disease ( COPD ) are causes of high morbidity and mortality worldwide . @DiseaseTgt$ is a multiorgan genetic disease caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive chronic obstructive lung disease . Most cases of COPD are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of @DiseaseTgt$ and COPD differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in COPD . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the @DiseaseTgt$ and COPD airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both respiratory diseases . Expert commentary : Drugs developed for people with @DiseaseTgt$ to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with COPD . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 3 1|3 3 8 8 8 3 1 30 10 14 14 30 17 15 14|17 19 17 19 17 25 25 25 17 27 25 27 30 30 33 33 30 33 33 30 30 43 43 43 43 43 43 43 46 44 49 49 49|53 53 53 53 46 43 56 43 62 62 62 62 62 56 43 65 70 67 65 70 70 70 73 73 70 73 77 77 70 77 82 82 82 77 70 85 85 85 96 89 96 89 89 93 89 93 93 100 100 100 100 85 103 103 100 100 108 105 108 110 110 100 112 110 114 112 116 114 116 116 118 122 122 119 122 125 122 125 128 126 85 131 138 131 131 131 131 131 138 138 144 142 142 144 144 138 148 148 148 144 148 151 148 138 154 155 155 157 155 160 160 157 163 163 160 166 166 163 170 170 170 155 155 173 176 173 176 176 178 176 180 178 182 176 185 185 182 182 182 191 191 191 187 195 195 195 176 197 195 199 197 176 202 206 205 205 202 206 206 209 206 206 212 206 214 206 217 217 214 217 217 206 222 206 222 226 226 223 206	1
29750581	1080	D012140	True	0	@GeneSrc$ dysfunction in cystic fibrosis and chronic obstructive pulmonary disease . INTRODUCTION : Obstructive lung diseases such as cystic fibrosis ( CF ) and chronic obstructive pulmonary disease ( COPD ) are causes of high morbidity and mortality worldwide . CF is a multiorgan genetic disease caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive chronic obstructive lung disease . Most cases of COPD are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of CF and COPD differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in COPD . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the CF and COPD airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both @DiseaseTgt$ . Expert commentary : Drugs developed for people with CF to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with COPD . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 4 4 1 4 9 9 9 4 1 32 11 15 15 32 19 16 19 15 21 19 21 19 27 27 27 19 29 27 29 32 32 35 35 32 35 35 32 32 45 45 45 45 45 45 45 48 46 51 51 51|55 55 55 55 48 45 58 45 64 64 64 64 64 58 45 67 72 69 67 72 72 72 75 75 72 75 79 79 72 79 84 84 84 79 72 87 87 87 98 91 98 91 91 95 91 95 95 102 102 102 102 87 105 105 102 102 110 107 110 112 112 102 114 112 116 114 118 116 118 118 120 124 124 121 124 127 124 127 130 128 87 133 140 133 133 133 133 133 140 140 146 144 144 146 146 140 150 150 150 146 150 153 150 140 156 157 157 159 157 162 162 159 165 165 162 168 168 165 171 171 171|157 157 174 177 174 177 177 179 177 181 179 183 177 186 186 183 183 183 192 192 192 188 196 196 196 177 198 196 200 198 177 203 207 206 206 203 207 207 210 207 207 213 207 215 207 218 218 215 218 218 207 223 207 223 227 227 224 207	0
29750581	1080	D029424	True	0	@GeneSrc$ dysfunction in cystic fibrosis and @DiseaseTgt$ . INTRODUCTION : Obstructive lung diseases such as cystic fibrosis ( CF ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are causes of high morbidity and mortality worldwide . CF is a multiorgan genetic disease caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive @DiseaseTgt$ . Most cases of @DiseaseTgt$ are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of CF and @DiseaseTgt$ differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in @DiseaseTgt$ . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the CF and @DiseaseTgt$ airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both respiratory diseases . Expert commentary : Drugs developed for people with CF to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with @DiseaseTgt$ . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 4 4 1 4 4|6 1 26 8 12 12 26 16 13 16 12 18 16 18 16 16|21 23 21 23 26 26 29 29 26 29 29 26 26 39 39 39 39 39 39 39 42 40 45 45 45|49 49 49 49 42 39 52 39 55 55 52|55 39 58 63 60 58 63 63 63 66 66 63 66 70 70 63 70 75 75 75 70 63 78 78 78 89 82 89 82 82 86 82 86 86 93 93 93 93 78 96 96 93 93 101 98 101 103 103 93 105 103 107 105 109 107 109 109 111 115 115 112 115 118 115 118 121 119 78 124 131 124 124 124 124 124 131 131 137 135 135 137 137 131 141 141 141 137 141 144 141 131 147 148 148 150 148 153 153 150 156 156 153 159 159 156 163 163 163 148 148 166 169 166 169 169 171 169 173 171 175 169 178 178 175 175 175 184 184 184 180 188 188 188 169 190 188 192 190 169 195 199 198 198 195 199 199 202 199 199 205 199 207 199 210 210 207 210 210 199 215 199 215 219 219 216 199	0
29750581	1080	D003643	False	1	@GeneSrc$ dysfunction in cystic fibrosis and chronic obstructive pulmonary disease . INTRODUCTION : Obstructive lung diseases such as cystic fibrosis ( CF ) and chronic obstructive pulmonary disease ( COPD ) are causes of high morbidity and @DiseaseTgt$ worldwide . CF is a multiorgan genetic disease caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive chronic obstructive lung disease . Most cases of COPD are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of CF and COPD differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in COPD . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the CF and COPD airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both respiratory diseases . Expert commentary : Drugs developed for people with CF to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with COPD . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 4 4 1 4 9 9 9 4 1 32 11 15 15 32 19 16 19 15 21 19 21 19 27 27 27 19 29 27 29 32 32 35 35 32 35 35 32 32 45 45 45 45 45 45 45 48 46 51 51 51|55 55 55 55 48 45 58 45 64 64 64 64 64 58 45 67 72 69 67 72 72 72 75 75 72 75 79 79 72 79 84 84 84 79 72 87 87 87 98 91 98 91 91 95 91 95 95 102 102 102 102 87 105 105 102 102 110 107 110 112 112 102 114 112 116 114 118 116 118 118 120 124 124 121 124 127 124 127 130 128 87 133 140 133 133 133 133 133 140 140 146 144 144 146 146 140 150 150 150 146 150 153 150 140 156 157 157 159 157 162 162 159 165 165 162 168 168 165 172 172 172 157 157 175 178 175 178 178 180 178 182 180 184 178 187 187 184 184 184 193 193 193 189 197 197 197 178 199 197 201 199 178 204 208 207 207 204 208 208 211 208 208 214 208 216 208 219 219 216 219 219 208 224 208 224 228 228 225 208	0
29750581	1080	D030342	True	0	@GeneSrc$ dysfunction in cystic fibrosis and chronic obstructive pulmonary disease . INTRODUCTION : Obstructive lung diseases such as cystic fibrosis ( CF ) and chronic obstructive pulmonary disease ( COPD ) are causes of high morbidity and mortality worldwide . CF is a multiorgan @DiseaseTgt$ caused by mutations in the @GeneSrc$ ( @GeneSrc$ ) gene and is characterized by progressive chronic obstructive lung disease . Most cases of COPD are a result of noxious particles , mainly cigarette smoke but also other environmental pollutants . Areas covered : Although the pathogenesis and pathophysiology of CF and COPD differ , they do share key phenotypic features and because of these similarities there is great interest in exploring common mechanisms and/or factors affected by @GeneSrc$ mutations and environmental insults involved in COPD . Various molecular , cellular and clinical studies have confirmed that @GeneSrc$ protein dysfunction is common in both the CF and COPD airways . This review provides an update of our understanding of the role of dysfunctional @GeneSrc$ in both respiratory diseases . Expert commentary : Drugs developed for people with CF to improve mutant @GeneSrc$ function and enhance @GeneSrc$ ion channel activity might also be beneficial in patients with COPD . A move toward personalized therapy using , for example , microRNA modulators in conjunction with @GeneSrc$ potentiators or correctors , could enhance treatment of both diseases .	1 1 4 4 1 4 9 9 9 4 1 32 11 15 15 32 19 16 19 15 21 19 21 19 27 27 27 19 29 27 29 32 32 35 35 32 35 35 32 32 44 44 44 44 44 44 47 45 50 50 50|54 54 54 54 47 44 57 44 63 63 63 63 63 57 44 66 71 68 66 71 71 71 74 74 71 74 78 78 71 78 83 83 83 78 71 86 86 86 97 90 97 90 90 94 90 94 94 101 101 101 101 86 104 104 101 101 109 106 109 111 111 101 113 111 115 113 117 115 117 117 119 123 123 120 123 126 123 126 129 127 86 132 139 132 132 132 132 132 139 139 145 143 143 145 145 139 149 149 149 145 149 152 149 139 155 156 156 158 156 161 161 158 164 164 161 167 167 164 171 171 171 156 156 174 177 174 177 177 179 177 181 179 183 177 186 186 183 183 183 192 192 192 188 196 196 196 177 198 196 200 198 177 203 207 206 206 203 207 207 210 207 207 213 207 215 207 218 218 215 218 218 207 223 207 223 227 227 224 207	0
31263285	15194	D006816	True	0	Allele-selective transcriptional repression of mutant @GeneSrc$ for the treatment of @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the @GeneSrc$ gene ( @GeneSrc$ ) , which codes for the pathologic mutant @GeneSrc$ ( mHTT ) protein . Since normal @GeneSrc$ is thought to be important for brain function , we engineered zinc finger protein transcription factors ( ZFP-TFs ) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy . Using patient-derived fibroblasts and neurons , we demonstrate that ZFP-TFs selectively repress > 99 % of @DiseaseTgt$ alleles over a wide dose range while preserving expression of > 86 % of normal alleles . Other CAG-containing genes are minimally affected , and virally delivered ZFP-TFs are active and well tolerated in @DiseaseTgt$ neurons beyond 100 days in culture and for at least nine months in the mouse brain . Using three @DiseaseTgt$ mouse models , we demonstrate improvements in a range of molecular , histopathological , electrophysiological and functional endpoints . Our findings support the continued development of an allele-selective ZFP-TF for the treatment of @DiseaseTgt$ .	2 2 2 5 5 2 8 8 2 10 8|10 2 12|21 14 12 14 21 21 19 21 21 21 21 27 27 27 27 22 31 31 31 27 33 31 33 31 37 31 46 46 46 46 46 46 46 46 37 21 52 50 52 52 61 55 55 52 58 58 55 61 61 61 66 66 66 66 61 68 66 68 71 61 75 75 75 71 71 78 71 78 83 83 83 71 61 92 87 85 87 87 92 92 92 96 96 96 92 96 99 97 102 102 99 107 107 107 107 96 109 96 109 114 114 114 110 117 117 114 92 121 121 124 124 124 124 124 124 128 124 128 131 124 131 131 131 137 137 134 140 140 134 142 140 140 148 146 147 148 140 152 152 152 124 124 161 158 158 158 154 154 161 161 161 165 165 162 167 165 167 167 167 167 167 167 167 161 177 178 178 181 181 178 185 185 185 181 188 188 181 190 188 178	1
31263285	15194	D020271	True	0	Allele-selective transcriptional repression of mutant @GeneSrc$ for the treatment of Huntington 's disease . Huntington 's disease ( HD ) is a dominantly @DiseaseTgt$ caused by a CAG trinucleotide expansion in the @GeneSrc$ gene ( @GeneSrc$ ) , which codes for the pathologic mutant @GeneSrc$ ( mHTT ) protein . Since normal @GeneSrc$ is thought to be important for brain function , we engineered zinc finger protein transcription factors ( ZFP-TFs ) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy . Using patient-derived fibroblasts and neurons , we demonstrate that ZFP-TFs selectively repress > 99 % of HD-causing alleles over a wide dose range while preserving expression of > 86 % of normal alleles . Other CAG-containing genes are minimally affected , and virally delivered ZFP-TFs are active and well tolerated in HD neurons beyond 100 days in culture and for at least nine months in the mouse brain . Using three HD mouse models , we demonstrate improvements in a range of molecular , histopathological , electrophysiological and functional endpoints . Our findings support the continued development of an allele-selective ZFP-TF for the treatment of HD .	2 2 2 5 5 2 8 8 2 12 12 10 8 2 16 14 23 18 16 18 23 23 23 23 23 29 29 29 29 24 33 33 33 29 35 33 35 33 39 33 48 48 48 48 48 48 48 48 39 23 54 52 54 54 63 57 57 54 60 60 57 63 63 63 68 68 68 68 63 70 68 70 73 63 77 77 77 73 73 80 73 80 85 85 85 73 63 94 89 87 89 89 94 94 94 98 98 98 94 98 101 99 104 104 101 109 109 109 109 98 111 98 111 116 116 116 112 119 119 116 94 123 123 126 126 126 126 126 126 130 126 130 133 126 133 133 133 139 139 136 142 142 136 144 142 142 150 148 149 150 142 154 154 154 126 126 163 160 160 160 156 156 163 163 163 167 167 164 169 167 169 169 169 169 169 169 169 163 179 180 180 183 183 180 187 187 187 183 190 190 183 192 190 180	0
30844401	348	D020521	True	0	A Quarter Century of @GeneSrc$ and Alzheimer 's Disease : Progress to Date and the Path Forward . Alzheimer 's disease ( AD ) is considered a polygenic disorder . This view is clouded , however , by lingering uncertainty over how to treat the quasi " monogenic " role of @GeneSrc$ ( @GeneSrc$ ) . The @GeneSrc$ allele is not only the strongest genetic risk factor for AD , it also affects risk for cardiovascular disease , @DiseaseTgt$ , and other neurodegenerative disorders . This review , based mostly on data from human studies , ranges across a variety of @GeneSrc$ pathologies , touching on evolutionary genetics and risk mitigation by ethnicity and sex . The authors also address one of the most fundamental question pertaining to @GeneSrc$ and AD : does @GeneSrc$ increase AD risk via a loss or gain of function ? The answer will be of the utmost importance in guiding future research in AD .	2 2 2 4 2 4 8 6 4 10 2 12 10 12 16 16 12 10 20 20 25 22 20 22 25 25 28 28 25 25 31 33 33 33 33 33 33 38 33 38 43 43 43 39 49 47 47 49 49 43 51 49|51 53 51 53 33 58 58 66 66 61 66 66 64 66 66 66 68 66 72 72 72 66 72 76 76 73 76 76 76 76 83 83 76 72 86 96 86 86 90 91 88 94 94 91 86 96 99 99 96 102 102 99 96 96 107 107 104 104 110 104 112 104 112 112 96 117 119 119 119 119 125 125 124 125 120 125 128 126 128 128 125 134 134 119 136 134 139 139 134 139 139 143 139 119 146 147 152 152 152 152 152 152 154 152 156 154 158 156 152	0
30844401	348	D014786	True	0	A Quarter Century of @GeneSrc$ and Alzheimer 's Disease : Progress to Date and the Path Forward . Alzheimer 's disease ( AD ) is considered a polygenic disorder . This view is clouded , however , by lingering uncertainty over how to treat the quasi " monogenic " role of @GeneSrc$ ( @GeneSrc$ ) . The @GeneSrc$ allele is not only the strongest genetic risk factor for AD , it also affects risk for cardiovascular disease , stroke , and other neurodegenerative disorders . This review , based mostly on data from human studies , ranges across a variety of @GeneSrc$ pathologies , touching on evolutionary genetics and risk mitigation by ethnicity and sex . The authors also address one of the most fundamental question pertaining to @GeneSrc$ and AD : does @GeneSrc$ increase AD risk via a @DiseaseTgt$ or gain of function ? The answer will be of the utmost importance in guiding future research in AD .	2 2 2 4 2 4 8 6 4 10 2 12 10 12 16 16 12 10 20 20 25 22 20 22 25 25 28 28 25 25 31 33 33 33 33 33 33 38 33 38 43 43 43 39 49 47 47 49 49 43 51 49|51 53 51 53 33 58 58 66 66 61 66 66 64 66 66 66 68 66 72 72 72 66 72 76 76 73 76 76 76 76 83 83 76 72 86 96 86 86 90 91 88 94 94 91 86 96 99 99 96 102 102 99 96 96 107 107 104 104 110 104 112 104 112 112 96 117 119 119 119 119 125 125 124 125 120 125 128 126 128 128 125 134 134 119 136 134 139 139 134 139 139 143 139 119 146 147 152 152 152 152 152 152 154 152 156 154 158 156 152	0
30844401	348	D002318	True	0	A Quarter Century of @GeneSrc$ and Alzheimer 's Disease : Progress to Date and the Path Forward . Alzheimer 's disease ( AD ) is considered a polygenic disorder . This view is clouded , however , by lingering uncertainty over how to treat the quasi " monogenic " role of @GeneSrc$ ( @GeneSrc$ ) . The @GeneSrc$ allele is not only the strongest genetic risk factor for AD , it also affects risk for @DiseaseTgt$ , stroke , and other neurodegenerative disorders . This review , based mostly on data from human studies , ranges across a variety of @GeneSrc$ pathologies , touching on evolutionary genetics and risk mitigation by ethnicity and sex . The authors also address one of the most fundamental question pertaining to @GeneSrc$ and AD : does @GeneSrc$ increase AD risk via a loss or gain of function ? The answer will be of the utmost importance in guiding future research in AD .	2 2 2 4 2 4 8 6 4 10 2 12 10 12 16 16 12 10 20 20 25 22 20 22 25 25 28 28 25 25 31 33 33 33 33 33 33 38 33 38 43 43 43 39 49 47 47 49 49 43 51 49|51 53 51 53 33 58 58 66 66 61 66 66 64 66 66 66 68 66 72 72 72 66 72 75 73|75 75 75 75 75 82 82 75 72 85 95 85 85 89 90 87 93 93 90 85 95 98 98 95 101 101 98 95 95 106 106 103 103 109 103 111 103 111 111 95 116 118 118 118 118 124 124 123 124 119 124 127 125 127 127 124 133 133 118 135 133 138 138 133 138 138 142 138 118 145 146 151 151 151 151 151 151 153 151 155 153 157 155 151	0
30844401	348	D019636	True	0	A Quarter Century of @GeneSrc$ and Alzheimer 's Disease : Progress to Date and the Path Forward . Alzheimer 's disease ( AD ) is considered a polygenic disorder . This view is clouded , however , by lingering uncertainty over how to treat the quasi " monogenic " role of @GeneSrc$ ( @GeneSrc$ ) . The @GeneSrc$ allele is not only the strongest genetic risk factor for AD , it also affects risk for cardiovascular disease , stroke , and other @DiseaseTgt$ . This review , based mostly on data from human studies , ranges across a variety of @GeneSrc$ pathologies , touching on evolutionary genetics and risk mitigation by ethnicity and sex . The authors also address one of the most fundamental question pertaining to @GeneSrc$ and AD : does @GeneSrc$ increase AD risk via a loss or gain of function ? The answer will be of the utmost importance in guiding future research in AD .	2 2 2 4 2 4 8 6 4 10 2 12 10 12 16 16 12 10 20 20 25 22 20 22 25 25 28 28 25 25 31 33 33 33 33 33 33 38 33 38 43 43 43 39 49 47 47 49 49 43 51 49|51 53 51 53 33 58 58 66 66 61 66 66 64 66 66 66 68 66 72 72 72 66 72 76 76 73 76 76 76 76 82 82|76 72 85 95 85 85 89 90 87 93 93 90 85 95 98 98 95 101 101 98 95 95 106 106 103 103 109 103 111 103 111 111 95 116 118 118 118 118 124 124 123 124 119 124 127 125 127 127 124 133 133 118 135 133 138 138 133 138 138 142 138 118 145 146 151 151 151 151 151 151 153 151 155 153 157 155 151	0
30844401	348	D000544	True	0	A Quarter Century of @GeneSrc$ and @DiseaseTgt$ : Progress to Date and the Path Forward . @DiseaseTgt$ ( @DiseaseTgt$ ) is considered a polygenic disorder . This view is clouded , however , by lingering uncertainty over how to treat the quasi " monogenic " role of @GeneSrc$ ( @GeneSrc$ ) . The @GeneSrc$ allele is not only the strongest genetic risk factor for @DiseaseTgt$ , it also affects risk for cardiovascular disease , stroke , and other neurodegenerative disorders . This review , based mostly on data from human studies , ranges across a variety of @GeneSrc$ pathologies , touching on evolutionary genetics and risk mitigation by ethnicity and sex . The authors also address one of the most fundamental question pertaining to @GeneSrc$ and @DiseaseTgt$ : does @GeneSrc$ increase @DiseaseTgt$ risk via a loss or gain of function ? The answer will be of the utmost importance in guiding future research in @DiseaseTgt$ .	2 2 2 4 2 4 4|6 8 2 10 8 10 14 14 10 8 16|21 18 16 18 21 21 24 24 21 21 27 29 29 29 29 29 29 34 29 34 39 39 39 35 45 43 43 45 45 39 47 45|47 49 47 49 29 54 54 62 62 57 62 62 60 62 62 62 64 62 68 68 68 62 68 72 72 69 72 72 72 72 79 79 72 68 82 92 82 82 86 87 84 90 90 87 82 92 95 95 92 98 98 95 92 92 103 103 100 100 106 100 108 100 108 108 92 113 115 115 115 115 121 121 120 121 116 121 124 122 124 124 121 130 130 115 132 130 135 135 130 135 135 139 135 115 142 143 148 148 148 148 148 148 150 148 152 150 154 152 148	0
27608955	27267	D007249	False	5	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and @DiseaseTgt$ . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	20208	D014947	False	1	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including @DiseaseTgt$ , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19 23 21 23 23 23 18 29 37 29 32 37 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 62 62 67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	0
27608955	27267	D007239	False	5	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , @DiseaseTgt$ , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	20208	D003072	False	1	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by @DiseaseTgt$ . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19|21 18 24 32 24 27 32 32 32 32 32 32 35 35 32 37 35 37 32 41 39 32 44 46 46 46 49 49 46 53 53 53 49 46 57 57 62 59 57 59 62 62 65 65 62 65 66 69 65 73 73 73 69 76 76 73 76 79 76 79 79 79 79 79 62 93 93 89 93 91 89 93 93 96 96 93 98 96 93 101 103 103 103 105 103 107 105 109 107 109 109 105 114 116 116 112 116 119 117 119 103 125 125 125 103 128 128 125 132 132 132 125 103 135 135 138 138 135 141 141 138 144 144 141 135 147 148 148 152 151 152 148 156 156 156 152 148 161 161 161 161 170 166 166 166 170 168 166 168 161 172 170 174 172 174 174 161 182 182 181 182 182 184 182 187 187 184 191 191 191 187 193 191 196 196 187 201 201 201 201 187 203 201 203 182 219 219 209 219 212 212 209 212 212 217 217 214 219 219 219 224 224 224 224 226 224 228 226 228 228 232 224 235 235 232 224 238 239 239 243 242 243 239 245 243 247 245 249 247 249 254 253 254 249 239 257 267 267 263 263 263 263 267 267 267 267 267 269 267 269 267	0
27608955	27267	D000544	False	3	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . @DiseaseTgt$ ( @DiseaseTgt$ ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In @DiseaseTgt$ , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and @DiseaseTgt$ using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 12|19 14 12 14 19 19 19 19 19 22 20 24 22 24 24 24 19 30 38 30 33 38 38 38 38 38 38 41 41 38 43 41 43 38 47 45 38 50 52 52 52 55 55 52 59 59 59 55 52 63 63 68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	27267	D000686	False	4	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of @DiseaseTgt$ . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	351	D014947	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including @DiseaseTgt$ , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 39 32 39|34 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 63 63|68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	27267	D019636	False	8	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a @DiseaseTgt$ characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 20 16 14 16 20 20 20 20 23 21 25 23 25 25 25 20 31 39 31 34 39 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 64 64 69 66 64 66 69 69 72 72 69 72 73 76 72 80 80 80 76 83 83 80 83 86 83 86 86 86 86 86 69 100 100 96 100 98 96 100 100 103 103 100 105 103 100 108 110 110 110 112 110 114 112 116 114 116 116 112 121 123 123 119 123 126 124 126 110 132 132 132 110 135 135 132 139 139 139 132 110 142 142 145 145 142 148 148 145 151 151 148 142 154 155 155 159 158 159 155 163 163 163 159 155 168 168 168 168 177 173 173 173 177 175 173 175 168 179 177 181 179 181 181 168 189 189 188 189 189 191 189 194 194 191 198 198 198 194 200 198 203 203 194 208 208 208 208 194 210 208 210 189 226 226 216 226 219 219 216 219 219 224 224 221 226 226 226 231 231 231 231 233 231 235 233 235 235 239 231 242 242 239 231 245 246 246 250 249 250 246 252 250 254 252 256 254 256 261 260 261 256 246 264 274 274 270 270 270 270 274 274 274 274 274 276 274 276 274	0
27608955	20208	D007249	False	1	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and @DiseaseTgt$ . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19 23 21 23 23 23 18 29 37 29 32 37 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 62 62 67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	0
27608955	20208	D000275	True	0	Overexpression of @GeneSrc$ induces @DiseaseTgt$ behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and @DiseaseTgt$ by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study @DiseaseTgt$ .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19 23 21 23 23 23 18 29 37 29 32 37 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 62 62 67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	0
27608955	27267	D003072	False	8	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by @DiseaseTgt$ . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22|24 21 27 35 27 30 35 35 35 35 35 35 38 38 35 40 38 40 35 44 42 35 47 49 49 49 52 52 49 56 56 56 52 49 60 60 65 62 60 62 65 65 68 68 65 68 69 72 68 76 76 76 72 79 79 76 79 82 79 82 82 82 82 82 65 96 96 92 96 94 92 96 96 99 99 96 101 99 96 104 106 106 106 108 106 110 108 112 110 112 112 108 117 119 119 115 119 122 120 122 106 128 128 128 106 131 131 128 135 135 135 128 106 138 138 141 141 138 144 144 141 147 147 144 138 150 151 151 155 154 155 151 159 159 159 155 151 164 164 164 164 173 169 169 169 173 171 169 171 164 175 173 177 175 177 177 164 185 185 184 185 185 187 185 190 190 187 194 194 194 190 196 194 199 199 190 204 204 204 204 190 206 204 206 185 222 222 212 222 215 215 212 215 215 220 220 217 222 222 222 227 227 227 227 229 227 231 229 231 231 235 227 238 238 235 227 241 242 242 246 245 246 242 248 246 250 248 252 250 252 257 256 257 252 242 260 270 270 266 266 266 266 270 270 270 270 270 272 270 272 270	0
27608955	20208;20208	D000275	False	4	Overexpression of serum amyloid a 1 induces @DiseaseTgt$ behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and @DiseaseTgt$ by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study @DiseaseTgt$ .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	351	D019636	False	1	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a @DiseaseTgt$ characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 20 16 14 16 20 20 20 20 23 21 25 23 25 25 25 20 31 38 31 38|33 38 38 38 38 38 41 41 38 43 41 43 38 47 45 38 50 52 52 52 55 55 52 59 59 59 55 52 62 62|67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	0
27608955	20208	D007239	False	1	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , @DiseaseTgt$ , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19 23 21 23 23 23 18 29 37 29 32 37 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 62 62 67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	0
27608955	20208	D000544	True	0	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . @DiseaseTgt$ ( @DiseaseTgt$ ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In @DiseaseTgt$ , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and @DiseaseTgt$ using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 9|16 11 9 11 16 16 16 16 16 19 17 21 19 21 21 21 16 27 35 27 30 35 35 35 35 35 35 38 38 35 40 38 40 35 44 42 35 47 49 49 49 52 52 49 56 56 56 52 49 60 60 65 62 60 62 65 65 68 68 65 68 69 72 68 76 76 76 72 79 79 76 79 82 79 82 82 82 82 82 65 96 96 92 96 94 92 96 96 99 99 96 101 99 96 104 106 106 106 108 106 110 108 112 110 112 112 108 117 119 119 115 119 122 120 122 106 128 128 128 106 131 131 128 135 135 135 128 106 138 138 141 141 138 144 144 141 147 147 144 138 150 151 151 155 154 155 151 159 159 159 155 151 164 164 164 164 173 169 169 169 173 171 169 171 164 175 173 177 175 177 177 164 185 185 184 185 185 187 185 190 190 187 194 194 194 190 196 194 199 199 190 204 204 204 204 190 206 204 206 185 222 222 212 222 215 215 212 215 215 220 220 217 222 222 222 227 227 227 227 229 227 231 229 231 231 235 227 238 238 235 227 241 242 242 246 245 246 242 248 246 250 248 252 250 252 257 256 257 252 242 260 270 270 266 266 266 266 270 270 270 270 270 272 270 272 270	0
27608955	20208	D000686	True	0	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of @DiseaseTgt$ . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 18 13 11 13 18 18 18 18 18 21 19 23 21 23 23 23 18 29 37 29 32 37 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 62 62 67 64 62 64 67 67 70 70 67 70 71 74 70 78 78 78 74 81 81 78 81 84 81 84 84 84 84 84 67 98 98 94 98 96 94 98 98 101 101 98 103 101 98 106 108 108 108 110 108 112 110 114 112 114 114 110 119 121 121 117 121 124 122 124 108 130 130 130 108 133 133 130 137 137 137 130 108 140 140 143 143 140 146 146 143 149 149 146 140 152 153 153 157 156 157 153 161 161 161 157 153 166 166 166 166 175 171 171 171 175 173 171 173 166 177 175 179 177 179 179 166 187 187 186 187 187 189 187 192 192 189 196 196 196 192 198 196 201 201 192 206 206 206 206 192 208 206 208 187 224 224 214 224 217 217 214 217 217 222 222 219 224 224 224 229 229 229 229 231 229 233 231 233 233 237 229 240 240 237 229 243 244 244 248 247 248 244 250 248 252 250 254 252 254 259 258 259 254 244 262 272 272 268 268 268 268 272 272 272 272 272 274 272 274 272	1
27608955	27267	D014947	False	5	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including @DiseaseTgt$ , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	11820	D019636	False	9	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a @DiseaseTgt$ characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 20 16 14 16 20 20 20 20 23 21 25 23 25 25 25 20 31 39 31 34 39 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 64 64 69 66 64 66 69 69 72 72 69 72 73 76 72 80 80 80 76 83 83 80 83 86 83 86 86 86 86 86 69 100 100 96 100 98 96 100 100 103 103 100 105 103 100 108 110 110 110 112 110 114 112 116 114 116 116 112 121 123 123 119 123 126 124 126 110 132 132 132 110 135 135 132 139 139 139 132 110 142 142 145 145 142 148 148 145 151 151 148 142 154 155 155 159 158 159 155 163 163 163 159 155 168 168 168 168 177 173 173 173 177 175 173 175 168 179 177 181 179 181 181 168 189 189 188 189 189 191 189 194 194 191 198 198 198 194 200 198 203 203 194 208 208 208 208 194 210 208 210 189 226 226 216 226 219 219 216 219 219 224 224 221 226 226 226 231 231 231 231 233 231 235 233 235 235 239 231 242 242 239 231 245 246 246 250 249 250 246 252 250 254 252 256 254 256 261 260 261 256 246 264 274 274 270 270 270 270 274 274 274 274 274 276 274 276 274	0
27608955	351	D007239	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , @DiseaseTgt$ , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 39 32 39|34 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 63 63|68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	20208	D019636	False	1	Overexpression of @GeneSrc$ induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a @DiseaseTgt$ characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of @GeneSrc$ is related to the development of amyloidosis . This study was designed to identify the relationship between @GeneSrc$ and AD using liver specific @GeneSrc$ overexpressing mice ( TG ) , because @GeneSrc$ is expressed in the liver during the acute phase . We detected exogenous @GeneSrc$ expression in the brain of TG mice . This result implies that liver-derived @GeneSrc$ migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between @GeneSrc$ and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the @GeneSrc$ TG mouse model is a valuable model to study depression .	3 2 0|2 3 5 3 7 3 3 11 11 17 13 11 13 17 17 17 17 20 18 22 20 22 22 22 17 28 36 28 31 36 36 36 36 36 36 39 39 36 41 39 41 36 45 43 36 48 50 50 50 53 53 50 57 57 57 53 50 61 61 66 63 61 63 66 66 69 69 66 69 70 73 69 77 77 77 73 80 80 77 80 83 80 83 83 83 83 83 66 97 97 93 97 95 93 97 97 100 100 97 102 100 97 105 107 107 107 109 107 111 109 113 111 113 113 109 118 120 120 116 120 123 121 123 107 129 129 129 107 132 132 129 136 136 136 129 107 139 139 142 142 139 145 145 142 148 148 145 139 151 152 152 156 155 156 152 160 160 160 156 152 165 165 165 165 174 170 170 170 174 172 170 172 165 176 174 178 176 178 178 165 186 186 185 186 186 188 186 191 191 188 195 195 195 191 197 195 200 200 191 205 205 205 205 191 207 205 207 186 223 223 213 223 216 216 213 216 216 221 221 218 223 223 223 228 228 228 228 230 228 232 230 232 232 236 228 239 239 236 228 242 243 243 247 246 247 243 249 247 251 249 253 251 253 258 257 258 253 243 261 271 271 267 267 267 267 271 271 271 271 271 273 271 273 271	0
27608955	11820	D000544	False	4	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . @DiseaseTgt$ ( @DiseaseTgt$ ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In @DiseaseTgt$ , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and @DiseaseTgt$ using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 12|19 14 12 14 19 19 19 19 19 22 20 24 22 24 24 24 19 30 38 30 33 38 38 38 38 38 38 41 41 38 43 41 43 38 47 45 38 50 52 52 52 55 55 52 59 59 59 55 52 63 63 68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	11820	D000686	False	5	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of @DiseaseTgt$ . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	11820	D007239	False	6	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , @DiseaseTgt$ , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	20208;20208	D003072	False	3	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by @DiseaseTgt$ . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22|24 21 27 35 27 30 35 35 35 35 35 35 38 38 35 40 38 40 35 44 42 35 47 49 49 49 52 52 49 56 56 56 52 49 60 60 65 62 60 62 65 65 68 68 65 68 69 72 68 76 76 76 72 79 79 76 79 82 79 82 82 82 82 82 65 96 96 92 96 94 92 96 96 99 99 96 101 99 96 104 106 106 106 108 106 110 108 112 110 112 112 108 117 119 119 115 119 122 120 122 106 128 128 128 106 131 131 128 135 135 135 128 106 138 138 141 141 138 144 144 141 147 147 144 138 150 151 151 155 154 155 151 159 159 159 155 151 164 164 164 164 173 169 169 169 173 171 169 171 164 175 173 177 175 177 177 164 185 185 184 185 185 187 185 190 190 187 194 194 194 190 196 194 199 199 190 204 204 204 204 190 206 204 206 185 222 222 212 222 215 215 212 215 215 220 220 217 222 222 222 227 227 227 227 229 227 231 229 231 231 235 227 238 238 235 227 241 242 242 246 245 246 242 248 246 250 248 252 250 252 257 256 257 252 242 260 270 270 266 266 266 266 270 270 270 270 270 272 270 272 270	0
27608955	20208;20208	D014947	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including @DiseaseTgt$ , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	11820	D000275	False	2	Overexpression of serum amyloid a 1 induces @DiseaseTgt$ behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and @DiseaseTgt$ by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study @DiseaseTgt$ .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	11820	D007249	False	6	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and @DiseaseTgt$ . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	27267	D000275	False	3	Overexpression of serum amyloid a 1 induces @DiseaseTgt$ behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and @GeneSrc$ . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and @DiseaseTgt$ by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study @DiseaseTgt$ .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	20208;20208	D019636	False	3	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a @DiseaseTgt$ characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 20 16 14 16 20 20 20 20 23 21 25 23 25 25 25 20 31 39 31 34 39 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 64 64 69 66 64 66 69 69 72 72 69 72 73 76 72 80 80 80 76 83 83 80 83 86 83 86 86 86 86 86 69 100 100 96 100 98 96 100 100 103 103 100 105 103 100 108 110 110 110 112 110 114 112 116 114 116 116 112 121 123 123 119 123 126 124 126 110 132 132 132 110 135 135 132 139 139 139 132 110 142 142 145 145 142 148 148 145 151 151 148 142 154 155 155 159 158 159 155 163 163 163 159 155 168 168 168 168 177 173 173 173 177 175 173 175 168 179 177 181 179 181 181 168 189 189 188 189 189 191 189 194 194 191 198 198 198 194 200 198 203 203 194 208 208 208 208 194 210 208 210 189 226 226 216 226 219 219 216 219 219 224 224 221 226 226 226 231 231 231 231 233 231 235 233 235 235 239 231 242 242 239 231 245 246 246 250 249 250 246 252 250 254 252 256 254 256 261 260 261 256 246 264 274 274 270 270 270 270 274 274 274 274 274 276 274 276 274	0
27608955	20208;20208	D000544	False	2	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . @DiseaseTgt$ ( @DiseaseTgt$ ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In @DiseaseTgt$ , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and @DiseaseTgt$ using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 12|19 14 12 14 19 19 19 19 19 22 20 24 22 24 24 24 19 30 38 30 33 38 38 38 38 38 38 41 41 38 43 41 43 38 47 45 38 50 52 52 52 55 55 52 59 59 59 55 52 63 63 68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	20208;20208	D000686	False	1	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of @DiseaseTgt$ . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	20208;20208	D007239	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , @DiseaseTgt$ , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	11820	D003072	False	9	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by @DiseaseTgt$ . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22|24 21 27 35 27 30 35 35 35 35 35 35 38 38 35 40 38 40 35 44 42 35 47 49 49 49 52 52 49 56 56 56 52 49 60 60 65 62 60 62 65 65 68 68 65 68 69 72 68 76 76 76 72 79 79 76 79 82 79 82 82 82 82 82 65 96 96 92 96 94 92 96 96 99 99 96 101 99 96 104 106 106 106 108 106 110 108 112 110 112 112 108 117 119 119 115 119 122 120 122 106 128 128 128 106 131 131 128 135 135 135 128 106 138 138 141 141 138 144 144 141 147 147 144 138 150 151 151 155 154 155 151 159 159 159 155 151 164 164 164 164 173 169 169 169 173 171 169 171 164 175 173 177 175 177 177 164 185 185 184 185 185 187 185 190 190 187 194 194 194 190 196 194 199 199 190 204 204 204 204 190 206 204 206 185 222 222 212 222 215 215 212 215 215 220 220 217 222 222 222 227 227 227 227 229 227 231 229 231 231 235 227 238 238 235 227 241 242 242 246 245 246 242 248 246 250 248 252 250 252 257 256 257 252 242 260 270 270 266 266 266 266 270 270 270 270 270 272 270 272 270	0
27608955	11820	D014947	False	6	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including @DiseaseTgt$ , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of @GeneSrc$ in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	351	D003072	False	1	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by @DiseaseTgt$ . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22|24 21 27 34 27 34|29 34 34 34 34 34 37 37 34 39 37 39 34 43 41 34 46 48 48 48 51 51 48 55 55 55 51 48 58 58|63 60 58 60 63 63 66 66 63 66 67 70 66 74 74 74 70 77 77 74 77 80 77 80 80 80 80 80 63 94 94 90 94 92 90 94 94 97 97 94 99 97 94 102 104 104 104 106 104 108 106 110 108 110 110 106 115 117 117 113 117 120 118 120 104 126 126 126 104 129 129 126 133 133 133 126 104 136 136 139 139 136 142 142 139 145 145 142 136 148 149 149 153 152 153 149 157 157 157 153 149 162 162 162 162 171 167 167 167 171 169 167 169 162 173 171 175 173 175 175 162 183 183 182 183 183 185 183 188 188 185 192 192 192 188 194 192 197 197 188 202 202 202 202 188 204 202 204 183 220 220 210 220 213 213 210 213 213 218 218 215 220 220 220 225 225 225 225 227 225 229 227 229 229 233 225 236 236 233 225 239 240 240 244 243 244 240 246 244 248 246 250 248 250 255 254 255 250 240 258 268 268 264 264 264 264 268 268 268 268 268 270 268 270 268	0
27608955	20208;20208	D007249	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , amyloid beta ( Abeta ) protein aggregates in the brain of patients , forming amyloid plaques . Abeta plaques are known to be surrounded by activated microglial cells . Serum amyloid A ( @GeneSrc$ ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and @DiseaseTgt$ . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 40 32 35 40 40 40 40 40 40 43 43 40 45 43 45 40 49 47 40 52 54 54 54 57 57 54 61 61 61 57 54 65 65 70 67 65 67 70 70 73 73 70 73 74 77 73 81 81 81 77 84 84 81 84 87 84 87 87 87 87 87 70 101 101 97 101 99 97 101 101 104 104 101 106 104 101 109 111 111 111 113 111 115 113 117 115 117 117 113 122 124 124 120 124 127 125 127 111 133 133 133 111 136 136 133 140 140 140 133 111 143 143 146 146 143 149 149 146 152 152 149 143 155 156 156 160 159 160 156 164 164 164 160 156 169 169 169 169 178 174 174 174 178 176 174 176 169 180 178 182 180 182 182 169 190 190 189 190 190 192 190 195 195 192 199 199 199 195 201 199 204 204 195 209 209 209 209 195 211 209 211 190 227 227 217 227 220 220 217 220 220 225 225 222 227 227 227 232 232 232 232 234 232 236 234 236 236 240 232 243 243 240 232 246 247 247 251 250 251 247 253 251 255 253 257 255 257 262 261 262 257 247 265 275 275 271 271 271 271 275 275 275 275 275 277 275 277 275	0
27608955	351	D000544	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . @DiseaseTgt$ ( @DiseaseTgt$ ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In @DiseaseTgt$ , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and @DiseaseTgt$ using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 12|19 14 12 14 19 19 19 19 19 22 20 24 22 24 24 24 19 30 37 30 37|32 37 37 37 37 37 40 40 37 42 40 42 37 46 44 37 49 51 51 51 54 54 51 58 58 58 54 51 61 61|66 63 61 63 66 66 69 69 66 69 70 73 69 77 77 77 73 80 80 77 80 83 80 83 83 83 83 83 66 97 97 93 97 95 93 97 97 100 100 97 102 100 97 105 107 107 107 109 107 111 109 113 111 113 113 109 118 120 120 116 120 123 121 123 107 129 129 129 107 132 132 129 136 136 136 129 107 139 139 142 142 139 145 145 142 148 148 145 139 151 152 152 156 155 156 152 160 160 160 156 152 165 165 165 165 174 170 170 170 174 172 170 172 165 176 174 178 176 178 178 165 186 186 185 186 186 188 186 191 191 188 195 195 195 191 197 195 200 200 191 205 205 205 205 191 207 205 207 186 223 223 213 223 216 216 213 216 216 221 221 218 223 223 223 228 228 228 228 230 228 232 230 232 232 236 228 239 239 236 228 242 243 243 247 246 247 243 249 247 251 249 253 251 253 258 257 258 253 243 261 271 271 267 267 267 267 271 271 271 271 271 273 271 273 271	0
27608955	351	D000686	False	1	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of @DiseaseTgt$ . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 39 32 39|34 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 63 63|68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	351	D007249	True	0	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and @DiseaseTgt$ . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and depression by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study depression .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 39 32 39|34 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 63 63|68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
27608955	351	D000275	False	2	Overexpression of serum amyloid a 1 induces @DiseaseTgt$ behavior in mice . Alzheimer 's disease ( AD ) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities . In AD , @GeneSrc$ ( @GeneSrc$ ) protein aggregates in the brain of patients , forming amyloid plaques . @GeneSrc$ plaques are known to be surrounded by activated microglial cells . Serum @GeneSrc$ ( SAA ) is elevated from several hundred to 1000-fold as part of the immune response against various injuries , including trauma , infection , and inflammation . Additionally , continuous elevation of SAA is related to the development of amyloidosis . This study was designed to identify the relationship between SAA1 and AD using liver specific SAA1 overexpressing mice ( TG ) , because SAA1 is expressed in the liver during the acute phase . We detected exogenous SAA1 expression in the brain of TG mice . This result implies that liver-derived SAA1 migrates to the brain tissues . Thus , we confirmed that the blood brain barrier ( BBB ) functioned normally using Evans-blue staining and CARS . Furthermore , our results show an increase in the accumulation of the 87kDa form of Abeta in TG mice compared to wild type mice ( WT ) . Additionally , the number of microglial cells and levels of pro-inflammatory cytokines were increased . Next , we investigated the relationship between SAA1 and @DiseaseTgt$ by performing social interaction tests . The results showed that TG mice have a tendency to avoid stranger mice and an impaired social recognition . In conclusion , the SAA1 TG mouse model is a valuable model to study @DiseaseTgt$ .	6 3 3 0 5 0 6 8 6 10 6 6 14 14 21 16 14 16 21 21 21 21 21 24 22 26 24 26 26 26 21 32 39 32 39|34 39 39 39 39 39 42 42 39 44 42 44 39 48 46 39 51 53 53 53 56 56 53 60 60 60 56 53 63 63|68 65 63 65 68 68 71 71 68 71 72 75 71 79 79 79 75 82 82 79 82 85 82 85 85 85 85 85 68 99 99 95 99 97 95 99 99 102 102 99 104 102 99 107 109 109 109 111 109 113 111 115 113 115 115 111 120 122 122 118 122 125 123 125 109 131 131 131 109 134 134 131 138 138 138 131 109 141 141 144 144 141 147 147 144 150 150 147 141 153 154 154 158 157 158 154 162 162 162 158 154 167 167 167 167 176 172 172 172 176 174 172 174 167 178 176 180 178 180 180 167 188 188 187 188 188 190 188 193 193 190 197 197 197 193 199 197 202 202 193 207 207 207 207 193 209 207 209 188 225 225 215 225 218 218 215 218 218 223 223 220 225 225 225 230 230 230 230 232 230 234 232 234 234 238 230 241 241 238 230 244 245 245 249 248 249 245 251 249 253 251 255 253 255 260 259 260 255 245 263 273 273 269 269 269 269 273 273 273 273 273 275 273 275 273	0
34237158	268903	D016472	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic @DiseaseTgt$ involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 55 53 51|53 53 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 169 167 171 167 175 175 175 167 152 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 210 177	0
34237158	268903	D006333	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , @DiseaseTgt$ , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , @DiseaseTgt$ , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 55 53 51|53 53 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 107|105 105 105 111 105 77 118 113 113 118 118 118 118 123 123 123 119 127 127 127 123 127 133 133 133 133 128 135 133 135 133 139 143 141 139 143 118 145 143 118 148 151 150 148 151 153 151 153 153 155 157|153 157 160 157 160 163 157 153 151 167 165 169 165 173 173 173 165 151 175 175 181 181 180 181 175 187 184 187 186 184 181 187 190 187 187 187 194 192 198 198 198 192 200 198 200 204 204 200 206 198 208 206 208 208 208 175	0
34237158	11666	D007249	True	0	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and @DiseaseTgt$ are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic @DiseaseTgt$ . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and @DiseaseTgt$ .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 57 54 54 51 54 54 57 59 57 61 59 61 61 61 57 57 68 73 72 72 72 68 57 73 73 79 79 79 79 81 79 83 81 88 88 88 88 81 91 91 88 93 91 93 91 98 98 91 101 101 98 101 104 102 107 107 104 107 110 107 107 107 114 107 79 121 116 116 121 121 121 121 126 126 126 122 130 130 130 126 130 136 136 136 136 131 138 136 138 136 142 146 144 142 146 121 148 146 121 151 154 153 151 154 156 154 156 156 158 161 156 161 164 161 164 167 161 156 154 171 169 173 169 177 177 177 169 154 179 179 185 185 184 185 179 191 188 191 190 188 185 191 194 191 191 191 198 196 202 202 202 196 204 202 204 208 208 204 210 202 212 210 212 212 179	0
34237158	11666	D028361	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : @DiseaseTgt$ and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 24 16 16|18 18 18 24 24 24 24 27 27 24 32 32 32 32 24 32 36 36 32 36 40 38 36 36 36 45 43 36 24 50 50 50 56 53 53 50 53 53 56 58 56 60 58 60 60 60 56 56 67 72 71 71 71 67 56 72 72 78 78 78 78 80 78 82 80 87 87 87 87 80 90 90 87 92 90 92 90 97 97 90 100 100 97 100 103 101 106 106 103 106 109 106 106 106 113 106 78 120 115 115 120 120 120 120 125 125 125 121 129 129 129 125 129 135 135 135 135 130 137 135 137 135 141 145 143 141 145 120 147 145 120 150 153 152 150 153 155 153 155 155 157 160 155 160 163 160 163 166 160 155 153 170 168 172 168 176 176 176 168 153 178 178 184 184 183 184 178 190 187 190 189 187 184 190 193 190 190 190 197 195 201 201 201 195 203 201 203 207 207 203 209 201 211 209 211 211 211 178	0
34237158	11666	D009103	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including @DiseaseTgt$ , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 36 33|36 36 40 38 36 36 36 45 43 36 25 50 50 50 56 53 53 50 53 53 56 58 56 60 58 60 60 60 56 56 67 72 71 71 71 67 56 72 72 78 78 78 78 80 78 82 80 87 87 87 87 80 90 90 87 92 90 92 90 97 97 90 100 100 97 100 103 101 106 106 103 106 109 106 106 106 113 106 78 120 115 115 120 120 120 120 125 125 125 121 129 129 129 125 129 135 135 135 135 130 137 135 137 135 141 145 143 141 145 120 147 145 120 150 153 152 150 153 155 153 155 155 157 160 155 160 163 160 163 166 160 155 153 170 168 172 168 176 176 176 168 153 178 178 184 184 183 184 178 190 187 190 189 187 184 190 193 190 190 190 197 195 201 201 201 195 203 201 203 207 207 203 209 201 211 209 211 211 211 178	0
34237158	11666	D016472	True	0	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic @DiseaseTgt$ involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 57 54 54 51 54 54 57 59 57 61 59 61 61 61 57 57 68 73 72 72 72 68 57 73 73 79 79 79 79 81 79 83 81 88 88 88 88 81 91 91 88 93 91 93 91 98 98 91 101 101 98 101 104 102 107 107 104 107 110 107 107 107 114 107 79 121 116 116 121 121 121 121 126 126 126 122 130 130 130 126 130 136 136 136 136 131 138 136 138 136 142 146 144 142 146 121 148 146 121 151 154 153 151 154 156 154 156 156 158 161 156 161 164 161 164 167 161 156 154 171 169 173 169 177 177 177 169 154 179 179 185 185 184 185 179 191 188 191 190 188 185 191 194 191 191 191 198 196 202 202 202 196 204 202 204 208 208 204 210 202 212 210 212 212 212 179	0
34237158	268903	D000326	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an @DiseaseTgt$ mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of @DiseaseTgt$ ( @DiseaseTgt$ ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in @DiseaseTgt$ . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in @DiseaseTgt$ mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in @DiseaseTgt$ , underscoring its potential as a therapeutic target for @DiseaseTgt$ and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 55 53 51|53 53 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 88 86|88 90 88 90 88 95 95 88 98 98 95 98 101 99 104 104 101 104 107 104 104 104 111 104 77 118 113 113 118 118 118 118 123 123 123 119 127 127 127 123 127 133 133 133 133 128 135 133 135 133 139 143 141 139 143 118 145 143 118 148 151 150 148 151 153 151 153 153 155 158 153 158 161 158 161 164 158 153 151 168 166 170 166 174 174 174 166 151 176 176 182 182 181 182 176 188 185 188 187 185 182 188 191 188 188 188 195 193 199 199 199 193 201 199 201 205 205 201 207 199 209 207 209 209 209 176	0
34237158	11666	D019636	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several @DiseaseTgt$ , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes @DiseaseTgt$ in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other @DiseaseTgt$ that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 31 31 25|31 31 35 35 31 35 39 37 35 35 35 44 42 35 25 49 49 49 55 52 52 49 52 52 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 169 167 171 167 175 175 175 167 152 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 205 202|205 207 200 209 207 209 209 209 177	0
34237158	11666	D010300	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and @DiseaseTgt$ . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 44|37 25 49 49 49 55 52 52 49 52 52 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 169 167 171 167 175 175 175 167 152 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 210 177	0
34237158	268903	D028361	False	1	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : @DiseaseTgt$ and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 24 16 16|18 18 18 24 24 24 24 27 27 24 32 32 32 32 24 32 36 36 32 36 40 38 36 36 36 45 43 36 24 50 50 50 54 52 50|52 52 54 56 54 58 56 58 58 58 54 54 65 70 69 69 69 65 54 70 70 76 76 76 76 78 76 80 78 85 85 85 85 78 88 88 85 90 88 90 88 95 95 88 98 98 95 98 101 99 104 104 101 104 107 104 104 104 111 104 76 118 113 113 118 118 118 118 123 123 123 119 127 127 127 123 127 133 133 133 133 128 135 133 135 133 139 143 141 139 143 118 145 143 118 148 151 150 148 151 153 151 153 153 155 158 153 158 161 158 161 164 158 153 151 168 166 170 166 174 174 174 166 151 176 176 182 182 181 182 176 188 185 188 187 185 182 188 191 188 188 188 195 193 199 199 199 193 201 199 201 205 205 201 207 199 209 207 209 209 209 176	0
34237158	11666	D009410	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of @DiseaseTgt$ in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , @DiseaseTgt$ and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 27 25|27 32 32 32 32 25 32 36 36 32 36 40 38 36 36 36 45 43 36 25 50 50 50 56 53 53 50 53 53 56 58 56 60 58 60 60 60 56 56 67 72 71 71 71 67 56 72 72 78 78 78 78 80 78 82 80 87 87 87 87 80 90 90 87 92 90 92 90 97 97 90 100 100 97 100 103 101 106 106 103 106 109 106 106 106 113 106 78 120 115 115 120 120 120 120 125 125 125 121 129 129 129 125 129 135 135 135 135 130 137 135 137 135 141 145 143 141 145 120 147 145 120 150 153 152 150 153 155 153 155 155 157 160 155 160 163 160 163 165|160 155 153 169 167 171 167 175 175 175 167 153 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 210 177	0
34237158	268903	D010300	False	1	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and @DiseaseTgt$ . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 44|37 25 49 49 49 53 51 49|51 51 53 55 53 57 55 57 57 57 53 53 64 69 68 68 68 64 53 69 69 75 75 75 75 77 75 79 77 84 84 84 84 77 87 87 84 89 87 89 87 94 94 87 97 97 94 97 100 98 103 103 100 103 106 103 103 103 110 103 75 117 112 112 117 117 117 117 122 122 122 118 126 126 126 122 126 132 132 132 132 127 134 132 134 132 138 142 140 138 142 117 144 142 117 147 150 149 147 150 152 150 152 152 154 157 152 157 160 157 160 163 157 152 150 167 165 169 165 173 173 173 165 150 175 175 181 181 180 181 175 187 184 187 186 184 181 187 190 187 187 187 194 192 198 198 198 192 200 198 200 204 204 200 206 198 208 206 208 208 208 175	0
34237158	11666	D000326	True	0	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an @DiseaseTgt$ mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of @DiseaseTgt$ ( @DiseaseTgt$ ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in @DiseaseTgt$ . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in @DiseaseTgt$ mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in @DiseaseTgt$ , underscoring its potential as a therapeutic target for @DiseaseTgt$ and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 57 54 54 51 54 54 57 59 57 61 59 61 61 61 57 57 68 73 72 72 72 68 57 73 73 79 79 79 79 81 79 83 81 88 88 88 88 81 90 88|90 92 90 92 90 97 97 90 100 100 97 100 103 101 106 106 103 106 109 106 106 106 113 106 79 120 115 115 120 120 120 120 125 125 125 121 129 129 129 125 129 135 135 135 135 130 137 135 137 135 141 145 143 141 145 120 147 145 120 150 153 152 150 153 155 153 155 155 157 160 155 160 163 160 163 166 160 155 153 170 168 172 168 176 176 176 168 153 178 178 184 184 183 184 178 190 187 190 189 187 184 190 193 190 190 190 197 195 201 201 201 195 203 201 203 207 207 203 209 201 211 209 211 211 211 178	0
34237158	268903	D019636	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several @DiseaseTgt$ , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes @DiseaseTgt$ in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other @DiseaseTgt$ that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 31 31 25|31 31 35 35 31 35 39 37 35 35 35 44 42 35 25 49 49 49 53 51 49|51 51 53 55 53 57 55 57 57 57 53 53 64 69 68 68 68 64 53 69 69 75 75 75 75 77 75 79 77 84 84 84 84 77 87 87 84 89 87 89 87 94 94 87 97 97 94 97 100 98 103 103 100 103 106 103 103 103 110 103 75 117 112 112 117 117 117 117 122 122 122 118 126 126 126 122 126 132 132 132 132 127 134 132 134 132 138 142 140 138 142 117 144 142 117 147 150 149 147 150 152 150 152 152 154 157 152 157 160 157 160 163 157 152 150 167 165 169 165 173 173 173 165 150 175 175 181 181 180 181 175 187 184 187 186 184 181 187 190 187 187 187 194 192 198 198 198 192 200 198 200 203 200|203 205 198 207 205 207 207 207 175	1
34237158	268903	D009069	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated @DiseaseTgt$ in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 55 53 51|53 53 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 167|168 170 167 174 174 174 167 152 176 176 182 182 181 182 176 188 185 188 187 185 182 188 191 188 188 188 195 193 199 199 199 193 201 199 201 205 205 201 207 199 209 207 209 209 209 176	0
34237158	11666	D009069	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated @DiseaseTgt$ in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 57 54 54 51 54 54 57 59 57 61 59 61 61 61 57 57 68 73 72 72 72 68 57 73 73 79 79 79 79 81 79 83 81 88 88 88 88 81 91 91 88 93 91 93 91 98 98 91 101 101 98 101 104 102 107 107 104 107 110 107 107 107 114 107 79 121 116 116 121 121 121 121 126 126 126 122 130 130 130 126 130 136 136 136 136 131 138 136 138 136 142 146 144 142 146 121 148 146 121 151 154 153 151 154 156 154 156 156 158 161 156 161 164 161 164 167 161 156 154 169|170 172 169 176 176 176 169 154 178 178 184 184 183 184 178 190 187 190 189 187 184 190 193 190 190 190 197 195 201 201 201 195 203 201 203 207 207 203 209 201 211 209 211 211 211 178	0
34237158	268903	D007249	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and @DiseaseTgt$ are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic @DiseaseTgt$ . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and @DiseaseTgt$ .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 55 53 51|53 53 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 169 167 171 167 175 175 175 167 152 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 177	0
34237158	11666	D006333	True	0	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , @DiseaseTgt$ , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , @DiseaseTgt$ , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 41 39 37 37 37 46 44 37 25 51 51 51 57 54 54 51 54 54 57 59 57 61 59 61 61 61 57 57 68 73 72 72 72 68 57 73 73 79 79 79 79 81 79 83 81 88 88 88 88 81 91 91 88 93 91 93 91 98 98 91 101 101 98 101 104 102 107 107 104 107 109|107 107 107 113 107 79 120 115 115 120 120 120 120 125 125 125 121 129 129 129 125 129 135 135 135 135 130 137 135 137 135 141 145 143 141 145 120 147 145 120 150 153 152 150 153 155 153 155 155 157 159|155 159 162 159 162 165 159 155 153 169 167 171 167 175 175 175 167 153 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 210 177	0
34237158	268903	D000544	False	1	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , @DiseaseTgt$ , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 37|39 37 37 44 42 37 25 49 49 49 53 51 49|51 51 53 55 53 57 55 57 57 57 53 53 64 69 68 68 68 64 53 69 69 75 75 75 75 77 75 79 77 84 84 84 84 77 87 87 84 89 87 89 87 94 94 87 97 97 94 97 100 98 103 103 100 103 106 103 103 103 110 103 75 117 112 112 117 117 117 117 122 122 122 118 126 126 126 122 126 132 132 132 132 127 134 132 134 132 138 142 140 138 142 117 144 142 117 147 150 149 147 150 152 150 152 152 154 157 152 157 160 157 160 163 157 152 150 167 165 169 165 173 173 173 165 150 175 175 181 181 180 181 175 187 184 187 186 184 181 187 190 187 187 187 194 192 198 198 198 192 200 198 200 204 204 200 206 198 208 206 208 208 208 175	0
34237158	268903	D009410	True	0	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of @DiseaseTgt$ in several multifactorial neurodegenerative diseases , including multiple sclerosis , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , @DiseaseTgt$ and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 27 25|27 32 32 32 32 25 32 36 36 32 36 40 38 36 36 36 45 43 36 25 50 50 50 54 52 50|52 52 54 56 54 58 56 58 58 58 54 54 65 70 69 69 69 65 54 70 70 76 76 76 76 78 76 80 78 85 85 85 85 78 88 88 85 90 88 90 88 95 95 88 98 98 95 98 101 99 104 104 101 104 107 104 104 104 111 104 76 118 113 113 118 118 118 118 123 123 123 119 127 127 127 123 127 133 133 133 133 128 135 133 135 133 139 143 141 139 143 118 145 143 118 148 151 150 148 151 153 151 153 153 155 158 153 158 161 158 161 163|158 153 151 167 165 169 165 173 173 173 165 151 175 175 181 181 180 181 175 187 184 187 186 184 181 187 190 187 187 187 194 192 198 198 198 192 200 198 200 204 204 200 206 198 208 206 208 208 208 175	0
34237158	268903	D009103	False	1	Modulation of mitochondrial and inflammatory homeostasis through @GeneSrc$ is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including @DiseaseTgt$ , Alzheimer 's disease , and Parkinson 's disease . The transcriptional coregulator @GeneSrc$ ( @GeneSrc$ ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of @GeneSrc$ in the Abcd1- mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that @GeneSrc$ is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of @GeneSrc$ prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of @GeneSrc$ promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 36 33|36 36 40 38 36 36 36 45 43 36 25 50 50 50 54 52 50|52 52 54 56 54 58 56 58 58 58 54 54 65 70 69 69 69 65 54 70 70 76 76 76 76 78 76 80 78 85 85 85 85 78 88 88 85 90 88 90 88 95 95 88 98 98 95 98 101 99 104 104 101 104 107 104 104 104 111 104 76 118 113 113 118 118 118 118 123 123 123 119 127 127 127 123 127 133 133 133 133 128 135 133 135 133 139 143 141 139 143 118 145 143 118 148 151 150 148 151 153 151 153 153 155 158 153 158 161 158 161 164 158 153 151 168 166 170 166 174 174 174 166 151 176 176 182 182 181 182 176 188 185 188 187 185 182 188 191 188 188 188 195 193 199 199 199 193 201 199 201 205 205 201 207 199 209 207 209 209 209 176	0
34237158	11666	D000544	False	2	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model . AIMS : Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases , including multiple sclerosis , @DiseaseTgt$ , and Parkinson 's disease . The transcriptional coregulator RIP140/NRIP1 ( receptor-interacting protein 140 ) modulates these functions in liver and adipose tissue , but its role in the nervous system remains unexplored . Here , we investigated the impact of RIP140 in the @GeneSrc$ mouse model of X-linked adrenoleukodystrophy ( X-ALD ) , a genetic model of chronic axonopathy involving the convergence of redox imbalance , bioenergetic failure , and chronic inflammation . METHODS AND RESULTS : We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids ( VLCFAs ) , the levels of which are increased in X-ALD . Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction , bioenergetic failure , inflammatory dysregulation , axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models . CONCLUSIONS : Together , these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD , underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis .	9 5 5 2 2 0 7 0 9 9 14 14 14 14 9 9 25 16 19 16 19 19 25 25 25 25 28 28 25 33 33 33 33 25 33 37 37 33 37 37|39 37 37 44 42 37 25 49 49 49 55 52 52 49 52 52 55 57 55 59 57 59 59 59 55 55 66 71 70 70 70 66 55 71 71 77 77 77 77 79 77 81 79 86 86 86 86 79 89 89 86 91 89 91 89 96 96 89 99 99 96 99 102 100 105 105 102 105 108 105 105 105 112 105 77 119 114 114 119 119 119 119 124 124 124 120 128 128 128 124 128 134 134 134 134 129 136 134 136 134 140 144 142 140 144 119 146 144 119 149 152 151 149 152 154 152 154 154 156 159 154 159 162 159 162 165 159 154 152 169 167 171 167 175 175 175 167 152 177 177 183 183 182 183 177 189 186 189 188 186 183 189 192 189 189 189 196 194 200 200 200 194 202 200 202 206 206 202 208 200 210 208 210 210 210 177	0
28004277	13666	D000690	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or @DiseaseTgt$ . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 56|44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D009069	False	3	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated @DiseaseTgt$ in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 321 321 321|314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26874	D009069	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated @DiseaseTgt$ in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 321 321 321|314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	C536857	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in @DiseaseTgt$ , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 181 179|181 164 185 185 164 188 188 185 185 189 192 185 164 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	D016472	False	4	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other @DiseaseTgt$ in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	13666	D006323	False	2	Tauroursodeoxycholic bile acid @DiseaseTgt$ by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 9 9 9 5 12 12 9 3 15 27 22 22 19 22 22 22 15 24 22 24 27 27 30 30 27 36 36 34 36 36 30 36 42 38 42 42 36 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 36 67 67 64 72 72 69 69 67 27 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D003711	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory @DiseaseTgt$ in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	26918	D003711	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory @DiseaseTgt$ in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	226641	D000690	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or @DiseaseTgt$ . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 56|44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26918	D000690	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or @DiseaseTgt$ . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 56|44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D030342	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a @DiseaseTgt$ that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 141 135|141 144 144 141 147 147 144 114 150 114 152 154 154 150 156 154 156 159 150 114 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	226641	C536857	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in @DiseaseTgt$ , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 181 179|181 164 185 185 164 188 188 185 185 189 192 185 164 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26918	C536857	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in @DiseaseTgt$ , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 181 179|181 164 185 185 164 188 188 185 185 189 192 185 164 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26918	D000326	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in @DiseaseTgt$ . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of @DiseaseTgt$ ( @DiseaseTgt$ ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using @DiseaseTgt$ mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and @DiseaseTgt$ patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in @DiseaseTgt$ fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in @DiseaseTgt$ . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for @DiseaseTgt$ and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 13 11|13 3 16 28 23 23 20 23 23 23 16 25 23 25 28 28 31 31 28 37 37 35 37 37 31 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 28 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 133 133|131 135 133 135 133 140 140 133 143 143 140 146 146 143 113 149 113 151 153 153 149 155 153 155 158 149 113 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D009410	False	3	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of @DiseaseTgt$ and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 316 314|316 314 321 321 321 314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26874	D006323	False	6	Tauroursodeoxycholic bile acid @DiseaseTgt$ by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 9 9 9 5 12 12 9 3 15 27 22 22 19 22 22 22 15 24 22 24 27 27 30 30 27 36 36 34 36 36 30 36 42 38 42 42 36 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 36 67 67 64 72 72 69 69 67 27 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	11666	D016472	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other @DiseaseTgt$ in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	26918	D006323	False	2	Tauroursodeoxycholic bile acid @DiseaseTgt$ by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 9 9 9 5 12 12 9 3 15 27 22 22 19 22 22 22 15 24 22 24 27 27 30 30 27 36 36 34 36 36 30 36 42 38 42 42 36 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 36 67 67 64 72 72 69 69 67 27 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D000544	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as @DiseaseTgt$ ( @DiseaseTgt$ ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of @DiseaseTgt$ , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 42 40 42|38 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D006323	False	2	Tauroursodeoxycholic bile acid @DiseaseTgt$ by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 9 9 9 5 12 12 9 3 15 27 22 22 19 22 22 22 15 24 22 24 27 27 30 30 27 36 36 34 36 36 30 36 42 38 42 42 36 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 36 67 67 64 72 72 69 69 67 27 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	226641	D010300	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , @DiseaseTgt$ or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 49|44 51 49 51 44 56 56 44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	C536857	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in @DiseaseTgt$ , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 181 179|181 164 185 185 164 188 188 185 185 189 192 185 164 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	226641	D019636	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent @DiseaseTgt$ , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 37 37 36 37 32|37 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 29 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 134 134 131 136 134 136 134 141 141 134 144 144 141 147 147 144 113 150 113 152 154 154 150 156 154 156 159 150 113 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26918	D010300	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , @DiseaseTgt$ or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 49|44 51 49 51 44 56 56 44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26918	D019636	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent @DiseaseTgt$ , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 37 37 36 37 32|37 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 29 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 134 134 131 136 134 136 134 141 141 134 144 144 141 147 147 144 113 150 113 152 154 154 150 156 154 156 159 150 113 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	11666	D010300	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , @DiseaseTgt$ or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 49|44 51 49 51 44 56 56 44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	11666	D019636	False	3	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent @DiseaseTgt$ , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 37 37 36 37 32|37 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 29 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 134 134 131 136 134 136 134 141 141 134 144 144 141 147 147 144 113 150 113 152 154 154 150 156 154 156 159 150 113 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26874	D000690	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or @DiseaseTgt$ . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 56|44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D000544	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as @DiseaseTgt$ ( @DiseaseTgt$ ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of @DiseaseTgt$ , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 42 40 42|38 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	11666	D009410	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of @DiseaseTgt$ and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 316 314|316 314 321 321 321 314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	226641	D016472	False	5	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other @DiseaseTgt$ in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	11666	D000326	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in @DiseaseTgt$ . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of @DiseaseTgt$ ( @DiseaseTgt$ ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using @DiseaseTgt$ mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and @DiseaseTgt$ patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in @DiseaseTgt$ fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in @DiseaseTgt$ . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for @DiseaseTgt$ and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 13 11|13 3 16 28 23 23 20 23 23 23 16 25 23 25 28 28 31 31 28 37 37 35 37 37 31 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 28 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 133 133|131 135 133 135 133 140 140 133 143 143 140 146 146 143 113 149 113 151 153 153 149 155 153 155 158 149 113 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	1
28004277	26918	D030342	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a @DiseaseTgt$ that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 141 135|141 144 144 141 147 147 144 114 150 114 152 154 154 150 156 154 156 159 150 114 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26874	D003711	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory @DiseaseTgt$ in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	13666	D009410	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of @DiseaseTgt$ and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 316 314|316 314 321 321 321 314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	226641	D030342	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a @DiseaseTgt$ that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 141 135|141 144 144 141 147 147 144 114 150 114 152 154 154 150 156 154 156 159 150 114 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	D000544	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as @DiseaseTgt$ ( @DiseaseTgt$ ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of @DiseaseTgt$ , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 42 40 42|38 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	13666	D010300	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , @DiseaseTgt$ or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 49|44 51 49 51 44 56 56 44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	13666	D019636	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent @DiseaseTgt$ , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 37 37 36 37 32|37 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 29 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 134 134 131 136 134 136 134 141 141 134 144 144 141 147 147 144 113 150 113 152 154 154 150 156 154 156 159 150 113 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	11666	D009069	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated @DiseaseTgt$ in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 321 321 321|314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26918	D009069	False	3	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated @DiseaseTgt$ in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 321 321 321|314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	D030342	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a @DiseaseTgt$ that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 141 135|141 144 144 141 147 147 144 114 150 114 152 154 154 150 156 154 156 159 150 114 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	11666	D030342	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a @DiseaseTgt$ that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 141 135|141 144 144 141 147 147 144 114 150 114 152 154 154 150 156 154 156 159 150 114 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26918	D009410	False	3	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of @DiseaseTgt$ and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 316 314|316 314 321 321 321 314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	226641	D000326	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in @DiseaseTgt$ . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , @GeneSrc$ and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of @DiseaseTgt$ ( @DiseaseTgt$ ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using @DiseaseTgt$ mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and @DiseaseTgt$ patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and @GeneSrc$ pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in @DiseaseTgt$ fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in @DiseaseTgt$ . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for @DiseaseTgt$ and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 13 11|13 3 16 28 23 23 20 23 23 23 16 25 23 25 28 28 31 31 28 37 37 35 37 37 31 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 28 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 133 133|131 135 133 135 133 140 140 133 143 143 140 146 146 143 113 149 113 151 153 153 149 155 153 155 158 149 113 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	13666	D003711	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory @DiseaseTgt$ in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	11666	D006323	False	4	Tauroursodeoxycholic bile acid @DiseaseTgt$ by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 9 9 9 5 12 12 9 3 15 27 22 22 19 22 22 22 15 24 22 24 27 27 30 30 27 36 36 34 36 36 30 36 42 38 42 42 36 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 36 67 67 64 72 72 69 69 67 27 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D016472	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other @DiseaseTgt$ in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	26918	D000544	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as @DiseaseTgt$ ( @DiseaseTgt$ ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of @DiseaseTgt$ , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 42 40 42|38 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	11666	C536857	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in @DiseaseTgt$ , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 181 179|181 164 185 185 164 188 188 185 185 189 192 185 164 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	D009069	False	2	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated @DiseaseTgt$ in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 321 321 321|314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	26874	D010300	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , @DiseaseTgt$ or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 49|44 51 49 51 44 56 56 44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26918	D016472	False	5	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and @GeneSrc$ . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the @GeneSrc$ pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other @DiseaseTgt$ in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
28004277	11666	D000690	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or @DiseaseTgt$ . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 56|44 58 56 58 44 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D019636	False	5	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent @DiseaseTgt$ , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 37 37 36 37 32|37 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 29 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 134 134 131 136 134 136 134 141 141 134 144 144 141 147 147 144 113 150 113 152 154 154 150 156 154 156 159 150 113 162 163 163 166 166 163 169 169 166 163 163 163 175 175 172 163 178 163 181 181 178 163 185 185 163 188 188 185 185 189 192 185 163 218 197 197 194 199 206 199 199 199 202 202 206 194 206 194 210 212 210 194 212 215 212 218 218 218 221 221 218 224 224 221 218 227 229 229 229 232 232 229 235 235 232 235 235 235 235 241 244 244 244 235 229 229 248 246 251 251 248 253 251 253 253 255 255 229 262 261 259 262 265 265 262 267 265 265 270 265 273 273 265 273 277 277 274 262 280 281 281 285 285 285 281 287 285 289 287 291 287 281 294 297 297 297 297 306 302 302 302 306 304 302 304 297 308 306 308 311 308 313 311 316 316 313 313 321 321 321 313 327 325 325 327 327 321 297 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	11666	D000544	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as @DiseaseTgt$ ( @DiseaseTgt$ ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of @DiseaseTgt$ , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 42 40 42|38 44 42 44 42 49 47 42 51 49 51 42 56 56 42 58 56 58 42 64 64 64 38 67 67 64 72 72 69 69 67 29 75 77 77 77 86 86 86 86 83 81 83 86 77 77 77 88 88 90 90 77 95 96 96 96 99 97 101 99 106 106 106 106 101 96 112 112 112 112 112 115 115 112 118 118 115 112 112 122 120 127 127 126 127 122 130 130 122 133 133 130 135 133 135 133 140 140 133 143 143 140 146 146 143 112 149 112 151 153 153 149 155 153 155 158 149 112 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D009410	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of @DiseaseTgt$ and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 316 314|316 314 321 321 321 314 327 325 325 327 327 321 298 334 334 333 333 334 334 334 337 335 339 337 344 344 344 344 337 348 348 348 344 334 351 353 353 353 356 356 353 358 356 361 361 356 363 361 363 366 363 368 373 371 371 373 373 363 353	0
28004277	13666	D000326	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in @DiseaseTgt$ . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : @GeneSrc$ , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of @DiseaseTgt$ ( @DiseaseTgt$ ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using @DiseaseTgt$ mouse model ( Abcd1 - and Abcd1 - /Abcd2 -/- mice ) and @DiseaseTgt$ patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the @GeneSrc$ and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of @GeneSrc$ leads to the disruption of homeostasis and increased apoptosis during ER stress induced in @DiseaseTgt$ fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in @DiseaseTgt$ . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for @DiseaseTgt$ and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 13 11|13 3 16 28 23 23 20 23 23 23 16 25 23 25 28 28 31 31 28 37 37 35 37 37 31 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 28 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 133 133|131 135 133 135 133 140 140 133 143 143 140 146 146 143 113 149 113 151 153 153 149 155 153 155 158 149 113 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	26874	D000326	True	0	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in @DiseaseTgt$ . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of @DiseaseTgt$ ( @DiseaseTgt$ ) , a neurometabolic disorder that is caused by ABCD1 malfunction ; ABCD1 transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory demyelination in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using @DiseaseTgt$ mouse model ( Abcd1 - and Abcd1 - @GeneSrc$ -/- mice ) and @DiseaseTgt$ patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in @DiseaseTgt$ fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in @DiseaseTgt$ . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in Abcd1 - @GeneSrc$ -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for @DiseaseTgt$ and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 13 11|13 3 16 28 23 23 20 23 23 23 16 25 23 25 28 28 31 31 28 37 37 35 37 37 31 37 43 39 43 43 37 45 43 45 43 50 48 43 52 50 52 43 57 57 43 59 57 59 43 65 65 65 37 68 68 65 73 73 70 70 68 28 76 78 78 78 87 87 87 87 84 82 84 87 78 78 78 89 89 91 91 78 96 97 97 97 100 98 102 100 107 107 107 107 102 97 113 113 113 113 113 116 116 113 119 119 116 113 113 123 121 128 128 127 128 123 131 131 123 133 133|131 135 133 135 133 140 140 133 143 143 140 146 146 143 113 149 113 151 153 153 149 155 153 155 158 149 113 161 162 162 165 165 162 168 168 165 162 162 162 174 174 171 162 177 162 180 180 177 162 184 184 162 187 187 184 184 188 191 184 162 217 196 196 193 198 205 198 198 198 201 201 205 193 205 193 209 211 209 193 211 214 211 217 217 217 220 220 217 223 223 220 217 226 228 228 228 231 231 228 234 234 231 234 234 234 234 240 243 243 243 234 228 228 247 245 250 250 247 252 250 252 252 254 254 228 261 260 258 261 264 264 261 266 264 264 269 264 272 272 264 272 276 276 273 261 279 280 280 284 284 284 280 286 284 288 286 290 286 280 293 296 296 296 296 305 301 301 301 305 303 301 303 296 307 305 307 310 307 312 310 315 315 312 312 320 320 320 312 326 324 324 326 326 320 296 333 333 332 332 333 333 333 336 334 338 336 343 343 343 343 336 347 347 347 343 333 350 352 352 352 355 355 352 357 355 360 360 355 362 360 362 365 362 367 372 370 370 372 372 362 352	0
28004277	11666	D003711	False	1	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy . The activation of the highly conserved unfolded protein response ( UPR ) is prominent in the pathogenesis of the most prevalent neurodegenerative disorders , such as Alzheimer 's disease ( AD ) , Parkinson 's disease ( PD ) and amyotrophic lateral sclerosis ( ALS ) , which are classically characterized by an accumulation of aggregated or misfolded proteins . This activation is orchestrated by three endoplasmic reticulum ( ER ) stress sensors : PERK , ATF6 and IRE1 . These sensors transduce signals that induce the expression of the UPR gene programme . Here , we first identified an early activator of the UPR and investigated the role of a chronically activated UPR in the pathogenesis of X-linked adrenoleukodystrophy ( X-ALD ) , a neurometabolic disorder that is caused by @GeneSrc$ malfunction ; @GeneSrc$ transports very long-chain fatty acids ( VLCFA ) into peroxisomes . The disease manifests as inflammatory @DiseaseTgt$ in the brain or and/or degeneration of corticospinal tracts , thereby resulting in spastic paraplegia , with the accumulation of intracellular VLCFA instead of protein aggregates . Using X-ALD mouse model ( @GeneSrc$ - and @GeneSrc$ - /Abcd2 -/- mice ) and X-ALD patient 's fibroblasts and brain samples , we discovered an early engagement of the UPR . The response was characterized by the activation of the PERK and ATF6 pathways , but not the IRE1 pathway , showing a difference from the models of AD , PD or ALS . Inhibition of PERK leads to the disruption of homeostasis and increased apoptosis during ER stress induced in X-ALD fibroblasts . Redox imbalance appears to be the mechanism that initiates ER stress in X-ALD . Most importantly , we demonstrated that the bile acid tauroursodeoxycholate ( TUDCA ) abolishes UPR activation , which results in improvement of axonal degeneration and its associated locomotor impairment in @GeneSrc$ - /Abcd2 -/- mice . Altogether , our preclinical data provide evidence for establishing the UPR as a key drug target in the pathogenesis cascade . Our study also highlights the potential role of TUDCA as a treatment for X-ALD and other axonopathies in which similar molecular mediators are implicated .	2 2 3 3 5 3 7 3 11 11 11 7 14 14 11 3 17 29 24 24 21 24 24 24 17 26 24 26 29 29 32 32 29 38 38 36 38 38 32 38 44 40 44 44 38 46 44 46 44 51 49 44 53 51 53 44 58 58 44 60 58 60 44 66 66 66 38 69 69 66 74 74 71 71 69 29 77 79 79 79 88 88 88 88 85 83 85 88 79 79 79 90 90 92 92 79 97 98 98 98 101 99 103 101 108 108 108 108 103 98 114 114 114 114 114 117 117 114 120 120 117 114 114 124 122 129 129 128 129 124 132 132 124 135 135 132 137 135 137 135 142 142 135 145 145 142 148 148 145 114 151 114 153 155 155 151 157 155 157 160 151 114 163 164 164 167 167 164 170 170 167 164 164 164 176 176 173 164 179 164 182 182 179 164 186 186 164 189 189 186 186 190 193 186 164 219 198 198 195 200 207 200 200 200 203 203 207 195 207 195 211 213 211 195 213 216 213 219 219 219 222 222 219 225 225 222 219 228 230 230 230 233 233 230 236 236 233 236 236 236 236 242 245 245 245 236 230 230 249 247 252 252 249 254 252 254 254 256 256 230 263 262 260 263 266 266 263 268 266 266 271 266 274 274 266 274 278 278 275 263 281 282 282 286 286 286 282 288 286 290 288 292 288 282 295 298 298 298 298 307 303 303 303 307 305 303 305 298 309 307 309 312 309 314 312 317 317 314 314 322 322 322 314 328 326 326 328 328 322 298 335 335 334 334 335 335 335 338 336 340 338 345 345 345 345 338 349 349 349 345 335 352 354 354 354 357 357 354 359 357 362 362 357 364 362 364 367 364 369 374 372 372 374 374 364 354	0
35568699	11666	D009461	False	6	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe @DiseaseTgt$ also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 24 18 16 18 24 24 24 24 24 24 28 28 25 32 32 32 28 24 24 34 43 43 39 43 43 43 43 35 43 46 43 24 49 56 51 49 51 56 56 56 56 58 56 60 56 60 60 56 65 78 71 71 71 71 71 65 73 71 73 78 78 78 78 81 81 78 86 82 86 84 81 86 89 86 89 93 93 89 78 96 97 97 99 97 101 99 108 108 108 108 108 108 99 111 111 108 113 99 120 120 120 120 120 120 113 122 120 125 125 122 97 129 129 132 132 132 132 135 135 132 135 135 139 143 139 142 139 132 143 149 145 148 145 143 152 152 132 152 152 132 157 157 160 160 157 163 163 160 163 166 169 168 169 163 172 172 169 172 172 176 177 172 177 163 179 179 185 185 185 163 188 188 185 188 188 157 198 196 195 196 192|196 198 198 200 198 203 203 200 207 207 207 203 207 198 212 212 214 214 214 217 217 214 217 220 217 220 220 225 225 222 225 225 229 225 229 225 214 234 235 235 242 242 242 242 242 242 235 246 246 246 242 242 249 242 251 235 251 255 255 251 259 259 259 255 235	0
35568699	10457	D000326	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , @DiseaseTgt$ protein . @DiseaseTgt$ ( cALD ) is a severe phenotype of @DiseaseTgt$ with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 9 9|7 0 19 13 11 13 19 19 19 19 19 19 23 23 20 27 27 27 23 19 19 29 38 38 34 38 38 38 38 30 38 41 38 19 43|50 45 43 45 50 50 50 50 52 50 54 50 54 54 50 59 65 61 59|61 65 65 65 65 68 68 65 73 69 73 71 68 73 76 73 76 80 80 76 65 83 84 84 86 84 88 86 95 95 95 95 95 95 86 98 98 95 100 86 107 107 107 107 107 107 100 109 107 112 112 109 84 116 116 119 119 119 119 122 122 119 122 122 126 130 126 129 126 119 130 136 132 135 132 130 139 139 119 139 139 119 144 144 147 147 144 150 150 147 150 153 156 155 156 150 159 159 156 159 159 163 164 159 164 150 166 166 172 172 172 150 175 175 172 175 175 144 186 184 182 183 184 179 186 186 188 186 191 191 188 195 195 195 191 195 186 200 200 202 202 202 205 205 202 205 208 205 208 208 213 213 210 213 213 217 213 217 213 202 222 223 223 230 230 230 230 230 230 223 234 234 234 230 230 237 230 239 223 239 243 243 239 247 247 247 243 223	0
35568699	10457	D018901	False	1	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an @DiseaseTgt$ caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 18 14 12 14 18 18 18 18 22 22 19 26 26 26 22 18 18 28 37 37 33 37 37 37 37 29 37 40 37 18 43 50 45 43 45 50 50 50 50 52 50 54 50 54 54 50 59 65 61 59|61 65 65 65 65 68 68 65 73 69 73 71 68 73 76 73 76 80 80 76 65 83 84 84 86 84 88 86 95 95 95 95 95 95 86 98 98 95 100 86 107 107 107 107 107 107 100 109 107 112 112 109 84 116 116 119 119 119 119 122 122 119 122 122 126 130 126 129 126 119 130 136 132 135 132 130 139 139 119 139 139 119 144 144 147 147 144 150 150 147 150 153 156 155 156 150 159 159 156 159 159 163 164 159 164 150 166 166 172 172 172 150 175 175 172 175 175 144 186 184 182 183 184 179 186 186 188 186 191 191 188 195 195 195 191 195 186 200 200 202 202 202 205 205 202 205 208 205 208 208 213 213 210 213 213 217 213 217 213 202 222 223 223 230 230 230 230 230 230 223 234 234 234 230 230 237 230 239 223 239 243 243 239 247 247 247 243 223	0
35568699	11666	D018901	True	0	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an @DiseaseTgt$ caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 22 18 16 18 22 22 22 22 26 26 23 30 30 30 26 22 22 32 41 41 37 41 41 41 41 33 41 44 41 22 47 54 49 47 49 54 54 54 54 56 54 58 54 58 58 54 63 76 69 69 69 69 69 63 71 69 71 76 76 76 76 79 79 76 84 80 84 82 79 84 87 84 87 91 91 87 76 94 95 95 97 95 99 97 106 106 106 106 106 106 97 109 109 106 111 97 118 118 118 118 118 118 111 120 118 123 123 120 95 127 127 130 130 130 130 133 133 130 133 133 137 141 137 140 137 130 141 147 143 146 143 141 150 150 130 150 150 130 155 155 158 158 155 161 161 158 161 164 167 166 167 161 170 170 167 170 170 174 175 170 175 161 177 177 183 183 183 161 186 186 183 186 186 155 197 195 193 194 195 190 197 197 199 197 202 202 199 206 206 206 202 206 197 211 211 213 213 213 216 216 213 216 219 216 219 219 224 224 221 224 224 228 224 228 224 213 233 234 234 241 241 241 241 241 241 234 245 245 245 241 241 248 241 250 234 250 254 254 250 258 258 258 254 234	0
35568699	10457	D000544	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as @DiseaseTgt$ , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 20 14 12 14 20 20 20 20 20 20 24 24 21 28 28 28 24 20 20 30 39 39 35 39 39 39 39 31 39 42 39 20 45 52 47 45 47 52 52 52 52 54 52 56 52 56 56 52 61 67 63 61|63 67 67 67 67 70 70 67 73 71 70|73 73 76 73 76 80 80 76 67 83 84 84 86 84 88 86 95 95 95 95 95 95 86 98 98 95 100 86 107 107 107 107 107 107 100 109 107 112 112 109 84 116 116 119 119 119 119 122 122 119 122 122 126 130 126 129 126 119 130 136 132 135 132 130 139 139 119 139 139 119 144 144 147 147 144 150 150 147 150 153 156 155 156 150 159 159 156 159 159 163 164 159 164 150 166 166 172 172 172 150 175 175 172 175 175 144 186 184 182 183 184 179 186 186 188 186 191 191 188 195 195 195 191 195 186 200 200 202 202 202 205 205 202 205 208 205 208 208 213 213 210 213 213 217 213 217 213 202 222 223 223 230 230 230 230 230 230 223 234 234 234 230 230 237 230 239 223 239 243 243 239 247 247 247 243 223	0
35568699	10457	D019636	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with @DiseaseTgt$ . Elevated levels of @GeneSrc$ have been recently documented in @DiseaseTgt$ such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 20 14 12 14 20 20 20 20 20 20 24 24 21 28 28 28 24 20 20 30 39 39 35 39 39 39 39 31 39 42 39 20 45 52 47 45 47 52 52 52 52 54 52 56 52|56 52 59 65 61 59|61 65 65 65 65 67 67|65 72 68 72 70 67 72 75 72 75 79 79 75 65 82 83 83 85 83 87 85 94 94 94 94 94 94 85 97 97 94 99 85 106 106 106 106 106 106 99 108 106 111 111 108 83 115 115 118 118 118 118 121 121 118 121 121 125 129 125 128 125 118 129 135 131 134 131 129 138 138 118 138 138 118 143 143 146 146 143 149 149 146 149 152 155 154 155 149 158 158 155 158 158 162 163 158 163 149 165 165 171 171 171 149 174 174 171 174 174 143 185 183 181 182 183 178 185 185 187 185 190 190 187 194 194 194 190 194 185 199 199 201 201 201 204 204 201 204 207 204 207 207 212 212 209 212 212 216 212 216 212 201 221 222 222 229 229 229 229 229 229 222 233 233 233 229 229 236 229 238 222 238 242 242 238 246 246 246 242 222	0
35568699	10457	D009461	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe @DiseaseTgt$ also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 20 14 12 14 20 20 20 20 20 20 24 24 21 28 28 28 24 20 20 30 39 39 35 39 39 39 39 31 39 42 39 20 45 52 47 45 47 52 52 52 52 54 52 56 52 56 56 52 61 67 63 61|63 67 67 67 67 70 70 67 75 71 75 73 70 75 78 75 78 82 82 78 67 85 86 86 88 86 90 88 97 97 97 97 97 97 88 100 100 97 102 88 109 109 109 109 109 109 102 111 109 114 114 111 86 118 118 121 121 121 121 124 124 121 124 124 128 132 128 131 128 121 132 138 134 137 134 132 141 141 121 141 141 121 146 146 149 149 146 152 152 149 152 155 158 157 158 152 161 161 158 161 161 165 166 161 166 152 168 168 174 174 174 152 177 177 174 177 177 146 187 185 184 185 181|185 187 187 189 187 192 192 189 196 196 196 192 196 187 201 201 203 203 203 206 206 203 206 209 206 209 209 214 214 211 214 214 218 214 218 214 203 223 224 224 231 231 231 231 231 231 224 235 235 235 231 231 238 231 240 224 240 244 244 240 248 248 248 244 224	0
35568699	11666	D003141	False	1	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( @DiseaseTgt$ ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in @DiseaseTgt$ patients to determine if GNMPB could be a potential biomarker in tracking @DiseaseTgt$ progression . CSF GNMPB levels were significantly higher in @DiseaseTgt$ patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of @DiseaseTgt$ state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 24 18 16 18 24 24 24 24 24 24 28 28 25 32 32 32 28 24 24 34 43 43 39 43 43 43 43 35 43 46 43 24 49 56 51 49 51 56 56 56 56 58 56 60 56 60 60 56 65 78 71 71 71 71 71 65 73 71 73 78 78 78 78 81 81 78 86 82 86 84 81 86 89 86 89 93 93 89 78 96 97 97 99 97 101 99 108 108 108 108 108 108 99 111 111 108 113 99 120 120 120 120 120 120 113 122 120 124 122 97 128 128 131 131 131 131 134 134 131 134 134 138 142 138 141 138 131 142 148 144 147 144 142 151 151 131 151 151 131 156 156 159 159 156 162 162 159 162 165 168 167 168 162 171 171 168 171 171 175 176 171 176 162 178 178 184 184 184 162 187 187 184 187 187 156 198 196 194 195 196 191 198 198 200 198 203 203 200 207 207 207 203 207 198 212 212 214 214 214 217 217 214 217 220 217 220 220 225 225 222 225 225 229 225 229 225 214 234 235 235 242 242 242 242 242 242 235 245 245 242 242 248 242 250 235 250 254 254 250 258 258 258 254 235	0
35568699	11666	D019636	False	1	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with @DiseaseTgt$ . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in @DiseaseTgt$ such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 24 18 16 18 24 24 24 24 24 24 28 28 25 32 32 32 28 24 24 34 43 43 39 43 43 43 43 35 43 46 43 24 49 56 51 49 51 56 56 56 56 58 56 60 56|60 56 63 76 69 69 69 69 69 63 71 69 71 76 76 76 76 78 78|76 83 79 83 81 78 83 86 83 86 90 90 86 76 93 94 94 96 94 98 96 105 105 105 105 105 105 96 108 108 105 110 96 117 117 117 117 117 117 110 119 117 122 122 119 94 126 126 129 129 129 129 132 132 129 132 132 136 140 136 139 136 129 140 146 142 145 142 140 149 149 129 149 149 129 154 154 157 157 154 160 160 157 160 163 166 165 166 160 169 169 166 169 169 173 174 169 174 160 176 176 182 182 182 160 185 185 182 185 185 154 196 194 192 193 194 189 196 196 198 196 201 201 198 205 205 205 201 205 196 210 210 212 212 212 215 215 212 215 218 215 218 218 223 223 220 223 223 227 223 227 223 212 232 233 233 240 240 240 240 240 240 233 244 244 244 240 240 247 240 249 233 249 253 253 249 257 257 257 253 233	0
35568699	11666	D000690	False	2	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , @DiseaseTgt$ . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 24 18 16 18 24 24 24 24 24 24 28 28 25 32 32 32 28 24 24 34 43 43 39 43 43 43 43 35 43 46 43 24 49 56 51 49 51 56 56 56 56 58 56 60 56 60 60 56 65 78 71 71 71 71 71 65 73 71 73 78 78 78 78 81 81 78 86 82 86 84 81 86 88|86 78 91 92 92 94 92 96 94 103 103 103 103 103 103 94 106 106 103 108 94 115 115 115 115 115 115 108 117 115 120 120 117 92 124 124 127 127 127 127 130 130 127 130 130 134 138 134 137 134 127 138 144 140 143 140 138 147 147 127 147 147 127 152 152 155 155 152 158 158 155 158 161 164 163 164 158 167 167 164 167 167 171 172 167 172 158 174 174 180 180 180 158 183 183 180 183 183 152 194 192 190 191 192 187 194 194 196 194 199 199 196 203 203 203 199 203 194 208 208 210 210 210 213 213 210 213 216 213 216 216 221 221 218 221 221 225 221 225 221 210 230 231 231 238 238 238 238 238 238 231 242 242 242 238 238 245 238 247 231 247 251 251 247 255 255 255 251 231	0
35568699	11666	D000544	False	2	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as @DiseaseTgt$ , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 14 14 11 4 24 18 16 18 24 24 24 24 24 24 28 28 25 32 32 32 28 24 24 34 43 43 39 43 43 43 43 35 43 46 43 24 49 56 51 49 51 56 56 56 56 58 56 60 56 60 60 56 65 78 71 71 71 71 71 65 73 71 73 78 78 78 78 81 81 78 84 82 81|84 84 87 84 87 91 91 87 78 94 95 95 97 95 99 97 106 106 106 106 106 106 97 109 109 106 111 97 118 118 118 118 118 118 111 120 118 123 123 120 95 127 127 130 130 130 130 133 133 130 133 133 137 141 137 140 137 130 141 147 143 146 143 141 150 150 130 150 150 130 155 155 158 158 155 161 161 158 161 164 167 166 167 161 170 170 167 170 170 174 175 170 175 161 177 177 183 183 183 161 186 186 183 186 186 155 197 195 193 194 195 190 197 197 199 197 202 202 199 206 206 206 202 206 197 211 211 213 213 213 216 216 213 216 219 216 219 219 224 224 221 224 224 228 224 228 224 213 233 234 234 241 241 241 241 241 241 234 245 245 245 241 241 248 241 250 234 250 254 254 250 258 258 258 254 234	0
35568699	10457	D000690	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( cALD ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , @DiseaseTgt$ . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in cALD patients to determine if @GeneSrc$ could be a potential biomarker in tracking cALD disease progression . CSF @GeneSrc$ levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 20 14 12 14 20 20 20 20 20 20 24 24 21 28 28 28 24 20 20 30 39 39 35 39 39 39 39 31 39 42 39 20 45 52 47 45 47 52 52 52 52 54 52 56 52 56 56 52 61 67 63 61|63 67 67 67 67 70 70 67 75 71 75 73 70 75 77|75 67 80 81 81 83 81 85 83 92 92 92 92 92 92 83 95 95 92 97 83 104 104 104 104 104 104 97 106 104 109 109 106 81 113 113 116 116 116 116 119 119 116 119 119 123 127 123 126 123 116 127 133 129 132 129 127 136 136 116 136 136 116 141 141 144 144 141 147 147 144 147 150 153 152 153 147 156 156 153 156 156 160 161 156 161 147 163 163 169 169 169 147 172 172 169 172 172 141 183 181 179 180 181 176 183 183 185 183 188 188 185 192 192 192 188 192 183 197 197 199 199 199 202 202 199 202 205 202 205 205 210 210 207 210 210 214 210 214 210 199 219 220 220 227 227 227 227 227 227 220 231 231 231 227 227 234 227 236 220 236 240 240 236 244 244 244 240 220	0
35568699	11666	D000326	True	0	Glycoprotein nonmetastatic melanoma protein B ( GNMPB ) as a novel biomarker for @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is an X-linked peroxisomal disease caused by a mutation in the @GeneSrc$ gene , producing mutations in the very long chain fatty acid transporter , @DiseaseTgt$ protein . @DiseaseTgt$ ( cALD ) is a severe phenotype of @DiseaseTgt$ with neuroinflammation and neurodegeneration . Elevated levels of Glycoprotein Nonmetastatic Melanoma Protein B ( GNMPB ) have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) GNMPB in cALD patients to determine if GNMPB could be a potential biomarker in tracking cALD disease progression . CSF GNMPB levels were significantly higher in cALD patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF GNMPB and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF GNMPB ( p < 0.0001 ) . A positive correlation was shown between CSF GNMPB and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that GNMPB could be a potential biomarker of cALD disease state and further studies should evaluate it as a predictor of the disease progression .	4 4 4 4 4 6 4 6 11 11 11 4 13 11|13 4 23 17 15 17 23 23 23 23 23 23 27 27 24 31 31 31 27 23 23 33 42 42 38 42 42 42 42 34 42 45 42 23 47|54 49 47 49 54 54 54 54 56 54 58 54 58 58 54 63 76 69 69 69 69 69 63 71 69 71 76 76 76 76 79 79 76 84 80 84 82 79 84 87 84 87 91 91 87 76 94 95 95 97 95 99 97 106 106 106 106 106 106 97 109 109 106 111 97 118 118 118 118 118 118 111 120 118 123 123 120 95 127 127 130 130 130 130 133 133 130 133 133 137 141 137 140 137 130 141 147 143 146 143 141 150 150 130 150 150 130 155 155 158 158 155 161 161 158 161 164 167 166 167 161 170 170 167 170 170 174 175 170 175 161 177 177 183 183 183 161 186 186 183 186 186 155 197 195 193 194 195 190 197 197 199 197 202 202 199 206 206 206 202 206 197 211 211 213 213 213 216 216 213 216 219 216 219 219 224 224 221 224 224 228 224 228 224 213 233 234 234 241 241 241 241 241 241 234 245 245 245 241 241 248 241 250 234 250 254 254 250 258 258 258 254 234	1
35568699	10457	D003141	True	0	@GeneSrc$ ( @GeneSrc$ ) as a novel biomarker for cerebral adrenoleukodystrophy . Adrenoleukodystrophy ( ALD ) is an X-linked peroxisomal disease caused by a mutation in the ABCD1 gene , producing mutations in the very long chain fatty acid transporter , ALD protein . Cerebral ALD ( @DiseaseTgt$ ) is a severe phenotype of ALD with neuroinflammation and neurodegeneration . Elevated levels of @GeneSrc$ have been recently documented in neurodegenerative diseases such as Alzheimer 's disease , Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Our objective was to measure the levels cerebral spinal fluid ( CSF ) @GeneSrc$ in @DiseaseTgt$ patients to determine if @GeneSrc$ could be a potential biomarker in tracking @DiseaseTgt$ progression . CSF @GeneSrc$ levels were significantly higher in @DiseaseTgt$ patients versus controls ( 2407 + - 1672 pg/mL vs. 639.5 + - 404 pg/mL , p = 0.0009 ) . We found a positive correlation between CSF @GeneSrc$ and MRI disease severity score levels ( R2 = 0.3225 , p < 0.0001 ) as well as the gadolinium intensity score ( p = 0.0204 ) . Boys with more severe neurologic deficits also had higher levels of CSF @GeneSrc$ ( p < 0.0001 ) . A positive correlation was shown between CSF @GeneSrc$ and another biomarker , chitotriosidase ( R2 = 0.2512 , p = 0.0244 ) . These data show that @GeneSrc$ could be a potential biomarker of @DiseaseTgt$ state and further studies should evaluate it as a predictor of the disease progression .	0 2 0 2 7 7 7 0 10 10 7 0 20 14 12 14 20 20 20 20 20 20 24 24 21 28 28 28 24 20 20 30 39 39 35 39 39 39 39 31 39 42 39 20 45 52 47 45 47 52 52 52 52 54 52 56 52 56 56 52 61 67 63 61|63 67 67 67 67 70 70 67 75 71 75 73 70 75 78 75 78 82 82 78 67 85 86 86 88 86 90 88 97 97 97 97 97 97 88 100 100 97 102 88 109 109 109 109 109 109 102 111 109 113 111 86 117 117 120 120 120 120 123 123 120 123 123 127 131 127 130 127 120 131 137 133 136 133 131 140 140 120 140 140 120 145 145 148 148 145 151 151 148 151 154 157 156 157 151 160 160 157 160 160 164 165 160 165 151 167 167 173 173 173 151 176 176 173 176 176 145 187 185 183 184 185 180 187 187 189 187 192 192 189 196 196 196 192 196 187 201 201 203 203 203 206 206 203 206 209 206 209 209 214 214 211 214 214 218 214 218 214 203 223 224 224 231 231 231 231 231 231 224 234 234 231 231 237 231 239 224 239 243 243 239 247 247 247 243 224	0
21098980	7124	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , @GeneSrc$ -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3458	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , @GeneSrc$ + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3156	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , @GeneSrc$ -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for @GeneSrc$ . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3569	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , @GeneSrc$ -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3458	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , @GeneSrc$ + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
21098980	12	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , @GeneSrc$ -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	3586	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : @GeneSrc$ -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3569	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , @GeneSrc$ -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
21098980	12	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , @GeneSrc$ -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
21098980	3156	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , @GeneSrc$ -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for @GeneSrc$ . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
21098980	7124	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , @GeneSrc$ -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	3458	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , @GeneSrc$ + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	3586	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : @GeneSrc$ -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
21098980	3156	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , @GeneSrc$ -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for @GeneSrc$ . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	3569	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , @GeneSrc$ -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	12	D007249	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote @DiseaseTgt$ and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , @GeneSrc$ -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 10 8 6 12 0 15 15 12 19 19 19 15 0 22 31 24 22 24 25 28 25 31 31 31 35 35 35 31 37 35 37 35 42 42 35 44 42 44 31 48 48 50 48 53 53 50 55 50 57 55 59 57 59 59 48 64 48 64 67 64 64 70 64 64 64 64 64 64 64 76 64 64 79 64 83 64 87 87 87 83 87 91 91 64 64 48 96 96 48 96 103 103 103 103 103 105 105 48 107 105 105 48 112 112 113 118 113 116 113 118 118 122 122 122 118 125 125 118 127 125 125 132 129 129 125 134 132 136 132 136 139 136 139 139 139 132 146 146 147 132 149 147 151 147 147 154 158 156 154 158 158 162 162 162 158 162 165 162 158 180 167 168 172 172 167 172 167 177 177 167 177 167 180 182 180 184 182 180 187 189 189 197 193 193 193 189 195 193 197 197 199 197 201 199 197 204 206 204 211 208 206 208 211 218 211 214 218 214 214 218 218 220 218 218 223 239 228 228 228 228 223 223 231 223 234 234 231 234 237 235 237 239 242 242 239 239 245 245 250 250 247 247 245 252 250 252 255 253 255 258 255 260 258 250 272 264 272 267 267 264 269 267 272 272 250 274 272 276 274 279 279 276 245	0
21098980	3586	D000544	False	1	Sharing pathogenetic mechanisms between acute myocardial infarction and @DiseaseTgt$ as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with acute myocardial infarction ( AMI ) and @DiseaseTgt$ ( @DiseaseTgt$ ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : @GeneSrc$ -1082G/A , IL6 -174G/C , TNF -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for HMGCR-TNF-APOE . Pro-inflammatory alleles for @GeneSrc$ were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for TNF+IL6 . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 6 6 6 2 6 8|6 10 0 13 13 10 17 17 17 13 0 20 29 22 20 22 23 26 23 29 29 29 33 33 33 29 35 33 35 33 38|33 40 38 40 29 44 44 46 44 49 49 46 51 46 53 51 55 53 55 55 44 60 44 60 63 60 60 66 60 60 60 60 60 60 60 72 60 60 75 60 79 60 83 83 83 79 83 87 87 60 60 44 92 92 44 92 99 99 99 99 99 101 101 44 103 101 101 44 108 108 109 114 109 112 109 114 114 118 118 118 114 121 121 114 123 121 121 128 125 125 121 130 128 132 128 132 135 132 135 135 135 128 142 142 143 128 145 143 147 143 143 150 154 152 150 154 154 158 158 158 154 158 161 158 154 176 163 164 168 168 163 168 163 173 173 163 173 163 176 178 176 180 178 176 183 185 185 193 189 189 189 185 191 189 193 193 195 193 197 195 193 200 202 200 207 204 202 204 207 214 207 210 214 210 210 214 214 216 214 214 219 235 224 224 224 224 219 219 227 219 230 230 227 230 233 231 233 235 238 238 235 235 241 241 246 246 243 243 241 248 246 248 251 249 251 254 251 256 254 246 268 260 268 263 263 260 265 263 268 268 246 270 268 272 270 275 275 272 241	0
21098980	7124	D009203	False	1	Sharing pathogenetic mechanisms between acute @DiseaseTgt$ and Alzheimer 's disease as shown by partially overlapping of gene variant profiles . Gene variants that promote inflammation and cholesterol metabolism have been associated with @DiseaseTgt$ ( @DiseaseTgt$ ) and Alzheimer 's disease ( AD ) . We investigated a panel of relevant polymorphisms to distinguish genetic backgrounds for AMI and AD : IL10 -1082G/A , IL6 -174G/C , @GeneSrc$ -308G/A , IFNG + 874T/A , SERPINA3 -51G/T , HMGCR -911C/A , APOE epsilon2/3/4 ( 280 AMI cases , 257 AD cases , and 1307 population controls , all Italian ( presumed risk alleles are shown in bold ) . Six genetic risk sets I to VI were identified by fuzzy latent classification : I had low risk ; II and III had low risk before age 65 ( II , III ) ; low risk sets lacked pro-inflammatory alleles for @GeneSrc$ . Pro-inflammatory alleles for SERPINA3-IL10-IFNG were found for high risk sets IV to VI . Set IV ' AMI < age 40 , AD < age 65 ' included risk alleles for HMGCR . Set V ' AMI over a broad range of age ' included risk alleles for @GeneSrc$ . Set VI ' AMI at ages 40 to 55 , AD ages 65 + ' included APOE epsilon4 . Close resemblance to the high risk sets , as indicated by membership scores close to one , defined high relative risks . We conclude that AMI and AD share genetic backgrounds involving cholesterol metabolism and the upregulation of inflammation and that gene-gene interactions in relevant sets of genes may be useful in defining inherited risk for common disorders .	0 2 0 5 5 2|5 5 9 7 5 11 0 14 14 11 18 18 18 14 0 21 30 23 21 23 24 27 24 30 30 30 32 30|32 34 32 34 32 39 39 32 41 39 41 30 45 45 47 45 50 50 47 52 47 54 52 56 54 56 56 45 61 45 61 64 61 61 67 61 61 61 61 61 61 61 73 61 61 76 61 80 61 84 84 84 80 84 88 88 61 61 45 93 93 45 93 100 100 100 100 100 102 102 45 104 102 102 45 109 109 110 115 110 113 110 115 115 119 119 119 115 122 122 115 124 122 122 129 126 126 122 131 129 133 129 133 136 133 136 136 136 129 143 143 144 129 146 144 148 144 144 151 155 153 151 155 155 159 159 159 155 159 162 159 155 177 164 165 169 169 164 169 164 174 174 164 174 164 177 179 177 181 179 177 184 186 186 194 190 190 190 186 192 190 194 194 196 194 198 196 194 201 203 201 208 205 203 205 208 215 208 211 215 211 211 215 215 217 215 215 220 236 225 225 225 225 220 220 228 220 231 231 228 231 234 232 234 236 239 239 236 236 242 242 247 247 244 244 242 249 247 249 252 250 252 255 252 257 255 247 269 261 269 264 264 261 266 264 269 269 247 271 269 273 271 276 276 273 242	0
28798684	25509	D000544	True	0	Differential Roles of Environmental Enrichment in @DiseaseTgt$ and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure neuronal deficits seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - @DiseaseTgt$ 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( @GeneSrc$ , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with @DiseaseTgt$ ( @DiseaseTgt$ ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the @DiseaseTgt$ model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 6 1|6 6 6 6 1 24 15 15 15 11 17 11 17 17 17 24 24 24 24 24 28 28 25 33 33 33 33 28 24 24 39 39 39 35 43 43 43 39 39 35 35 50 50 50 46 24 53 59 55 53 55 59 59 59 63 63 63 59 65 63 67 65 65 70 65 72 70 70 70 76 70 78 76 78 81 79 81 81 81 59 89 89 89 89 91 89 94 94 91 97 97 94 100 100 94 102 103 91 105 91 109 109 109 105 111 89 89 114 127 114 118 116 114 120 118 120 120 124 118 118 127 127 131 131 131 127 134 134 131 127 137 137 142 140 142 142 137 144 142 146 144 146 150 150 147 150 153 150 150 156 144 158 156 158 158 158 158 158 158 158 168 168 156 172 171 172 168 172 172 176 176|174 178 176 178 144 144 183 142 186 186 142 137 208 192 192 192 188 195 195 188 198 198 195 198 202 202 199 205 205 202 207 199 208 212 212 212 208 214 212 218 218 218 214 220 212 224 224 224 212 227 227 212 231 231 231 227 231 237 237 237 237 232 237 231 244 244 244 244 231 248 248 248 244 251 251 248 253 248 248 208 257 268 260 260 257 260 263 261 268 268 268 268 268 271 271 268 275 275 275 271 277 268 279 268 279 279 287 287 287 284 284 279 287 279 268 304 304 295 295 304 295 299 299 296 304 304 304 304 304 307 307 304 304	0
28798684	29458	D019636	False	1	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated @DiseaseTgt$ , and to cure neuronal deficits seen in neurodevelopmental and @DiseaseTgt$ . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of @DiseaseTgt$ and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , @GeneSrc$ , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 82 80 82 85 83 85 85 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	25509	D019636	False	1	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated @DiseaseTgt$ , and to cure neuronal deficits seen in neurodevelopmental and @DiseaseTgt$ . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of @DiseaseTgt$ and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( @GeneSrc$ , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 82 80 82 85 83 85 85 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	29458	D000544	True	0	Differential Roles of Environmental Enrichment in @DiseaseTgt$ and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure neuronal deficits seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - @DiseaseTgt$ 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , @GeneSrc$ , NeuN ) in the hippocampus of young adult rats or rats with @DiseaseTgt$ ( @DiseaseTgt$ ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the @DiseaseTgt$ model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 6 1|6 6 6 6 1 24 15 15 15 11 17 11 17 17 17 24 24 24 24 24 28 28 25 33 33 33 33 28 24 24 39 39 39 35 43 43 43 39 39 35 35 50 50 50 46 24 53 59 55 53 55 59 59 59 63 63 63 59 65 63 67 65 65 70 65 72 70 70 70 76 70 78 76 78 81 79 81 81 81 59 89 89 89 89 91 89 94 94 91 97 97 94 100 100 94 102 103 91 105 91 109 109 109 105 111 89 89 114 127 114 118 116 114 120 118 120 120 124 118 118 127 127 131 131 131 127 134 134 131 127 137 137 142 140 142 142 137 144 142 146 144 146 150 150 147 150 153 150 150 156 144 158 156 158 158 158 158 158 158 158 168 168 156 172 171 172 168 172 172 176 176|174 178 176 178 144 144 183 142 186 186 142 137 208 192 192 192 188 195 195 188 198 198 195 198 202 202 199 205 205 202 207 199 208 212 212 212 208 214 212 218 218 218 214 220 212 224 224 224 212 227 227 212 231 231 231 227 231 237 237 237 237 232 237 231 244 244 244 244 231 248 248 248 244 251 251 248 253 248 248 208 257 268 260 260 257 260 263 261 268 268 268 268 268 271 271 268 275 275 275 271 277 268 279 268 279 279 287 287 287 284 284 279 287 279 268 304 304 295 295 304 295 299 299 296 304 304 304 304 304 307 307 304 304	0
28798684	295475	D009410	False	3	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure @DiseaseTgt$ seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , @GeneSrc$ , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 80|81 81 84 82 84 84 84 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	287847	D019636	False	1	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated @DiseaseTgt$ , and to cure neuronal deficits seen in neurodevelopmental and @DiseaseTgt$ . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of @DiseaseTgt$ and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , @GeneSrc$ ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 82 80 82 85 83 85 85 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	54226	D019636	False	4	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated @DiseaseTgt$ , and to cure neuronal deficits seen in neurodevelopmental and @DiseaseTgt$ . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of @DiseaseTgt$ and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in @GeneSrc$ brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 82 80 82 85 83 85 85 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	29458	D009410	False	3	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure @DiseaseTgt$ seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , @GeneSrc$ , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 80|81 81 84 82 84 84 84 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	287847	D000544	True	0	Differential Roles of Environmental Enrichment in @DiseaseTgt$ and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure neuronal deficits seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - @DiseaseTgt$ 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , @GeneSrc$ ) in the hippocampus of young adult rats or rats with @DiseaseTgt$ ( @DiseaseTgt$ ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the @DiseaseTgt$ model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 6 1|6 6 6 6 1 24 15 15 15 11 17 11 17 17 17 24 24 24 24 24 28 28 25 33 33 33 33 28 24 24 39 39 39 35 43 43 43 39 39 35 35 50 50 50 46 24 53 59 55 53 55 59 59 59 63 63 63 59 65 63 67 65 65 70 65 72 70 70 70 76 70 78 76 78 81 79 81 81 81 59 89 89 89 89 91 89 94 94 91 97 97 94 100 100 94 102 103 91 105 91 109 109 109 105 111 89 89 114 127 114 118 116 114 120 118 120 120 124 118 118 127 127 131 131 131 127 134 134 131 127 137 137 142 140 142 142 137 144 142 146 144 146 150 150 147 150 153 150 150 156 144 158 156 158 158 158 158 158 158 158 168 168 156 172 171 172 168 172 172 176 176|174 178 176 178 144 144 183 142 186 186 142 137 208 192 192 192 188 195 195 188 198 198 195 198 202 202 199 205 205 202 207 199 208 212 212 212 208 214 212 218 218 218 214 220 212 224 224 224 212 227 227 212 231 231 231 227 231 237 237 237 237 232 237 231 244 244 244 244 231 248 248 248 244 251 251 248 253 248 248 208 257 268 260 260 257 260 263 261 268 268 268 268 268 271 271 268 275 275 275 271 277 268 279 268 279 279 287 287 287 284 284 279 287 279 268 304 304 295 295 304 295 299 299 296 304 304 304 304 304 307 307 304 304	0
28798684	54226	D000544	False	2	Differential Roles of Environmental Enrichment in @DiseaseTgt$ and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure neuronal deficits seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - @DiseaseTgt$ 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with @DiseaseTgt$ ( @DiseaseTgt$ ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the @DiseaseTgt$ model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in @GeneSrc$ brain could not be directly extrapolated to aged brain .	1 1 4 4 1 6 1|6 6 6 6 1 24 15 15 15 11 17 11 17 17 17 24 24 24 24 24 28 28 25 33 33 33 33 28 24 24 39 39 39 35 43 43 43 39 39 35 35 50 50 50 46 24 53 59 55 53 55 59 59 59 63 63 63 59 65 63 67 65 65 70 65 72 70 70 70 76 70 78 76 78 81 79 81 81 81 59 89 89 89 89 91 89 94 94 91 97 97 94 100 100 94 102 103 91 105 91 109 109 109 105 111 89 89 114 127 114 118 116 114 120 118 120 120 124 118 118 127 127 131 131 131 127 134 134 131 127 137 137 142 140 142 142 137 144 142 146 144 146 150 150 147 150 153 150 150 156 144 158 156 158 158 158 158 158 158 158 168 168 156 172 171 172 168 172 172 176 176|174 178 176 178 144 144 183 142 186 186 142 137 208 192 192 192 188 195 195 188 198 198 195 198 202 202 199 205 205 202 207 199 208 212 212 212 208 214 212 218 218 218 214 220 212 224 224 224 212 227 227 212 231 231 231 227 231 237 237 237 237 232 237 231 244 244 244 244 231 248 248 248 244 251 251 248 253 248 248 208 257 268 260 260 257 260 263 261 268 268 268 268 268 271 271 268 275 275 275 271 277 268 279 268 279 279 287 287 287 284 284 279 287 279 268 304 304 295 295 304 295 299 299 296 304 304 304 304 304 307 307 304 304	0
28798684	25509	D009410	False	3	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure @DiseaseTgt$ seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( @GeneSrc$ , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 80|81 81 84 82 84 84 84 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	287847	D009410	False	3	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure @DiseaseTgt$ seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , @GeneSrc$ ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 80|81 81 84 82 84 84 84 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	54226	D009410	False	6	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure @DiseaseTgt$ seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , Ngn2 , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in @GeneSrc$ brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 80|81 81 84 82 84 84 84 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
28798684	295475	D000544	True	0	Differential Roles of Environmental Enrichment in @DiseaseTgt$ and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated neurodegeneration , and to cure neuronal deficits seen in neurodevelopmental and neurodegenerative disorders . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - @DiseaseTgt$ 's type of neurodegeneration and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , @GeneSrc$ , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with @DiseaseTgt$ ( @DiseaseTgt$ ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the @DiseaseTgt$ model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 6 1|6 6 6 6 1 24 15 15 15 11 17 11 17 17 17 24 24 24 24 24 28 28 25 33 33 33 33 28 24 24 39 39 39 35 43 43 43 39 39 35 35 50 50 50 46 24 53 59 55 53 55 59 59 59 63 63 63 59 65 63 67 65 65 70 65 72 70 70 70 76 70 78 76 78 81 79 81 81 81 59 89 89 89 89 91 89 94 94 91 97 97 94 100 100 94 102 103 91 105 91 109 109 109 105 111 89 89 114 127 114 118 116 114 120 118 120 120 124 118 118 127 127 131 131 131 127 134 134 131 127 137 137 142 140 142 142 137 144 142 146 144 146 150 150 147 150 153 150 150 156 144 158 156 158 158 158 158 158 158 158 168 168 156 172 171 172 168 172 172 176 176|174 178 176 178 144 144 183 142 186 186 142 137 208 192 192 192 188 195 195 188 198 198 195 198 202 202 199 205 205 202 207 199 208 212 212 212 208 214 212 218 218 218 214 220 212 224 224 224 212 227 227 212 231 231 231 227 231 237 237 237 237 232 237 231 244 244 244 244 231 248 248 248 244 251 251 248 253 248 248 208 257 268 260 260 257 260 263 261 268 268 268 268 268 271 271 268 275 275 275 271 277 268 279 268 279 279 287 287 287 284 284 279 287 279 268 304 304 295 295 304 295 299 299 296 304 304 304 304 304 307 307 304 304	0
28798684	295475	D019636	False	1	Differential Roles of Environmental Enrichment in Alzheimer 's Type of Neurodegeneration and Physiological Aging . Impairment of hippocampal adult neurogenesis in aging or degenerating brain is a well-known phenomenon caused by the shortage of brain stem cell pool , alterations in the local microenvironment within the neurogenic niches , or deregulation of stem cell development . Environmental enrichment ( EE ) has been proposed as a potent tool to restore brain functions , to prevent aging-associated @DiseaseTgt$ , and to cure neuronal deficits seen in neurodevelopmental and @DiseaseTgt$ . Here , we report our data on the effects of environmental enrichment on hippocampal neurogenesis in vivo and neurosphere-forming capacity of hippocampal stem/progenitor cells in vitro . Two models - Alzheimer 's type of @DiseaseTgt$ and physiological brain aging - were chosen for the comparative analysis of EE effects . We found that environmental enrichment greatly affects the expression of markers specific for stem cells , progenitor cells and differentiated neurons ( Pax6 , @GeneSrc$ , NeuroD1 , NeuN ) in the hippocampus of young adult rats or rats with Alzheimer 's disease ( AD ) model but less efficiently in aged animals . Application of time-lag mathematical model for the analysis of impedance traces obtained in real-time monitoring of cell proliferation in vitro revealed that EE could restore neurosphere-forming capacity of hippocampal stem/progenitor cells more efficiently in young adult animals ( fourfold greater in the control group comparing to the AD model group ) but not in the aged rats ( no positive effect of environmental enrichment at all ) . In accordance with the results obtained in vivo , EE was almost ineffective in the recovery of hippocampal neurogenic reserve in vitro in aged , but not in amyloid-treated or young adult , rats . Therefore , EE-based neuroprotective strategies effective in Abeta-affected brain could not be directly extrapolated to aged brain .	1 1 4 4 1 8 8 6 1 10 8 10 10 8 1 28 19 19 19 15 21 15 21 21 21 28 28 28 28 28 32 32 29 37 37 37 37 32 28 28 43 43 43 39 47 47 47 43 43 39 39 54 54 54 50 28 57 63 59 57 59 63 63 63 67 67 67 63 69 67 71 69 69 74 69 76 74 74 74 80 74 82 80 82 85 83 85 85 63 92 92 92 92 94 92 97 97 94 100 100 97 103 103 97 105 106 94 108 94 112 112 112 108 114 92 92 117 130 117 121 119 117 123 121 123 123 127 121 121 130 130 134 134 134 130 137 137 134 130 140 140 145 143 145 145 140 147 145 149 147 149 153 153 150 153 156 153 153 159 147 161 159 161 161 161 161 161 161 161 171 171 159 175 174 175 171 175 175 181 181 181 177 183 181 183 147 147 188 145 191 191 145 140 213 197 197 197 193 200 200 193 203 203 200 203 207 207 204 210 210 207 212 204 213 217 217 217 213 219 217 223 223 223 219 225 217 229 229 229 217 232 232 217 236 236 236 232 236 242 242 242 242 237 242 236 249 249 249 249 236 253 253 253 249 256 256 253 258 253 253 213 262 273 265 265 262 265 268 266 273 273 273 273 273 276 276 273 280 280 280 276 282 273 284 273 284 284 292 292 292 289 289 284 292 284 273 309 309 300 300 309 300 304 304 301 309 309 309 309 309 312 312 309 309	0
23246927	26060	D007635	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of @GeneSrc$ in AD and control brains . @GeneSrc$ accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst @GeneSrc$ granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , @GeneSrc$ also co-localized with perisomatic granules ( non-plaque @DiseaseTgt$ ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of @GeneSrc$ in the synaptic modifications in AD . Thus , the immunohistochemical distribution of @GeneSrc$ in AD brain was distinct from that in non-AD control brains , suggesting that signaling via @GeneSrc$ might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 172 172 172 172 164 134 183 183 179 179 179 183 183 183 183 183 186 186 183 189 189 186|189 189 186 193 191 193 193 193 183 183 201 201 198 203 201 207 207 207 201 209 207 183 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 243 243 243 236 245 243 222	0
23246927	759	D008569	False	2	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although @DiseaseTgt$ in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( @GeneSrc$ and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the @DiseaseTgt$ in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 95 85|95 89 89 89 85 91 89 91 95 95 103 97 95 100 100 97 103 103 103 105 103 108 108 105 112 112 112 103 103 117 117 117 121 121 121 121 121 123 121 125 123 127 123 127 127 127 121 133 133 133 136 133 138 136 141 141 133 144 144 141 146 144 146 146 146 152 152 141 133 159 156 159 159 159 133 162 162 159 162 166 166 163 171 171 171 171 163 133 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 193 191 193 193 193 182 182 201 201 198 203 201 207 207 207 201 209 207 182 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 242 242 236|242 244 242 222	0
23246927	759	D000544	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in @DiseaseTgt$ hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in @DiseaseTgt$ and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( @GeneSrc$ and subiculum ) in @DiseaseTgt$ brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the @DiseaseTgt$ hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in @DiseaseTgt$ . Thus , the immunohistochemical distribution of APPL1 in @DiseaseTgt$ brain was distinct from that in @DiseaseTgt$ control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in @DiseaseTgt$ .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 22 21|22 0 0 26 26 0 0 29 45 29 33 33 30 33 36 33 33 40 40 33 42 40 42 45 45 49 49 49 45 53 53 53 49 56 56 49 56 57 57 61 56 64 64 61 67 67 64 67 67 45 72 72 74 72 77 77 74 80 80 74 72 92 84 92 86 84|86 88 86 88 92 92 100 94 92 97 97 94 100 100 100 102 100 105 105 102 109 109 109 100 100 114 114 114 118 118 118 118 118 120 118 122 120 124 120 124 124 124 118 130 130 130 133 130 135 133 138 138 130 141 141 138 143 141 143 143 143 149 149 138 130 156 153 156 156 156 130 159 159 156 159 163 163 160 168 168 168 168 160 130 179 179 175 175 175 179 179 179 179 179 182 182 179 186 186 186 182 186 182 190 188 190 190 190 179 179 198 198 195 200 198 204 204 204 198 206 204 179 219 219 212 212 219 214 212 217 217 212 219 219 221 219 225 225 225 221 219 219 233 233 231 229 233 227 236 236 233 240 240 240 233 242 240 219	0
23246927	2891	D007635	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque @DiseaseTgt$ ) expressing @GeneSrc$ and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 172 172 172 172 164 134 183 183 179 179 179 183 183 183 183 183 186 186 183 189 189 186|189 189 186 191|192 192 192 183 183 199 199 196 201 199 205 205 205 199 207 205 183 220 220 213 213 220 215 213 218 218 213 220 220 222 220 226 226 226 222 220 220 234 234 232 230 234 228 237 237 234 241 241 241 234 243 241 220	0
23246927	26060	D003072	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of @GeneSrc$ in AD and control brains . @GeneSrc$ accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst @GeneSrc$ granules were rarely identified in control brains derived from elderly individuals with no known @DiseaseTgt$ . Interestingly , in the AD hippocampus , @GeneSrc$ also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of @GeneSrc$ in the synaptic modifications in AD . Thus , the immunohistochemical distribution of @GeneSrc$ in AD brain was distinct from that in non-AD control brains , suggesting that signaling via @GeneSrc$ might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 171 171 171 171|164 134 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 193 191 193 193 193 182 182 201 201 198 203 201 207 207 207 201 209 207 182 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 243 243 243 236 245 243 222	0
23246927	2891	D003072	False	1	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known @DiseaseTgt$ . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing @GeneSrc$ and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 171 171 171 171|164 134 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 191|192 192 192 182 182 199 199 196 201 199 205 205 205 199 207 205 182 220 220 213 213 220 215 213 218 218 213 220 220 222 220 226 226 226 222 220 220 234 234 232 230 234 228 237 237 234 241 241 241 234 243 241 220	0
23246927	2891	D008569	False	1	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although @DiseaseTgt$ in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing @GeneSrc$ and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the @DiseaseTgt$ in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 95 85|95 89 89 89 85 91 89 91 95 95 103 97 95 100 100 97 103 103 103 105 103 108 108 105 112 112 112 103 103 117 117 117 121 121 121 121 121 123 121 125 123 127 123 127 127 127 121 133 133 133 136 133 138 136 141 141 133 144 144 141 146 144 146 146 146 152 152 141 133 159 156 159 159 159 133 162 162 159 162 166 166 163 171 171 171 171 163 133 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 191|192 192 192 182 182 199 199 196 201 199 205 205 205 199 207 205 182 220 220 213 213 220 215 213 218 218 213 220 220 222 220 226 226 226 222 220 220 234 234 232 230 234 228 237 237 234 240 240 234|240 242 240 220	0
23246927	2891	D000544	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in @DiseaseTgt$ hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in @DiseaseTgt$ and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in @DiseaseTgt$ brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the @DiseaseTgt$ hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing @GeneSrc$ and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in @DiseaseTgt$ . Thus , the immunohistochemical distribution of APPL1 in @DiseaseTgt$ brain was distinct from that in @DiseaseTgt$ control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in @DiseaseTgt$ .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 22 21|22 0 0 26 26 0 0 29 45 29 33 33 30 33 36 33 33 40 40 33 42 40 42 45 45 49 49 49 45 53 53 53 49 56 56 49 56 57 57 61 56 64 64 61 67 67 64 67 67 45 72 72 74 72 77 77 74 80 80 74 72 92 84 92 86 84|86 88 86 88 92 92 100 94 92 97 97 94 100 100 100 102 100 105 105 102 109 109 109 100 100 114 114 114 118 118 118 118 118 120 118 122 120 124 120 124 124 124 118 130 130 130 133 130 135 133 138 138 130 141 141 138 143 141 143 143 143 149 149 138 130 156 153 156 156 156 130 159 159 156 159 163 163 160 168 168 168 168 160 130 179 179 175 175 175 179 179 179 179 179 182 182 179 186 186 186 182 186 182 188|189 189 189 179 179 196 196 193 198 196 202 202 202 196 204 202 179 217 217 210 210 217 212 210 215 215 210 217 217 219 217 223 223 223 219 217 217 231 231 229 227 231 225 234 234 231 238 238 238 231 240 238 217	0
23246927	759	D007635	False	1	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( @GeneSrc$ and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque @DiseaseTgt$ ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 172 172 172 172 164 134 183 183 179 179 179 183 183 183 183 183 186 186 183 189 189 186|189 189 186 193 191 193 193 193 183 183 201 201 198 203 201 207 207 207 201 209 207 183 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 243 243 243 236 245 243 222	0
23246927	26060	D008569	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although @DiseaseTgt$ in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of @GeneSrc$ in AD and control brains . @GeneSrc$ accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in AD brain , whilst @GeneSrc$ granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the AD hippocampus , @GeneSrc$ also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of @GeneSrc$ in the synaptic modifications in AD . Thus , the immunohistochemical distribution of @GeneSrc$ in AD brain was distinct from that in non-AD control brains , suggesting that signaling via @GeneSrc$ might play a critical role in the @DiseaseTgt$ in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 95 85|95 89 89 89 85 91 89 91 95 95 103 97 95 100 100 97 103 103 103 105 103 108 108 105 112 112 112 103 103 117 117 117 121 121 121 121 121 123 121 125 123 127 123 127 127 127 121 133 133 133 136 133 138 136 141 141 133 144 144 141 146 144 146 146 146 152 152 141 133 159 156 159 159 159 133 162 162 159 162 166 166 163 171 171 171 171 163 133 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 193 191 193 193 193 182 182 201 201 198 203 201 207 207 207 201 209 207 182 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 242 242 236|242 244 242 222	0
23246927	26060	D000544	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) in @DiseaseTgt$ hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( @GeneSrc$ ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in @DiseaseTgt$ ( @DiseaseTgt$ ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of @GeneSrc$ in @DiseaseTgt$ and control brains . @GeneSrc$ accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( CA1 and subiculum ) in @DiseaseTgt$ brain , whilst @GeneSrc$ granules were rarely identified in control brains derived from elderly individuals with no known cognitive impairment . Interestingly , in the @DiseaseTgt$ hippocampus , @GeneSrc$ also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of @GeneSrc$ in the synaptic modifications in @DiseaseTgt$ . Thus , the immunohistochemical distribution of @GeneSrc$ in @DiseaseTgt$ brain was distinct from that in @DiseaseTgt$ control brains , suggesting that signaling via @GeneSrc$ might play a critical role in the memory impairment in @DiseaseTgt$ .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 22 21|22 0 0 26 26 0 0 29 45 29 33 33 30 33 36 33 33 40 40 33 42 40 42 45 45 49 49 49 45 53 53 53 49 56 56 49 56 57 57 61 56 64 64 61 67 67 64 67 67 45 72 72 74 72 77 77 74 80 80 74 72 92 84 92 86 84|86 88 86 88 92 92 100 94 92 97 97 94 100 100 100 102 100 105 105 102 109 109 109 100 100 114 114 114 118 118 118 118 118 120 118 122 120 124 120 124 124 124 118 130 130 130 133 130 135 133 138 138 130 141 141 138 143 141 143 143 143 149 149 138 130 156 153 156 156 156 130 159 159 156 159 163 163 160 168 168 168 168 160 130 179 179 175 175 175 179 179 179 179 179 182 182 179 186 186 186 182 186 182 190 188 190 190 190 179 179 198 198 195 200 198 204 204 204 198 206 204 179 219 219 212 212 219 214 212 217 217 212 219 219 221 219 225 225 225 221 219 219 233 233 231 229 233 227 236 236 233 240 240 240 233 242 240 219	0
23246927	759	D003072	True	0	Characterization and distribution of adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) in Alzheimer 's disease hippocampus : an immunohistochemical study . Adaptor protein containing a PH domain , PTB domain and leucine zipper motif ( APPL1 ) is emerging as a critical regulator of various cellular processes in non-neuronal cells as well as in neurons where it localizes to dendritic spines and synapses . It regulates the development of these structures in hippocampal neurons . Although memory impairment in Alzheimer 's disease ( AD ) has been attributed to disruption of synaptic plasticity , there is scant information on this protein in the human brain . In the present study , we immunohistochemically characterized the localization of APPL1 in AD and control brains . APPL1 accumulated perisomatically as granules around neurons within vulnerable sectors of the hippocampus ( @GeneSrc$ and subiculum ) in AD brain , whilst APPL1-positive granules were rarely identified in control brains derived from elderly individuals with no known @DiseaseTgt$ . Interestingly , in the AD hippocampus , APPL1 also co-localized with perisomatic granules ( non-plaque dystrophic dendrites ) expressing glutamate receptor 2 and ubiquitin , suggesting the possible involvement of APPL1 in the synaptic modifications in AD . Thus , the immunohistochemical distribution of APPL1 in AD brain was distinct from that in non-AD control brains , suggesting that signaling via APPL1 might play a critical role in the memory impairment in AD .	0 0 0 5 5 0 5 9 9 6 9 12 9 9 16 16 9 18 16 18 24 24 21 24 0 0 28 28 0 0 31 47 31 35 35 32 35 38 35 35 42 42 35 44 42 44 47 47 51 51 51 47 55 55 55 51 58 58 51 58 59 59 63 58 66 66 63 69 69 66 69 69 47 74 74 76 74 79 79 76 82 82 76 74 96 86 96 90 90 90 86 92 90 92 96 96 104 98 96 101 101 98 104 104 104 106 104 109 109 106 113 113 113 104 104 118 118 118 122 122 122 122 122 124 122 126 124 128 124 128 128 128 122 134 134 134 137 134 139 137 142 142 134 145 145 142 147 145 147 147 147 153 153 142 134 160 157 160 160 160 134 163 163 160 163 167 167 164 171 171 171 171|164 134 182 182 178 178 178 182 182 182 182 182 185 185 182 189 189 189 185 189 185 193 191 193 193 193 182 182 201 201 198 203 201 207 207 207 201 209 207 182 222 222 215 215 222 217 215 220 220 215 222 222 224 222 228 228 228 224 222 222 236 236 234 232 236 230 239 239 236 243 243 243 236 245 243 222	0
36498925	6648	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and @GeneSrc$ ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	348	D003072	False	1	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The @GeneSrc$ status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	3553	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , @GeneSrc$ , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	2309	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( @GeneSrc$ , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	627	D003072	True	0	Gene- and Gender-Related Decrease in Serum @GeneSrc$ Levels in Alzheimer 's Disease . @GeneSrc$ ( @GeneSrc$ ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , @GeneSrc$ was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of @GeneSrc$ ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum @GeneSrc$ was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with @GeneSrc$ homozygous also had significantly lower circulating @GeneSrc$ compared with controls ( p = 0.010 ) . Moreover , lower @GeneSrc$ was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( @GeneSrc$ , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of @GeneSrc$ were found in AD ; polymorphisms of the IL-1alpha and @GeneSrc$ genes appear to be involved in changes in serum @GeneSrc$ , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 13|17 15 13 15 17 20 20 17 24 24 24 20 26 24 26 17 30 36 30 33 30 36 36 36 39 39 36 36 43 43 47 47 47 47 47 49 47 51 49 49 54 49|54 56 54 56 49 47 47 62 60 65 65 62 67 65 69 67 69 72 69 69 67 79 79 78 79 67 81 79 81 81 81 81 81 81 81 81 79 67 95 95 95 67 97 95 97 97 97 97 97 97 47 107 107 118 107 111 111 107 113 115 115 107 118 118 118 118 121 124 124 124 124 126 124 129 129 126 129 129 126 135 135 124 138 138 135 141 141 138 141 141 124 150 148 148 145 150 150 152 154 154 150 157 157 150 160 160 157 160 160 150 169 169 167 169 169 169 172 172 169 177 177 177 177 172 179 177 179 182 177 185 185 182 185 185 169 190 194 194 193 194 194 198 198 198 194 200 194 203 203 200 203 200 200 209 209 200 209 200 200 212 212 200 194 218 226 226 222 222 226 224 222 226 226 228 226 226 237 233 233 230 233 233 233 226 240 240 237 242 240 245 245 242 245 250 250 250 242 237 264 254 264 258 258 258 254 258 261 259 264 264 237 226 267 268 268 270 268 272 268 274 272 276 274 268	0
36498925	84639	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and @GeneSrc$ ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	2739	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , @GeneSrc$ , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	627	D000544	True	0	Gene- and Gender-Related Decrease in Serum @GeneSrc$ Levels in @DiseaseTgt$ . @GeneSrc$ ( @GeneSrc$ ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , @GeneSrc$ was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of @GeneSrc$ ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum @GeneSrc$ was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with @GeneSrc$ homozygous also had significantly lower circulating @GeneSrc$ compared with controls ( p = 0.010 ) . Moreover , lower @GeneSrc$ was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( @GeneSrc$ , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of @GeneSrc$ were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and @GeneSrc$ genes appear to be involved in changes in serum @GeneSrc$ , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 11|15 13 11 13 15 18 18 15 20 20|18 22 20 22 15 26 32 26 29 26 32 32 32 35 35 32 32 39 39 43 43 43 43 43 45 43 47 45 45 51 51 45 53 51 53 45 43 43 59 57 62 62 59 64 62 66 64 66 69 66 66 64 76 76 75 76 64 78 76 78 78 78 78 78 78 78 78 76 64 92 92 92 64 94 92 94 94 94 94 94 94 43 104 104 115 104 108 108 104 110 112 112 104 115 115 115 115 118 121 121 121 121 123 121 126 126 123 126 126 123 132 132 121 135 135 132 138 138 135 138 138 121 147 145 145 142 147 147 149 151 151 147 154 154 147 157 157 154 157 157 147 166 166 164 166 166 166 169 169 166 174 174 174 174 169 176 174 176 179 174 182 182 179 182 182 166 187 191 191 190 191 191 195 195 195 191 197 191 200 200 197 200 197 197 206 206 197 206 197 197 209 209 197 191 215 223 223 219 219 223 221 219 223 223 225 223 223 234 230 230 227 230 230 230 223 237 237 234 239 237 242 242 239 242 247 247 247 239 234 261 251 261 255 255 255 251 255 258 256 261 261 234 223 264 265 265 267 265 269 265 271 269 273 271 265	0
36498925	3553	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , @GeneSrc$ , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	6648	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and @GeneSrc$ ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	2309	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( @GeneSrc$ , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	3552	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( @GeneSrc$ , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of @GeneSrc$ ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; @GeneSrc$ , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the @GeneSrc$ and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	23410	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , @GeneSrc$ , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	2739	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , @GeneSrc$ , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	84639	D000544	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and @GeneSrc$ ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
36498925	23410	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , @GeneSrc$ , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	3552	D003072	True	0	Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer 's Disease . Brain-derived neurotrophic factor ( BDNF ) has a protective role in Alzheimer 's disease ( AD ) . Oxidative stress and inflammatory cytokines are potentially implicated in AD risk . In this study , BDNF was detected in serum of AD and mild @DiseaseTgt$ ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( @GeneSrc$ , IL-1beta , and IL-38 ) . The APOE status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in AD ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of @GeneSrc$ ) in AD ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; @GeneSrc$ , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in AD ; polymorphisms of the @GeneSrc$ and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to AD .	0 0 3 0 7 7 7 0 11 11 9 0 0 15 15 19 17 15 17 19 22 22 19 26 26 26 22 28 26 28 19 32 38 32 35 32 38 38 38 41 41 38 38 45 45 49 49 49 49 49 51 49 53 51 51 56 51|56 58 56 58 51 49 49 64 62 67 67 64 69 67 71 69 71 74 71 71 69 81 81 80 81 69 83 81 83 83 83 83 83 83 83 83 81 69 97 97 97 69 99 97 99 99 99 99 99 99 49 109 109 120 109 113 113 109 115 117 117 109 120 120 120 120 123 126 126 126 126 128 126 131 131 128 131 131 128 137 137 126 140 140 137 143 143 140 143 143 126 152 150 150 147 152 152 154 156 156 152 159 159 152 162 162 159 162 162 152 171 171 169 171 171 171 174 174 171 179 179 179 179 174 181 179 181 184 179 187 187 184 187 187 171 192 196 196 195 196 196 200 200 200 196 202 196 205 205 202 205 202 202 211 211 202 211 202 202 214 214 202 196 220 228 228 224 224 228 226 224 228 228 230 228 228 239 235 235 232 235 235 235 228 242 242 239 244 242 247 247 244 247 252 252 252 244 239 266 256 266 260 260 260 256 260 263 261 266 266 239 228 269 270 270 272 270 274 270 276 274 278 276 270	0
36498925	348	D000544	False	1	Gene- and Gender-Related Decrease in Serum BDNF Levels in @DiseaseTgt$ . Brain-derived neurotrophic factor ( BDNF ) has a protective role in @DiseaseTgt$ ( @DiseaseTgt$ ) . Oxidative stress and inflammatory cytokines are potentially implicated in @DiseaseTgt$ risk . In this study , BDNF was detected in serum of @DiseaseTgt$ and mild cognitive impairment ( MCI ) patients and investigated in association with gene polymorphisms of BDNF ( Val66Met and C270 T ) , of some oxidative stress-related genes ( FOXO3A , SIRT3 , GLO1 , and SOD2 ) , and of interleukin-1 family genes ( IL-1alpha , IL-1beta , and IL-38 ) . The @GeneSrc$ status and mini-mental state examination ( MMSE ) score were also evaluated . Serum BDNF was significantly lower in @DiseaseTgt$ ( p = 0.029 ) , especially when comparing the female subsets ( p = 0.005 ) . Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls ( p = 0.010 ) . Moreover , lower BDNF was associated with the presence of the T mutant allele of IL-1alpha(rs1800587 ) in @DiseaseTgt$ ( p = 0.040 ) . These results were even more significant in the female subsets ( BDNFVal/Val , p = 0.001 ; IL-1alpha , p = 0.013 ; males : ns ) . In conclusion , reduced serum levels of BDNF were found in @DiseaseTgt$ ; polymorphisms of the IL-1alpha and BDNF genes appear to be involved in changes in serum BDNF , particularly in female patients , while no effects of other gene variants affecting oxidative stress have been found . These findings add another step in identifying gender-related susceptibility to @DiseaseTgt$ .	0 0 3 0 7 7 7 0 9 0|9 0 13 13 17 15 13 15 17 20 20 17 22 20|22 24 22 24 17 28 34 28 31 28 34 34 34 37 37 34 34 41 41 45 45 45 45 45 47 45 49 47 47 53 53 47 55 53 55 47 45 45 61 59 64 64 61 66 64 68 66 68 71 68 68 66 78 78 77 78 66 80 78 80 80 80 80 80 80 80 80 78 66 94 94 94 66 96 94 96 96 96 96 96 96 45 106 106 117 106 110 110 106 112 114 114 106 117 117 117 117 120 123 123 123 123 125 123 128 128 125 128 128 125 134 134 123 137 137 134 140 140 137 140 140 123 149 147 147 144 149 149 151 153 153 149 156 156 149 159 159 156 159 159 149 168 168 166 168 168 168 171 171 168 176 176 176 176 171 178 176 178 181 176 184 184 181 184 184 168 189 193 193 192 193 193 197 197 197 193 199 193 202 202 199 202 199 199 208 208 199 208 199 199 211 211 199 193 217 225 225 221 221 225 223 221 225 225 227 225 225 236 232 232 229 232 232 232 225 239 239 236 241 239 244 244 241 244 249 249 249 241 236 263 253 263 257 257 257 253 257 260 258 263 263 236 225 266 267 267 269 267 271 267 273 271 275 273 267	0
23766857	11315	D028361	False	2	Neuroprotective function of @GeneSrc$ in Parkinson 's disease . Parkinson 's disease ( PD ) is caused by dopaminergic neuronal death in the substantia nigra , resulting in a reduced level of dopamine in the striatum . Oxidative stress and @DiseaseTgt$ are thought to be major causes of neurodegeneration in PD . Although genetic and environmental factors are thought to affect the onset of PD , precise mechanisms at the molecular level have not been elucidated . The @GeneSrc$ gene is a causative gene for familial PD ( @GeneSrc$ ) and also an oncogene . @GeneSrc$ has various functions , including transcriptional regulation , antioxidative stress reaction , and chaperone , protease , and mitochondrial regulation , and its activity is regulated by its oxidative status , especially that of cysteine 106 ( C106 ) of @GeneSrc$ . Excess oxidation of @GeneSrc$ , which renders @GeneSrc$ inactive , has been observed in patients with sporadic PD and Alzheimer 's disease , suggesting that @GeneSrc$ also participates in the onset and pathogenesis of sporadic PD as well as familial PD . @GeneSrc$ is also a stress sensor and its expression is increased upon various stresses , including oxidative stress . In this review , we describe functions of @GeneSrc$ against oxidative stress and possible roles of @GeneSrc$ in the pathogenesis of PD .	1 1 3 1 7 7 5 1 1 11 11 16 13 11 13 16 16 20 20 20 16 24 24 24 20 16 16 30 30 30 26 32 30 35 35 30 16 38 42 38 38|40 42 42 46 46 46 42 48 46 50 48 42 58 58 53 53 53 58 75 60 58 62 60 64 62 64 67 60 71 71 71 67 75 75 75 75 75 79 79 83 83 83 83 83 86 86 83 88 86 88 86 93 93 86 83 96 96 98 96 98 102 102 98 102 106 106 102 102 102 102 109 109 109 102 115 102 96 96 119 121 121 96 125 125 125 121 125 128 125 133 133 130 133 128 133 136 128 121 139 150 141 139 141 144 139 146 144 139 150 150 150 152 150 155 155 152 155 159 157 155 150 150 165 165 165 161 168 168 165 165 165 173 173 170 173 174 174 178 173 150 185 185 185 185 185 190 185 188 185 190 190 193 193 190 193 197 197 193 190 201 201 204 204 204 204 204 207 205 210 210 205 210 213 210 215 210 218 218 205 220 218 204	0
23766857	11315	D010300	True	0	Neuroprotective function of @GeneSrc$ in @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is caused by dopaminergic neuronal death in the substantia nigra , resulting in a reduced level of dopamine in the striatum . Oxidative stress and mitochondrial dysfunction are thought to be major causes of neurodegeneration in @DiseaseTgt$ . Although genetic and environmental factors are thought to affect the onset of @DiseaseTgt$ , precise mechanisms at the molecular level have not been elucidated . The @GeneSrc$ gene is a causative gene for familial @DiseaseTgt$ ( @GeneSrc$ ) and also an oncogene . @GeneSrc$ has various functions , including transcriptional regulation , antioxidative stress reaction , and chaperone , protease , and mitochondrial regulation , and its activity is regulated by its oxidative status , especially that of cysteine 106 ( C106 ) of @GeneSrc$ . Excess oxidation of @GeneSrc$ , which renders @GeneSrc$ inactive , has been observed in patients with sporadic @DiseaseTgt$ and Alzheimer 's disease , suggesting that @GeneSrc$ also participates in the onset and pathogenesis of sporadic @DiseaseTgt$ as well as familial @DiseaseTgt$ . @GeneSrc$ is also a stress sensor and its expression is increased upon various stresses , including oxidative stress . In this review , we describe functions of @GeneSrc$ against oxidative stress and possible roles of @GeneSrc$ in the pathogenesis of @DiseaseTgt$ .	1 1 3 1 5 1|5 1 7|12 9 7 9 12 12 16 16 16 12 20 20 20 16 12 12 26 26 26 22 28 26 31 31 26 12 34 39 34 37 34 39 39 43 43 43 39 45 43 47 45 39 55 55 50 50 50 55 72 57 55 59 57 61 59 61 64 57 68 68 68 64 72 72 72 72 72 76 76 80 80 80 80 80 83 83 80 85 83 85 83 90 90 83 80 93 93 95 93 95 99 99 95 99 103 103 99 99 99 99 106 106 106 99 112 99 93 93 116 118 118 93 122 122 122 118 122 125 122 130 130 127 130 125 130 133 125 118 136 147 138 136 138 141 136 143 141 136 147 147 147 149 147 152 152 149 152 156 154 152 147 147 162 162 162 158 165 165 162 162 162 170 170 167 170 171 171 175 170 147 182 182 182 182 182 187 182 185 182 187 187 190 190 187 190 194 194 190 187 198 198 201 201 201 201 201 204 202 207 207 202 207 210 207 212 207 215 215 202 217 215 201	1
23766857	11315	D000544	True	0	Neuroprotective function of @GeneSrc$ in Parkinson 's disease . Parkinson 's disease ( PD ) is caused by dopaminergic neuronal death in the substantia nigra , resulting in a reduced level of dopamine in the striatum . Oxidative stress and mitochondrial dysfunction are thought to be major causes of neurodegeneration in PD . Although genetic and environmental factors are thought to affect the onset of PD , precise mechanisms at the molecular level have not been elucidated . The @GeneSrc$ gene is a causative gene for familial PD ( @GeneSrc$ ) and also an oncogene . @GeneSrc$ has various functions , including transcriptional regulation , antioxidative stress reaction , and chaperone , protease , and mitochondrial regulation , and its activity is regulated by its oxidative status , especially that of cysteine 106 ( C106 ) of @GeneSrc$ . Excess oxidation of @GeneSrc$ , which renders @GeneSrc$ inactive , has been observed in patients with sporadic PD and @DiseaseTgt$ , suggesting that @GeneSrc$ also participates in the onset and pathogenesis of sporadic PD as well as familial PD . @GeneSrc$ is also a stress sensor and its expression is increased upon various stresses , including oxidative stress . In this review , we describe functions of @GeneSrc$ against oxidative stress and possible roles of @GeneSrc$ in the pathogenesis of PD .	1 1 3 1 7 7 5 1 1 11 11 16 13 11 13 16 16 20 20 20 16 24 24 24 20 16 16 30 30 30 26 32 30 35 35 30 16 38 43 38 41 38 43 43 47 47 47 43 49 47 51 49 43 59 59 54 54 54 59 76 61 59 63 61 65 63 65 68 61 72 72 72 68 76 76 76 76 76 80 80 84 84 84 84 84 87 87 84 89 87 89 87 94 94 87 84 97 97 99 97 99 103 103 99 103 107 107 103 103 103 103 110 110 110 103 116 103 97 97 120 122 122 97 126 126 126 122 126 129 126 134 134 131 134 129 134 137 129 122 140 151 142 140 142 145 140 147 145 140 151 151 151 153 151 156 156 153 156 156|158 151 151 164 164 164 160 167 167 164 164 164 172 172 169 172 173 173 177 172 151 184 184 184 184 184 189 184 187 184 189 189 192 192 189 192 196 196 192 189 200 200 203 203 203 203 203 206 204 209 209 204 209 212 209 214 209 217 217 204 219 217 203	0
23766857	11315	D019636	False	2	Neuroprotective function of @GeneSrc$ in Parkinson 's disease . Parkinson 's disease ( PD ) is caused by dopaminergic neuronal death in the substantia nigra , resulting in a reduced level of dopamine in the striatum . Oxidative stress and mitochondrial dysfunction are thought to be major causes of @DiseaseTgt$ in PD . Although genetic and environmental factors are thought to affect the onset of PD , precise mechanisms at the molecular level have not been elucidated . The @GeneSrc$ gene is a causative gene for familial PD ( @GeneSrc$ ) and also an oncogene . @GeneSrc$ has various functions , including transcriptional regulation , antioxidative stress reaction , and chaperone , protease , and mitochondrial regulation , and its activity is regulated by its oxidative status , especially that of cysteine 106 ( C106 ) of @GeneSrc$ . Excess oxidation of @GeneSrc$ , which renders @GeneSrc$ inactive , has been observed in patients with sporadic PD and Alzheimer 's disease , suggesting that @GeneSrc$ also participates in the onset and pathogenesis of sporadic PD as well as familial PD . @GeneSrc$ is also a stress sensor and its expression is increased upon various stresses , including oxidative stress . In this review , we describe functions of @GeneSrc$ against oxidative stress and possible roles of @GeneSrc$ in the pathogenesis of PD .	1 1 3 1 7 7 5 1 1 11 11 16 13 11 13 16 16 20 20 20 16 24 24 24 20 16 16 30 30 30 26 32 30 35 35 30 16 38 43 38 41 38 43 43 47 47 47 43 49 47 51 49 43 59 59 54 54 54 59 76 61 59 63 61 65 63 65 68 61 72 72 72 68 76 76 76 76 76 80 80 84 84 84 84 84 87 87 84 89 87 89 87 94 94 87 84 97 97 99 97 99 103 103 99 103 107 107 103 103 103 103 110 110 110 103 116 103 97 97 120 122 122 97 126 126 126 122 126 129 126 134 134 131 134 129 134 137 129 122 140 151 142 140 142 145 140 147 145 140 151 151 151 153 151 156 156 153 156 160 158 156 151 151 166 166 166 162 169 169 166 166 166 174 174 171 174 175 175 179 174 151 186 186 186 186 186 191 186 189 186 191 191 194 194 191 194 198 198 194 191 202 202 205 205 205 205 205 208 206 211 211 206 211 214 211 216 211 219 219 206 221 219 205	0
23766857	11315	D009410	False	1	Neuroprotective function of @GeneSrc$ in Parkinson 's disease . Parkinson 's disease ( PD ) is caused by dopaminergic @DiseaseTgt$ in the substantia nigra , resulting in a reduced level of dopamine in the striatum . Oxidative stress and mitochondrial dysfunction are thought to be major causes of neurodegeneration in PD . Although genetic and environmental factors are thought to affect the onset of PD , precise mechanisms at the molecular level have not been elucidated . The @GeneSrc$ gene is a causative gene for familial PD ( @GeneSrc$ ) and also an oncogene . @GeneSrc$ has various functions , including transcriptional regulation , antioxidative stress reaction , and chaperone , protease , and mitochondrial regulation , and its activity is regulated by its oxidative status , especially that of cysteine 106 ( C106 ) of @GeneSrc$ . Excess oxidation of @GeneSrc$ , which renders @GeneSrc$ inactive , has been observed in patients with sporadic PD and Alzheimer 's disease , suggesting that @GeneSrc$ also participates in the onset and pathogenesis of sporadic PD as well as familial PD . @GeneSrc$ is also a stress sensor and its expression is increased upon various stresses , including oxidative stress . In this review , we describe functions of @GeneSrc$ against oxidative stress and possible roles of @GeneSrc$ in the pathogenesis of PD .	1 1 3 1 7 7 5 1 1 11 11 16 13 11 13 16 16 19 19 19|16 23 23 23 19 16 16 29 29 29 25 31 29 34 34 29 16 37 42 37 40 37 42 42 46 46 46 42 48 46 50 48 42 58 58 53 53 53 58 75 60 58 62 60 64 62 64 67 60 71 71 71 67 75 75 75 75 75 79 79 83 83 83 83 83 86 86 83 88 86 88 86 93 93 86 83 96 96 98 96 98 102 102 98 102 106 106 102 102 102 102 109 109 109 102 115 102 96 96 119 121 121 96 125 125 125 121 125 128 125 133 133 130 133 128 133 136 128 121 139 150 141 139 141 144 139 146 144 139 150 150 150 152 150 155 155 152 155 159 157 155 150 150 165 165 165 161 168 168 165 165 165 173 173 170 173 174 174 178 173 150 185 185 185 185 185 190 185 188 185 190 190 193 193 190 193 197 197 193 190 201 201 204 204 204 204 204 207 205 210 210 205 210 213 210 215 210 218 218 205 220 218 204	0
19235789	1815	D011605	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , @DiseaseTgt$ and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1812	D006212	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , @DiseaseTgt$ , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1812	D003704	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of @DiseaseTgt$ ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1813	D006212	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , @DiseaseTgt$ , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1814	D011605	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , @DiseaseTgt$ and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1815	D000275	True	0	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with agitation/aggression and with @DiseaseTgt$ ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of @DiseaseTgt$ in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	1
19235789	1812	D011595	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with @DiseaseTgt$ and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1815	D003704	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of @DiseaseTgt$ ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1814	D000544	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in @DiseaseTgt$ . OBJECTIVE : @DiseaseTgt$ ( @DiseaseTgt$ ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in @DiseaseTgt$ has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable @DiseaseTgt$ patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in @DiseaseTgt$ patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 12 12|5 0 14 14 22|16 18 16 18 22 22 14 27 27 24 24 22 29 27 31 27 31 14 36 36 46 39 39 36 41 39 43 39 46 46 46 46 62 51 51 48 51 52 52 52 52 52 52 62 62 62 62 67 67 67 67 62 70 70 67 70 70 70 73 77 77 74 62 79 79 83 83 89 88 88 88 88 83 79 91 89 94 94 89 97 97 94 97 94 102 102 94 104 102 104 111 111 111 111 111 102 115 115 115 111 119 119 119 111 119 111 111 89 125 127 127 127 130 130 127 133 133 130 133 130 138 138 130 138 130 140 130 145 145 130 145 130 152 150 148 150 130 152 155 152 127 157 157 161 161 157 163 161 163 163 163 163 169 163 171 169 171 174 163 161 182 182 179 182 182 182 161 182 185 183 188 188 185 161 191 193 193 193 198 198 198 198 193 198 201 198 193 204 206 206 193 208 206 212 212 212 208 208 213 208 215 208 217 208 219 223 223 219 193 239 225 228 239 228 231 228 234 234 231 237 237 234 239 239 242 242 239 246 246 246 242 248 246 251 251 242 253 251 256 256 251 239 259 262 259 260 262 265 265 262 272 270 270 270 272 272 265 262	0
19235789	1814	D000275	True	0	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with agitation/aggression and with @DiseaseTgt$ ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of @DiseaseTgt$ in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1814	D003704	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of @DiseaseTgt$ ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1813	D011595	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with @DiseaseTgt$ and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1815	D011595	True	0	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with @DiseaseTgt$ and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1815	D000544	True	0	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in @DiseaseTgt$ . OBJECTIVE : @DiseaseTgt$ ( @DiseaseTgt$ ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in @DiseaseTgt$ has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable @DiseaseTgt$ patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of depression in @DiseaseTgt$ patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 12 12|5 0 14 14 22|16 18 16 18 22 22 14 27 27 24 24 22 29 27 31 27 31 14 36 36 46 39 39 36 41 39 43 39 46 46 46 46 62 51 51 48 51 52 52 52 52 52 52 62 62 62 62 67 67 67 67 62 70 70 67 70 70 70 73 77 77 74 62 79 79 83 83 89 88 88 88 88 83 79 91 89 94 94 89 97 97 94 97 94 102 102 94 104 102 104 111 111 111 111 111 102 115 115 115 111 119 119 119 111 119 111 111 89 125 127 127 127 130 130 127 133 133 130 133 130 138 138 130 138 130 140 130 145 145 130 145 130 152 150 148 150 130 152 155 152 127 157 157 161 161 157 163 161 163 163 163 163 169 163 171 169 171 174 163 161 182 182 179 182 182 182 161 182 185 183 188 188 185 161 191 193 193 193 198 198 198 198 193 198 201 198 193 204 206 206 193 208 206 212 212 212 208 208 213 208 215 208 217 208 219 223 223 219 193 239 225 228 239 228 231 228 234 234 231 237 237 234 239 239 242 242 239 246 246 246 242 248 246 251 251 242 253 251 256 256 251 239 259 262 259 260 262 265 265 262 272 270 270 270 272 272 265 262	0
19235789	1813	D000544	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in @DiseaseTgt$ . OBJECTIVE : @DiseaseTgt$ ( @DiseaseTgt$ ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in @DiseaseTgt$ has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable @DiseaseTgt$ patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in @DiseaseTgt$ patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 12 12|5 0 14 14 22|16 18 16 18 22 22 14 27 27 24 24 22 29 27 31 27 31 14 36 36 46 39 39 36 41 39 43 39 46 46 46 46 62 51 51 48 51 52 52 52 52 52 52 62 62 62 62 67 67 67 67 62 70 70 67 70 70 70 73 77 77 74 62 79 79 83 83 89 88 88 88 88 83 79 91 89 94 94 89 97 97 94 97 94 102 102 94 104 102 104 111 111 111 111 111 102 115 115 115 111 119 119 119 111 119 111 111 89 125 127 127 127 130 130 127 133 133 130 133 130 138 138 130 138 130 140 130 145 145 130 145 130 152 150 148 150 130 152 155 152 127 157 157 161 161 157 163 161 163 163 163 163 169 163 171 169 171 174 163 161 182 182 179 182 182 182 161 182 185 183 188 188 185 161 191 193 193 193 198 198 198 198 193 198 201 198 193 204 206 206 193 208 206 212 212 212 208 208 213 208 215 208 217 208 219 223 223 219 193 239 225 228 239 228 231 228 234 234 231 237 237 234 239 239 242 242 239 246 246 246 242 248 246 251 251 242 253 251 256 256 251 239 259 262 259 260 262 265 265 262 272 270 270 270 272 272 265 262	0
19235789	1815	D006212	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , DRD3 and @GeneSrc$ have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and @GeneSrc$ ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between @GeneSrc$ with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , @DiseaseTgt$ , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of @GeneSrc$ in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1812	D000275	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with @DiseaseTgt$ ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of @DiseaseTgt$ in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1813	D003704	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of @DiseaseTgt$ ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1812	D011605	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , @DiseaseTgt$ and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1813	D000275	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with @DiseaseTgt$ ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of @DiseaseTgt$ in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1814	D011595	True	0	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with @DiseaseTgt$ and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1812	D000544	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in @DiseaseTgt$ . OBJECTIVE : @DiseaseTgt$ ( @DiseaseTgt$ ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in @DiseaseTgt$ has been supported . Polymorphisms within dopamine receptors @GeneSrc$ , DRD2 , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable @DiseaseTgt$ patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the @GeneSrc$ ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in @DiseaseTgt$ patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 12 12|5 0 14 14 22|16 18 16 18 22 22 14 27 27 24 24 22 29 27 31 27 31 14 36 36 46 39 39 36 41 39 43 39 46 46 46 46 62 51 51 48 51 52 52 52 52 52 52 62 62 62 62 67 67 67 67 62 70 70 67 70 70 70 73 77 77 74 62 79 79 83 83 89 88 88 88 88 83 79 91 89 94 94 89 97 97 94 97 94 102 102 94 104 102 104 111 111 111 111 111 102 115 115 115 111 119 119 119 111 119 111 111 89 125 127 127 127 130 130 127 133 133 130 133 130 138 138 130 138 130 140 130 145 145 130 145 130 152 150 148 150 130 152 155 152 127 157 157 161 161 157 163 161 163 163 163 163 169 163 171 169 171 174 163 161 182 182 179 182 182 182 161 182 185 183 188 188 185 161 191 193 193 193 198 198 198 198 193 198 201 198 193 204 206 206 193 208 206 212 212 212 208 208 213 208 215 208 217 208 219 223 223 219 193 239 225 228 239 228 231 228 234 234 231 237 237 234 239 239 242 242 239 246 246 246 242 248 246 251 251 242 253 251 256 256 251 239 259 262 259 260 262 265 265 262 272 270 270 270 272 272 265 262	0
19235789	1814	D006212	False	1	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , DRD2 , @GeneSrc$ and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , DRD2 ( ser311cys ; C-ins/del ) , @GeneSrc$ ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between @GeneSrc$ and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , @DiseaseTgt$ , psychosis and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
19235789	1813	D011605	False	2	Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer 's disease . OBJECTIVE : Alzheimer 's disease ( AD ) patients commonly suffer from behavioural and psychological symptoms of dementia ( BPSD ) . A genetic component to the development of BPSD in AD has been supported . Polymorphisms within dopamine receptors DRD1 , @GeneSrc$ , DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort . METHODS : Our large cohort of 395 probable AD patients had longitudinal information on the BPSD ( Neuropsychiatric Inventory ) , which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period , or not . These measures were related to the DRD1 ( A-48 G ) , @GeneSrc$ ( ser311cys ; C-ins/del ) , DRD3 ( ser9gly ) and DRD4 ( VNTR ) genotype and allele frequencies . RESULTS : Associations were revealed between DRD3 and elation , and between DRD4 with agitation/aggression and with depression ; however , these findings do not remain significant after correction for multiple testing . No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions , hallucinations , @DiseaseTgt$ and aberrant motor behaviour . CONCLUSION : Our data , in combination with a review of the literature , reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients . The findings presented here need to be replicated in large , well characterised longitudinal cohorts .	0 3 3 0 5 0 7 5 7 7 7 14 14 14 5 0 16 16 20 20 26 22 20 22 26 26 16 31 31 28 28 26 33 31 35 31 35 16 40 40 50 43 43 40 45 43 47 43 50 50 50 50 66 55 55 52 55 56 56 56 56 56 56 66 66 66 66 71 71 71 71 66 74 74 71 74 74 74 77 81 81 78 66 83 83 87 87 93 92 92 92 92 87 83 95 93 98 98 93 101 101 98 101 98 106 106 98 108 106 108 115 115 115 115 115 106 119 119 119 115 123 123 123 115 123 115 115 93 129 131 131 131 134 134 131 137 137 134 137 134 142 142 134 142 134 144 134 149 149 134 149 134 156 154 152 154 134 156 159 156 131 161 161 165 165 161 167 165 167 167 167 167 173 167 175 173 175 178 167 165 186 186 183 186 186 186 165 186 189 187 192 192 189 165 195 197 197 197 202 202 202 202 197 202 205 202 197 208 210 210 197 212 210 216 216 216 212 212 217 212 219 212 221 212 223 227 227 223 197 243 229 232 243 232 235 232 238 238 235 241 241 238 243 243 246 246 243 250 250 250 246 252 250 255 255 246 257 255 260 260 255 243 263 266 263 264 266 269 269 266 276 274 274 274 276 276 269 266	0
33812000	54664	D000544	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	203228	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	1
33812000	54664	D019636	False	2	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	54664	D010300	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	23435	D019636	False	1	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 73 73 70|73 70 52 75 79 79 52 48 92 92 84 92 86 84 86 87 87 91 92 92 92 95 93 98 98 95 95 95 102 100 102 106 106 102 106 109 106 109 112 109 106 106 106 106 118 106 92 122 122 125 125 125 125 125 163 129 163 129 129 134 134 131 137 137 134 137 137 137 137 137 137 137 134 134 148 146 150 151 134 153 151 153 153 153 129 163 163 161 163 163 126 165 163 165 165 125 170 181 174 174 174 170 176 174 179 179 176 181 181 181 184 181 184 187 185 189 187 191 189 193 191 193 193 181 210 197 197 201 197 203 201 203 204 208 208 205 210 210 214 214 214 214|210 214 217 214 217 221 221 217 221 221 221 221 221 217 238 228 232 232 238 232 232 232 232 238 217 210 242 242 243 259 249 249 249 246 246 243 252 252 249 255 255 243 257 255 259 259 259 262 260 264 262 268 268 268 264 259	0
33812000	23435	D010300	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 75 75 72|75 72 54 77 81 81 54 50 94 94 86 94 88 86 88 89 89 93 94 94 94 97 95 100 100 97 97 97 104 102 104 108 108 104 108 111 108 111 114 111 108 108 108 108 120 108 94 124 124 127 127 127 127 127 165 131 165 131 131 136 136 133 139 139 136 139 139 139 139 139 139 139 136 136 150 148 152 153 136 155 153 155 155 155 131 165 165 163 165 165 128 167 165 167 167 127 172 183 176 176 176 172 178 176 181 181 178 183 183 183 186 183 186 189 187 191 189 193 191 195 193 195 195 183 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 231|240 234 234 240 234 234 234 234 240 220 212 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	23435	D000544	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 75 75 72|75 72 54 77 81 81 54 50 94 94 86 94 88 86 88 89 89 93 94 94 94 97 95 100 100 97 97 97 104 102 104 108 108 104 108 111 108 111 114 111 108 108 108 108 120 108 94 124 124 127 127 127 127 127 165 131 165 131 131 136 136 133 139 139 136 139 139 139 139 139 139 139 136 136 150 148 152 153 136 155 153 155 155 155 131 165 165 163 165 165 128 167 165 167 167 127 172 183 176 176 176 172 178 176 181 181 178 183 183 183 186 183 186 189 187 191 189 193 191 195 193 195 195 183 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217|220 223 223 220 223 223 223 223 223 220 240 230 234 234 240 234 234 234 234 240 220 212 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	2629	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	7942	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	120892	D003704	False	4	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	23400	D000690	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	4137	D019636	False	2	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	4137	D010300	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	2629	D000690	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	2896	D003704	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	7942	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	23435	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 71 71 68|71 68 50 73 77 77 50 46 90 90 82 90 84 82 84 85 85 89 90 90 90 93 91 96 96 93 93 93 100 98 100 104 104 100 104 107 104 107 110 107 104 104 104 104 116 104 90 120 120 123 123 123 123 123 161 127 161 127 127 132 132 129 135 135 132 135 135 135 135 135 135 135 132 132 146 144 148 149 132 151 149 151 151 151 127 161 161 159 161 161 124 163 161 163 163 123 168 179 172 172 172 168 174 172 177 177 174 179 179 179 182 179 182 185 183 187 185 189 187 191 189 191 191 179 208 195 195 199 195 201 199 201 202 206 206 203 208 208 213 213 213 213 208 213 216 213 216 220 220 216 220 220 220 220 220 216 237 227 231 231 237 231 231 231 231 237 216 208 241 241 242 258 248 248 248 245 245 242 251 251 248 254 254 242 256 254 258 258 258 261 259 263 261 267 267 267 263 258	1
33812000	2629	D003704	False	4	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	5663	D019636	True	0	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , @GeneSrc$ , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	5663	D010300	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , @GeneSrc$ , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	2896	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	348	D010300	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. @GeneSrc$ , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	120892	D000690	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	23400	D019636	True	0	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	203228	D016464	True	0	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	1
33812000	4137	D016464	True	0	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	1
33812000	5663	D000690	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , @GeneSrc$ , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	348	D000690	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. @GeneSrc$ , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	2629	D000544	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	7942	D000544	False	3	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	2629	D019636	True	0	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	2629	D010300	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. @GeneSrc$ , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	4137	D003704	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	54664	D003704	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	203228	D000544	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	120892	D019636	True	0	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	54664	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	120892	D010300	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	203228	D019636	False	1	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	203228	D010300	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	2896	D019636	False	2	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	2896	D010300	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	4137	D000544	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	2896	D000544	False	2	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	5663	D003704	False	4	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , @GeneSrc$ , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	348	D003704	False	4	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. @GeneSrc$ , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	5663	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , @GeneSrc$ , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	23400	D000544	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	7942	D019636	False	2	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	7942	D010300	False	3	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	348	D000544	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. @GeneSrc$ , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	23435	D003704	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 75 75 72|75 72 54 77 81 81 54 50 94 94 86 94 88 86 88 89 89 93 94 94 94 97 95 100 100 97 97 97 104 102 104 108 108 104 108 111 108 111 114 111 108 108 108 108 120 108 94 124 124 127 127 127 127 127 165 131 165 131 131 136 136 133 139 139 136 139 139 139 139 139 139 139 136 136 150 148 152 153 136 155 153 155 155 155 131 165 165 163 165 165 128 167 165 167 167 127 172 183 176 176 176 172 178 176 181 181 178 183 183 183 186 183 186 189 187 191 189 193 191 195 193 195 195 183 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	1
33812000	120892	D000544	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	23435	D016464	True	0	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. @GeneSrc$ ; @GeneSrc$ ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of @GeneSrc$ or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 74 74 71|74 71 53 76 80 80 53 49 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 163 129|163 129 129 134 134 131 137 137 134 137 137 137 137 137 137 137 134 134 148 146 150 151 134 153 151 153 153 153 129 163 163 161 163 163 127 165 163 165 165 126 170 181 174 174 174 170 176 174 179 179 176 181 181 181 184 181 184 187 185 189 187 189|190 192 190 192 192 181 209 196 196 200 196 202 200 202 203 207 207 204 209 209 214 214 214 214 209 214 217 214 217 221 221 217 221 221 221 221 221 217 238 228 232 232 238 232 232 232 232 238 217 209 242 242 243 259 249 249 249 246 246 243 252 252 249 255 255 243 257 255 259 259 259 262 260 264 262 268 268 268 264 259	1
33812000	54664	D016464	True	0	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , @GeneSrc$ ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	1
33812000	23400	D003704	False	4	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	23400	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	2896	D016464	True	0	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , @GeneSrc$ , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	1
33812000	7942	D003704	False	1	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or @GeneSrc$ activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	0
33812000	4137	D000690	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and @DiseaseTgt$ . Frontotemporal dementia ( FTD ) and @DiseaseTgt$ ( @DiseaseTgt$ ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and @DiseaseTgt$ are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or @DiseaseTgt$ when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , @GeneSrc$ , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or @GeneSrc$ ) , is an important pathogenic disease mechanism in FTD and @DiseaseTgt$ . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and @DiseaseTgt$ . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 12|14 1 17 29 19 17 19 17 17|22 24 22 24 29 29 29 29 32 32 29 34 32 40 40 40 37 37 34 29 46 42 42 46 46 50 50 50 46 56 56 56 56 56 50 56 50 50 59 63 61 50 68 68 65 65 63 73 73 73 73 68 73 68 50 76 80 80 50 46 93 93 85 93 87 85 87 88 88 92 93 93 93 96 94 99 99 96 96 96 103 101 103 107 107 103 107 110 107 110 113 110 107 107 107 107 119 107 93 123 123 126 126 126 126 126 164 130 164 130 130 135 135 132 138 138 135 138 138 138 138 138 138 138 135 135 149 147 151 152 135 154 152 154 154 154 130 164 164 162 164 164 127 166 164 166 166 126 171 182 175 175 175 171 177 175 180 180 177 182 182 182 185 182 185 188 186 190 188 192 190 194 192 194 194 182 211 198 198 202 198 204 202 204 205 209 209 206 211 211 216 216 216 216 211 216 219 216 219 223 223 219 223 223 223 223 223 219 240 230 234 234 240 234 234 234 234 240 219 211 244 244 245 261 251 251 251 248 248 245 254 254 251 257 257 245 259 257 261 261 261 264 262 266 264 270 270 270 266 261	0
33812000	348	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. @GeneSrc$ , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	5663	D000544	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including @DiseaseTgt$ ( e.g. APOE , @GeneSrc$ , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220|223 226 226 223 226 226 226 226 226 223 243 233 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
33812000	348	D019636	True	0	Lysosome dysfunction as a cause of @DiseaseTgt$ : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal @DiseaseTgt$ that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent @DiseaseTgt$ , including Alzheimer 's ( e.g. @GeneSrc$ , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of @DiseaseTgt$ will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 6 4|6 1 1 11 11 8 11 15 15 11 1 18 31 20 18 20 18 25 25 18 27 25 27 31 31 31 34 34 31 36 34 42 42 42 39 39 36 31 48 44 44 48 48 52 52 52 48 58 58 58 58 58 52 58 52 52 61 65 63 52 70 70 67 67 65 75 75 75 75 70 75 70 52 78 82 82 52 48 95 95 87 95 89 87 89 90 90 94 95 95 95 98 96 101 101 98 98 98 105 103 105 109 109 105 109 112 109 112 115 112 109 109 109 109 121 109 95 125 125 128 128 128 128 128 166 132 166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 129 168 166 168 168 128 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 194 192 196 194 196 196 184 213 200 200 204 200 206 204 206 207 211 211 208 213 213 217 217 217 217|213 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 213 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	203228	D003704	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal @DiseaseTgt$ and amyotrophic lateral sclerosis . Frontotemporal @DiseaseTgt$ ( @DiseaseTgt$ ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . @DiseaseTgt$ and ALS are linked by shared genetic causes ( e.g. @GeneSrc$ hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. @GeneSrc$ , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , LRRK2 , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 244 234 238 238 244 238 238 238 238 244 223 215 248 248 249 265 255 255 255 252 252 249 258 258 255 261 261 249 263 261 265 265 265 268 266 270 268 274 274 274 270 265	1
33812000	120892	D016464	False	1	@DiseaseTgt$ as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that @DiseaseTgt$ , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause @DiseaseTgt$ in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and Parkinson 's ( e.g. GBA , @GeneSrc$ , ATP13A2 ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	0 3 3 0 6 6 3 0 0 11 11 8 11 15 15 11 0 18 32 20 18 20 18 25 25 18 27 25 27 32 32 32 32 35 35 32 37 35 43 43 43 40 40 37 32 49 45 45 49 49 53 53 53 49 59 59 59 59 59 53 59 53 53 62 66 64 53 71 71 68 68 66 76 76 76 76 71 76 71 53 79 83 83 53 49 96 96 88 96 90 88 90 91 91 95 96 96 96 99 97 102 102 99 99 99 106 104 106 110 110 106 110 113 110 113 116 113 110 110 110 110 122 110 96 126 126 129 129 129 129 129 166 132|166 132 132 137 137 134 140 140 137 140 140 140 140 140 140 140 137 137 151 149 153 154 137 156 154 156 156 156 132 166 166 164 166 166 130 168 166 168 168 129 173 184 177 177 177 173 179 177 182 182 179 184 184 184 187 184 187 190 188 192 190 192|193 195 193 195 195 184 212 199 199 203 199 205 203 205 206 210 210 207 212 212 217 217 217 217 212 217 220 217 220 224 224 220 224 224 224 224 224 220 241 231 235 235 241 235 235 235 235 241 220 212 245 245 246 262 252 252 252 249 249 246 255 255 252 258 258 246 260 258 262 262 262 265 263 267 265 271 271 271 267 262	0
33812000	23400	D010300	True	0	Lysosome dysfunction as a cause of neurodegenerative diseases : Lessons from frontotemporal dementia and amyotrophic lateral sclerosis . Frontotemporal dementia ( FTD ) and amyotrophic lateral sclerosis ( ALS ) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum . FTD and ALS are linked by shared genetic causes ( e.g. C9orf72 hexanucleotide repeat expansions ) and neuropathology , such as inclusions of ubiquitinated , misfolded proteins ( e.g. TAR DNA-binding protein 43 ; TDP-43 ) in the CNS . Furthermore , some genes that cause FTD or ALS when mutated encode proteins that localize to the lysosome or modulate endosome-lysosome function , including lysosomal fusion , cargo trafficking , lysosomal acidification , autophagy , or TFEB activity . In this review , we summarize evidence that lysosomal dysfunction , caused by genetic mutations ( e.g. C9orf72 , GRN , MAPT , TMEM106B ) or toxic-gain of function ( e.g. aggregation of TDP-43 or tau ) , is an important pathogenic disease mechanism in FTD and ALS . Further studies into the normal function of many of these proteins are required and will help uncover the mechanisms that cause lysosomal dysfunction in FTD and ALS . Mutations or polymorphisms in genes that encode proteins important for endosome-lysosome function also occur in other age-dependent neurodegenerative diseases , including Alzheimer 's ( e.g. APOE , PSEN1 , APP ) and @DiseaseTgt$ ( e.g. GBA , LRRK2 , @GeneSrc$ ) disease . A more complete understanding of the common and unique features of lysosome dysfunction across the spectrum of neurodegeneration will help guide the development of therapies for these devastating diseases .	1 1 4 4 1 7 7 4 1 1 12 12 9 12 16 16 12 1 19 33 21 19 21 19 26 26 19 28 26 28 33 33 33 33 36 36 33 38 36 44 44 44 41 41 38 33 50 46 46 50 50 54 54 54 50 60 60 60 60 60 54 60 54 54 63 67 65 54 72 72 69 69 67 77 77 77 77 72 77 72 54 80 84 84 54 50 97 97 89 97 91 89 91 92 92 96 97 97 97 100 98 103 103 100 100 100 107 105 107 111 111 107 111 114 111 114 117 114 111 111 111 111 123 111 97 127 127 130 130 130 130 130 168 134 168 134 134 139 139 136 142 142 139 142 142 142 142 142 142 142 139 139 153 151 155 156 139 158 156 158 158 158 134 168 168 166 168 168 131 170 168 170 170 130 175 186 179 179 179 175 181 179 184 184 181 186 186 186 189 186 189 192 190 194 192 196 194 198 196 198 198 186 215 202 202 206 202 208 206 208 209 213 213 210 215 215 220 220 220 220 215 220 223 220 223 227 227 223 227 227 227 227 227 223 234|243 237 237 243 237 237 237 237 243 223 215 247 247 248 264 254 254 254 251 251 248 257 257 254 260 260 248 262 260 264 264 264 267 265 269 267 273 273 273 269 264	0
19943343	6622	D009127	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , @DiseaseTgt$ , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D009127	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , @DiseaseTgt$ , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	11315	D013575	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and @DiseaseTgt$ , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 51 34 38 38 35 40 38 40 40 42 42 42 42 47|42 51 51 51 51 54 54 51 56 54 59 59 54 51 64 64 64 73 73 68 68 73 70 68 73 73 73 73 80 78 78 75 80 80 83 83 80 85 83 85 85 85 85 85 85 93 85 95 85 95 95 95 95 95 95 95 95 80 106 108 108 108 112 112 112 108 114 112 117 117 114 117 120 117 124 124 124 120 108	0
19943343	65018	D018476	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of @DiseaseTgt$ , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	23400	D018476	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of @DiseaseTgt$ , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	65018	D009069	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive @DiseaseTgt$ typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 33 33 33|53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	120892	D013575	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and @DiseaseTgt$ , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 51 34 38 38 35 40 38 40 40 42 42 42 42 47|42 51 51 51 51 54 54 51 56 54 59 59 54 51 64 64 64 73 73 68 68 73 70 68 73 73 73 73 80 78 78 75 80 80 83 83 80 85 83 85 85 85 85 85 85 93 85 95 85 95 95 95 95 95 95 95 95 80 106 108 108 108 112 112 112 108 114 112 117 117 114 117 120 117 124 124 124 120 108	0
19943343	65018	D010300	True	0	From genes to proteins in mendelian @DiseaseTgt$ : an overview . @DiseaseTgt$ ( @DiseaseTgt$ ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , @DiseaseTgt$ is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of @DiseaseTgt$ have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive @DiseaseTgt$ ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian @DiseaseTgt$ and the function of their encoded proteins .	1 1 3 1 6 6 3|6 3 9 3 1 11|21 13 11 13 21 21 19 19 20 21 21 25 25 25 21 21 30 30 30 50 30 34 34 31 36 34 36 36 38 38 38 38 38 46 46 43 50 50 50 50 53 53 50 55 53 58 58 53 50 63 63 63 72 72 67 67 72 69 67 72 72 72 72 79 77 77 74 79 79 82 82 79 84 82 84 84 84 84 84 84 92 84 94 84 94 94 94 94 94 94 94 94 79 105 107 107 107 111 111 111 107 113 111 116 116 113 116 119 116 123 123 123 119 107	1
19943343	65018	D019636	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common @DiseaseTgt$ after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 24 17 15 17 24 24 23 23 24 24 28 28 28 24 24 33 33 33 53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	6622	D013575	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and @DiseaseTgt$ , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 51 34 38 38 35 40 38 40 40 42 42 42 42 47|42 51 51 51 51 54 54 51 56 54 59 59 54 51 64 64 64 73 73 68 68 73 70 68 73 73 73 73 80 78 78 75 80 80 83 83 80 85 83 85 85 85 85 85 85 93 85 95 85 95 95 95 95 95 95 95 95 80 106 108 108 108 112 112 112 108 114 112 117 117 114 117 120 117 124 124 124 120 108	0
19943343	23400	D019636	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common @DiseaseTgt$ after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 24 17 15 17 24 24 23 23 24 24 28 28 28 24 24 33 33 33 53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	65018	D009127	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , @DiseaseTgt$ , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D014202	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , @DiseaseTgt$ , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	6622	D009069	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive @DiseaseTgt$ typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 33 33 33|53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	120892	D018476	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of @DiseaseTgt$ , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	11315	D010300	True	0	From genes to proteins in mendelian @DiseaseTgt$ : an overview . @DiseaseTgt$ ( @DiseaseTgt$ ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , @DiseaseTgt$ is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of @DiseaseTgt$ have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive @DiseaseTgt$ ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian @DiseaseTgt$ and the function of their encoded proteins .	1 1 3 1 6 6 3|6 3 9 3 1 11|21 13 11 13 21 21 19 19 20 21 21 25 25 25 21 21 30 30 30 50 30 34 34 31 36 34 36 36 38 38 38 38 38 46 46 43 50 50 50 50 53 53 50 55 53 58 58 53 50 63 63 63 72 72 67 67 72 69 67 72 72 72 72 79 77 77 74 79 79 82 82 79 84 82 84 84 84 84 84 84 92 84 94 84 94 94 94 94 94 94 94 94 79 105 107 107 107 111 111 111 107 113 111 116 116 113 116 119 116 123 123 123 119 107	1
19943343	11315	D019636	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common @DiseaseTgt$ after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 24 17 15 17 24 24 23 23 24 24 28 28 28 24 24 33 33 33 53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	6622	D018476	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of @DiseaseTgt$ , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D009069	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive @DiseaseTgt$ typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 33 33 33|53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	11315	D014202	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , @DiseaseTgt$ , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	11315	D018476	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of @DiseaseTgt$ , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	65018	D013575	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and @DiseaseTgt$ , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 51 34 38 38 35 40 38 40 40 42 42 42 42 47|42 51 51 51 51 54 54 51 56 54 59 59 54 51 64 64 64 73 73 68 68 73 70 68 73 73 73 73 80 78 78 75 80 80 83 83 80 85 83 85 85 85 85 85 85 93 85 95 85 95 95 95 95 95 95 95 95 80 106 108 108 108 112 112 112 108 114 112 117 117 114 117 120 117 124 124 124 120 108	0
19943343	23400	D014202	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , @DiseaseTgt$ , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D010300	True	0	From genes to proteins in mendelian @DiseaseTgt$ : an overview . @DiseaseTgt$ ( @DiseaseTgt$ ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , @DiseaseTgt$ is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of @DiseaseTgt$ have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive @DiseaseTgt$ ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian @DiseaseTgt$ and the function of their encoded proteins .	1 1 3 1 6 6 3|6 3 9 3 1 11|21 13 11 13 21 21 19 19 20 21 21 25 25 25 21 21 30 30 30 50 30 34 34 31 36 34 36 36 38 38 38 38 38 46 46 43 50 50 50 50 53 53 50 55 53 58 58 53 50 63 63 63 72 72 67 67 72 69 67 72 72 72 72 79 77 77 74 79 79 82 82 79 84 82 84 84 84 84 84 84 92 84 94 84 94 94 94 94 94 94 94 94 79 105 107 107 107 111 111 111 107 113 111 116 116 113 116 119 116 123 123 123 119 107	1
19943343	6622	D014202	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , @DiseaseTgt$ , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D019636	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common @DiseaseTgt$ after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 24 17 15 17 24 24 23 23 24 24 28 28 28 24 24 33 33 33 53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	11315	D009069	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive @DiseaseTgt$ typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 33 33 33|53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	65018	D000544	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after @DiseaseTgt$ . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 27 25|27 25 32 32 32 52 32 36 36 33 38 36 38 38 40 40 40 40 40 48 48 45 52 52 52 52 55 55 52 57 55 60 60 55 52 65 65 65 74 74 69 69 74 71 69 74 74 74 74 81 79 79 76 81 81 84 84 81 86 84 86 86 86 86 86 86 94 86 96 86 96 96 96 96 96 96 96 96 81 107 109 109 109 113 113 113 109 115 113 118 118 115 118 121 118 125 125 125 121 109	0
19943343	6622	D010300	True	0	From genes to proteins in mendelian @DiseaseTgt$ : an overview . @DiseaseTgt$ ( @DiseaseTgt$ ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , @DiseaseTgt$ is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of @DiseaseTgt$ have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive @DiseaseTgt$ ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian @DiseaseTgt$ and the function of their encoded proteins .	1 1 3 1 6 6 3|6 3 9 3 1 11|21 13 11 13 21 21 19 19 20 21 21 25 25 25 21 21 30 30 30 50 30 34 34 31 36 34 36 36 38 38 38 38 38 46 46 43 50 50 50 50 53 53 50 55 53 58 58 53 50 63 63 63 72 72 67 67 72 69 67 72 72 72 72 79 77 77 74 79 79 82 82 79 84 82 84 84 84 84 84 84 92 84 94 84 94 94 94 94 94 94 94 94 79 105 107 107 107 111 111 111 107 113 111 116 116 113 116 119 116 123 123 123 119 107	1
19943343	6622	D019636	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common @DiseaseTgt$ after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 24 17 15 17 24 24 23 23 24 24 28 28 28 24 24 33 33 33 53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	6622	D000544	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after @DiseaseTgt$ . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( @GeneSrc$ and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 27 25|27 25 32 32 32 52 32 36 36 33 38 36 38 38 40 40 40 40 40 48 48 45 52 52 52 52 55 55 52 57 55 60 60 55 52 65 65 65 74 74 69 69 74 71 69 74 74 74 74 81 79 79 76 81 81 84 84 81 86 84 86 86 86 86 86 86 94 86 96 86 96 96 96 96 96 96 96 96 81 107 109 109 109 113 113 113 109 115 113 118 118 115 118 121 118 125 125 125 121 109	0
19943343	65018	D014202	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , @DiseaseTgt$ , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , @GeneSrc$ , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	23400	D000544	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after @DiseaseTgt$ . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 27 25|27 25 32 32 32 52 32 36 36 33 38 36 38 38 40 40 40 40 40 48 48 45 52 52 52 52 55 55 52 57 55 60 60 55 52 65 65 65 74 74 69 69 74 71 69 74 74 74 74 81 79 79 76 81 81 84 84 81 86 84 86 86 86 86 86 86 94 86 96 86 96 96 96 96 96 96 96 96 81 107 109 109 109 113 113 113 109 115 113 118 118 115 118 121 118 125 125 125 121 109	0
19943343	23400	D013575	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and @DiseaseTgt$ , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 51 34 38 38 35 40 38 40 40 42 42 42 42 47|42 51 51 51 51 54 54 51 56 54 59 59 54 51 64 64 64 73 73 68 68 73 70 68 73 73 73 73 80 78 78 75 80 80 83 83 80 85 83 85 85 85 85 85 85 93 85 95 85 95 95 95 95 95 95 95 95 80 106 108 108 108 112 112 112 108 114 112 117 117 114 117 120 117 124 124 124 120 108	0
19943343	23400	D009127	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , @DiseaseTgt$ , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	120892	D000544	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after @DiseaseTgt$ . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and @GeneSrc$ ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 27 25|27 25 32 32 32 52 32 36 36 33 38 36 38 38 40 40 40 40 40 48 48 45 52 52 52 52 55 55 52 57 55 60 60 55 52 65 65 65 74 74 69 69 74 71 69 74 74 74 74 81 79 79 76 81 81 84 84 81 86 84 86 86 86 86 86 86 94 86 96 86 96 96 96 96 96 96 96 96 81 107 109 109 109 113 113 113 109 115 113 118 118 115 118 121 118 125 125 125 121 109	0
19943343	11315	D000544	False	3	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after @DiseaseTgt$ . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 27 25|27 25 32 32 32 52 32 36 36 33 38 36 38 38 40 40 40 40 40 48 48 45 52 52 52 52 55 55 52 57 55 60 60 55 52 65 65 65 74 74 69 69 74 71 69 74 74 74 74 81 79 79 76 81 81 84 84 81 86 84 86 86 86 86 86 86 94 86 96 86 96 96 96 96 96 96 96 96 81 107 109 109 109 113 113 113 109 115 113 118 118 115 118 121 118 125 125 125 121 109	0
19943343	23400	D009069	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive @DiseaseTgt$ typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 33 33 33|53 33 37 37 34 39 37 39 39 41 41 41 41 41 49 49 46 53 53 53 53 56 56 53 58 56 61 61 56 53 66 66 66 75 75 70 70 75 72 70 75 75 75 75 82 80 80 77 82 82 85 85 82 87 85 87 87 87 87 87 87 95 87 97 87 97 97 97 97 97 97 97 97 82 108 110 110 110 114 114 114 110 116 114 119 119 116 119 122 119 126 126 126 122 110	0
19943343	11315	D009127	False	2	From genes to proteins in mendelian Parkinson 's disease : an overview . Parkinson 's disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , @DiseaseTgt$ , and impairment of postural reflexes , PD is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of PD have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive PD ( Parkin , PINK1 , @GeneSrc$ , and ATP13A2 ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian PD and the function of their encoded proteins .	1 1 3 1 8 8 8 6 3 3 11 3 1 15 15 25 17 15 17 25 25 23 23 24 25 25 29 29 29 25 25 34 34 34 54 34 38 38 35 40 38 40 40 42 42 42 42 42 50 50 47 54 54 54 54 57 57 54 59 57 62 62 57 54 67 67 67 76 76 71 71 76 73 71 76 76 76 76 83 81 81 78 83 83 86 86 83 88 86 88 88 88 88 88 88 96 88 98 88 98 98 98 98 98 98 98 98 83 109 111 111 111 115 115 115 111 117 115 120 120 117 120 123 120 127 127 127 123 111	0
19943343	23400	D010300	True	0	From genes to proteins in mendelian @DiseaseTgt$ : an overview . @DiseaseTgt$ ( @DiseaseTgt$ ) is the second most common neurodegenerative disorder after Alzheimer 's disease . A progressive movement disorder typified by the production of bradykinesia , tremor , rigidity , and impairment of postural reflexes , @DiseaseTgt$ is characterized by a depletion of dopamine in the striatum . For the last decade , several Mendelian forms of @DiseaseTgt$ have been identified . Mutations in these genes potentially lead to autosomal dominant ( alpha-synuclein and LRRK2 ) , or autosomal recessive @DiseaseTgt$ ( Parkin , PINK1 , DJ1 , and @GeneSrc$ ) . This article will spotlight these six distinct genes unambiguously associated with Mendelian @DiseaseTgt$ and the function of their encoded proteins .	1 1 3 1 6 6 3|6 3 9 3 1 11|21 13 11 13 21 21 19 19 20 21 21 25 25 25 21 21 30 30 30 50 30 34 34 31 36 34 36 36 38 38 38 38 38 46 46 43 50 50 50 50 53 53 50 55 53 58 58 53 50 63 63 63 72 72 67 67 72 69 67 72 72 72 72 79 77 77 74 79 79 82 82 79 84 82 84 84 84 84 84 84 92 84 94 84 94 94 94 94 94 94 94 94 79 105 107 107 107 111 111 111 107 113 111 116 116 113 116 119 116 123 123 123 119 107	1
17593875	20655	D009461	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 109 109 106|109 109 109 109 109 109 101 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	20656	D000690	False	3	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	6647	D000690	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20617	D000690	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	17708	D010300	False	3	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 248 241 241 241|244 241 241 248 248 253 253 253 253 248 248 260 259 259 259 255 260 262 260 262 265 267 267 262 262 262 272 272 274 274 260 276 274 279 279 276 260 282 283 283 283 287 287 283 283 290 291 291 303 295 295 303 295 295 300 300 297 303 303 291 307 307 307 303 310 310 303 312 310 312 312 291	0
17593875	17708	D019636	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 252 245 245 245|248 245 245 252 252 257 257 257 257 252 252 264 263 263 263 259 264 266 264 266 269 271 271 266 266 266 276 276 278 278 264 280 278 283 283 280 264 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	23336	D064420	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6622	D064420	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	23336	D020271	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	18126	D000079225	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 271|273 273 269 269 269 278 278 280 280 267 282 280 285 285 282 267 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	6622	D000690	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	6622	D020271	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	16473	D010300	False	6	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	16473	D019636	False	5	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	16473	D000079225	False	6	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20656	D010300	False	3	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20656	D019636	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20656	D000079225	False	3	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	18126	D010300	False	2	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 267|269 269 265 265 265 274 274 276 276 263 278 276 281 281 278 263 284 285 285 285 289 289 285 285 292 293 293 305 297 297 305 297 297 302 302 299 305 305 293 309 309 309 305 312 312 305 314 312 314 314 293	0
17593875	18126	D019636	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 271|273 273 269 269 269 278 278 280 280 267 282 280 285 285 282 267 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	6622	D028361	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	17708	D000079225	False	3	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 252 245 245 245|248 245 245 252 252 257 257 257 257 252 252 264 263 263 263 259 264 266 264 266 269 271 271 266 266 266 276 276 278 278 264 280 278 283 283 280 264 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	6622	D009461	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20656	D020271	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	23336	D009461	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	6647	D020271	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	17708	D009461	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 251 244 244 244|247 244 244 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20656	D064420	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6647	D064420	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	23336	D010243	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	23336	D010300	False	2	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	23336	D019636	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20655	D000690	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 68 64 64 64 64 59|64 66 64 66 68 68 68 72 84 76 76 76 72 76 76 76 81 79 84 84 84 84 90 88 86 88 97 90 94 94 91 94 94 97 101 101 101 97 101 106 106 106 102 106 106 106 106 106 97 115 115 117 117 125 117 117 117 125 125 125 125 126 126 129 129 126 126 150 150 142 135 142 139 139 139 135 142 142 150 142 146 146 150 148 146 148 150 152 150 150 157 157 157 169 157 160 157 162 160 157 157 167 167 169 169 169 169 176 176 176 175 173 176 178 176 176 176 182 180 186 186 186 182 176 189 190 190 193 193 190 197 197 197 190 190 201 201 202 202 202 207 207 207 203 202 202 211 209 215 215 215 211 217 215 220 220 209 202 224 224 225 225 228 226 225 228 232 232 229 232 238 238 235 235 233 225 250 240 240 246 246 246 240 240 240 250 250 255 255 255 255 250 250 262 261 261 261 257 262 264 262 264 267 269 269 264 264 264 274 274 276 276 262 278 276 281 281 278 262 284 285 285 285 289 289 285 285 292 293 293 305 297 297 305 297 297 302 302 299 305 305 293 309 309 309 305 312 312 305 314 312 314 314 293	1
17593875	6622	D010243	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6622	D000079225	False	11	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20656	D009461	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	18126	D009461	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 270|272 272 268 268 268 277 277 279 279 266 281 279 284 284 281 266 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	17708	D020271	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 250 243 243 243|246 243 243 250 250 255 255 255 255 250 250 262 261 261 261 257 262 264 262 264 267 269 269 264 264 264 274 274 276 276 262 278 276 281 281 278 262 284 285 285 285 289 289 285 285 292 293 293 305 297 297 305 297 297 302 302 299 305 305 293 309 309 309 305 312 312 305 314 312 314 314 293	0
17593875	6647	D009461	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	23336	D000079225	False	12	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	16473	D009461	False	5	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	17708	D064420	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 252 245 245 245|248 245 245 252 252 257 257 257 257 252 252 264 263 263 263 259 264 266 264 266 269 271 271 266 266 266 276 276 278 278 264 280 278 283 283 280 264 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	17708	D000690	False	3	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 248 241 241 241|244 241 241 248 248 253 253 253 253 248 248 260 259 259 259 255 260 262 260 262 265 267 267 262 262 262 272 272 274 274 260 276 274 279 279 276 260 282 283 283 283 287 287 283 283 290 291 291 303 295 295 303 295 295 300 300 297 303 303 291 307 307 307 303 310 310 303 312 310 312 312 291	0
17593875	23336	D028361	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	16473	D064420	False	6	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	18126	D020271	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 269|271 271 267 267 267 276 276 278 278 265 280 278 283 283 280 265 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	16473	D020271	False	5	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	20655	D028361	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 110 110 110 106 110 110 110 110 110 101 119 119 121 121 129 121 121 121 129 129 129 129 130 130 132 130|132 130 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	6622	D010300	False	3	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	6622	D019636	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant @GeneSrc$ or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	18126	D064420	False	10	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 271|273 273 269 269 269 278 278 280 280 267 282 280 285 285 282 267 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20656	D010243	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20655	D000079225	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 110 110 110 106 110 110 110 110 110 101 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	6647	D010243	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	16473	D028361	False	4	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20617	D000079225	False	10	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20617	D010243	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	20617	D010300	True	0	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	1
17593875	20617	D019636	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	18126	D028361	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 270|272 272 268 268 268 277 277 279 279 266 281 279 284 284 281 266 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	20655	D010243	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 110 110 110 106 110 110 110 110 110 101 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20656	D028361	False	7	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated @GeneSrc$ accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	17708	D010243	False	8	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 252 245 245 245|248 245 245 252 252 257 257 257 257 252 252 264 263 263 263 259 264 266 264 266 269 271 271 266 266 266 276 276 278 278 264 280 278 283 283 280 264 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	6647	D000079225	False	11	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative @DiseaseTgt$ and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6647	D019636	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6647	D028361	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	16473	D010243	False	5	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	18126	D000690	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 267|269 269 265 265 265 274 274 276 276 263 278 276 281 281 278 263 284 285 285 285 289 289 285 285 292 293 293 305 297 297 305 297 297 302 302 299 305 305 293 309 309 309 305 312 312 305 314 312 314 314 293	0
17593875	20617	D028361	True	0	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	18126	D010243	False	9	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , @DiseaseTgt$ , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and @GeneSrc$ @GeneSrc$ immunoreactivity , and @GeneSrc$ gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 271|273 273 269 269 269 278 278 280 280 267 282 280 285 285 282 267 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	16473	D000690	False	6	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated @GeneSrc$ accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	17708	D028361	False	7	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent @DiseaseTgt$ . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated @GeneSrc$ and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 133 131|133 131 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 251 244 244 244|247 244 244 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20617	D020271	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 104 102|104 104 109 109 109 105 109 109 109 109 109 102 118 118 120 120 128 120 120 120 128 128 128 128 129 129 132 132 129 129 153 153 145 138 145 142 142 142 138 145 145 153 145 149 149 153 151 149 151 153 155 153 153 160 160 160 172 160 163 160 165 163 160 160 170 170 172 172 172 172 179 179 179 178 176 179 181 179 179 179 185 183 189 189 189 185 179 192 193 193 196 196 193 200 200 200 193 193 204 204 205 205 205 210 210 210 206 205 205 214 212 218 218 218 214 220 218 223 223 212 205 227 227 228 228 231 229 228 231 235 235 232 235 241 241 238 238 236 228 253 243 243 249 249 249 243 243 243 253 253 258 258 258 258 253 253 265 264 264 264 260 265 267 265 267 270 272 272 267 267 267 277 277 279 279 265 281 279 284 284 281 265 287 288 288 288 292 292 288 288 295 296 296 308 300 300 308 300 300 305 305 302 308 308 296 312 312 312 308 315 315 308 317 315 317 317 296	0
17593875	23336	D000690	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and @DiseaseTgt$ provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or @DiseaseTgt$ ( @DiseaseTgt$ ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause @DiseaseTgt$ . The mechanisms of human mutant @GeneSrc$ and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and @DiseaseTgt$ .	1 12 5 5 5 1 1 9 7 6 9 9|11 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 37 37 37 33 39 37 39 37 42|37 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20655	D010300	False	1	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 68 64 64 64 64 59|64 66 64 66 68 68 68 72 84 76 76 76 72 76 76 76 81 79 84 84 84 84 90 88 86 88 97 90 94 94 91 94 94 97 101 101 101 97 101 106 106 106 102 106 106 106 106 106 97 115 115 117 117 125 117 117 117 125 125 125 125 126 126 129 129 126 126 150 150 142 135 142 139 139 139 135 142 142 150 142 146 146 150 148 146 148 150 152 150 150 157 157 157 169 157 160 157 162 160 157 157 167 167 169 169 169 169 176 176 176 175 173 176 178 176 176 176 182 180 186 186 186 182 176 189 190 190 193 193 190 197 197 197 190 190 201 201 202 202 202 207 207 207 203 202 202 211 209 215 215 215 211 217 215 220 220 209 202 224 224 225 225 228 226 225 228 232 232 229 232 238 238 235 235 233 225 250 240 240 246 246 246 240 240 240 250 250 255 255 255 255 250 250 262 261 261 261 257 262 264 262 264 267 269 269 264 264 264 274 274 276 276 262 278 276 281 281 278 262 284 285 285 285 289 289 285 285 292 293 293 305 297 297 305 297 297 302 302 299 305 305 293 309 309 309 305 312 312 305 314 312 314 314 293	0
17593875	20655	D019636	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and @DiseaseTgt$ . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 110 110 110 106 110 110 110 110 110 101 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20655	D020271	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound @DiseaseTgt$ characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 103 101|103 103 108 108 108 104 108 108 108 108 108 101 117 117 119 119 127 119 119 119 127 127 127 127 128 128 131 131 128 128 152 152 144 137 144 141 141 141 137 144 144 152 144 148 148 152 150 148 150 152 154 152 152 159 159 159 171 159 162 159 164 162 159 159 169 169 171 171 171 171 178 178 178 177 175 178 180 178 178 178 184 182 188 188 188 184 178 191 192 192 195 195 192 199 199 199 192 192 203 203 204 204 204 209 209 209 205 204 204 213 211 217 217 217 213 219 217 222 222 211 204 226 226 227 227 230 228 227 230 234 234 231 234 240 240 237 237 235 227 252 242 242 248 248 248 242 242 242 252 252 257 257 257 257 252 252 264 263 263 263 259 264 266 264 266 269 271 271 266 266 266 276 276 278 278 264 280 278 283 283 280 264 286 287 287 287 291 291 287 287 294 295 295 307 299 299 307 299 299 304 304 301 307 307 295 311 311 311 307 314 314 307 316 314 316 316 295	0
17593875	20617	D064420	False	2	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 111 111 111 107 111 111 111 111 111 102 120 120 122 122 130 122 122 122 130 130 130 130 131 131 134 134 131 131 155 155 147 140 147 144 144 144 140 147 147 155 147 151 151 155 153 151 153 155 157 155 155 162 162 162 174 162 165 162 167 165 162 162 172 172 174 174 174 174 181 181 181 180 178 181 183 181 181 181 187 185 191 191 191 187 181 194 195 195 198 198 195 202 202 202 195 195 206 206 207 207 207 212 212 212 208 207 207 216 214 220 220 220 216 222 220 225 225 214 207 229 229 230 230 233 231 230 233 237 237 234 237 243 243 240 240 238 230 255 245 245 251 251 251 245 245 245 255 255 260 260 260 260 255 255 267 266 266 266 262 267 269 267 269 272 274 274 269 269 269 279 279 281 281 267 283 281 286 286 283 267 289 290 290 290 294 294 290 290 297 298 298 310 302 302 310 302 302 307 307 304 310 310 298 314 314 314 310 317 317 310 319 317 319 319 298	0
17593875	6647	D010300	False	2	Transgenic mice with human mutant genes causing @DiseaseTgt$ and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of @DiseaseTgt$ ( @DiseaseTgt$ ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause @DiseaseTgt$ . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and @GeneSrc$ toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or @GeneSrc$ develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of @DiseaseTgt$ and ALS .	1 12 5 5 5 1 1 6|7 7 11 11 7 12 14 12 16 14 21 20 20 21 16 23 21 12 26 31 29 29 26 31 31 33 31 35 33|35 37 35 37 35 42 42 35 44 42 44 31 56 52 52 52 52 47 54 52 54 56 56 56 69 65 65 65 65 65 59 67 65 67 69 69 69 73 85 77 77 77 73 77 77 77 82 80 85 85 85 85 91 89 87 89 98 91 95 95 92 95 95 98 102 102 102 98 102 107 107 107 103 107 107 107 107 107 98 116 116 118 118 126 118 118 118 126 126 126 126 127 127 130 130 127 127 151 151 143 136 143 140 140 140 136 143 143 151 143 147 147 151 149 147 149 151 153 151 151 158 158 158 170 158 161 158 163 161 158 158 168 168 170 170 170 170 177 177 177 176 174 177 179 177 177 177 183 181 187 187 187 183 177 190 191 191 194 194 191 198 198 198 191 191 202 202 203 203 203 208 208 208 204 203 203 212 210 216 216 216 212 218 216 221 221 210 203 225 225 226 226 229 227 226 229 233 233 230 233 239 239 236 236 234 226 251 241 241 247 247 247 241 241 241 251 251 256 256 256 256 251 251 263 262 262 262 258 263 265 263 265 268 270 270 265 265 265 275 275 277 277 263 279 277 282 282 279 263 285 286 286 286 290 290 286 286 293 294 294 306 298 298 306 298 298 303 303 300 306 306 294 310 310 310 306 313 313 306 315 313 315 315 294	0
17593875	20655	D064420	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein alpha-synuclein ( alpha-Syn ) cause PD . Mutations in the antioxidant enzyme @GeneSrc$ ( @GeneSrc$ ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 @DiseaseTgt$ to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive motor deficits , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant alpha-Syn and Gly-93 - ->Ala (G93A)-mutant @GeneSrc$ tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . @GeneSrc$ mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . @GeneSrc$ mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in @GeneSrc$ mouse spinal cord . Mitochondria in @GeneSrc$ mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of @GeneSrc$ mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 72 68 68 68 68 63|68 70 68 70 72 72 72 76 88 80 80 80 76 80 80 80 85 83 88 88 88 88 94 92 90 92 101 94 98 98 95 98 98 101 105 105 105 101 105 110 110 110 106 110 110 110 110 110 101 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
17593875	20617	D009461	False	1	Transgenic mice with human mutant genes causing Parkinson 's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration . A variety of gene mutations can cause familial forms of Parkinson 's disease ( PD ) or amyotrophic lateral sclerosis ( ALS ) . Mutations in the synaptic protein @GeneSrc$ ( @GeneSrc$ ) cause PD . Mutations in the antioxidant enzyme superoxide dismutase-1 ( SOD1 ) cause ALS . The mechanisms of human mutant a-Syn and SOD1 toxicity to neurons are not known . Transgenic ( tg ) mice expressing human mutant alpha-Syn or SOD1 develop profound fatal neurologic disease characterized by progressive @DiseaseTgt$ , paralysis , and neurodegeneration . Ala-53 - ->Thr (A53T)-mutant @GeneSrc$ and Gly-93 - ->Ala (G93A)-mutant SOD1 tg mice develop prominent mitochondrial abnormalities . Interestingly , although nigral neurons in A53 T mice are relatively preserved , spinal motor neurons ( MNs ) undergo profound degeneration . In A53 T mice , mitochondria degenerate in neurons , and complex IV activity is reduced . Furthermore , mitochondria in neurons develop DNA breaks and have p53 targeted to the outer membrane . Nitrated a-Syn accumulates in degenerating MNs in A53 T mice . mSOD1 mouse MNs accumulate mitochondria from the axon terminals and generate higher levels of reactive oxygen/nitrogen species than MNs in control mice . mSOD1 mouse MNs accumulate DNA single-strand breaks prior to double-strand breaks occurring in nuclear and mitochondrial DNA . Nitrated and aggregated cytochrome c oxidase subunit-I and nitrated SOD2 accumulate in mSOD1 mouse spinal cord . Mitochondria in mSOD1 mouse MNs accumulate NADPH diaphorase and inducible NOS (iNOS)-like immunoreactivity , and iNOS gene deletion significantly extends the lifespan of G93A-mSOD1 mice . Mitochondrial changes develop long before symptoms emerge . These experiments reveal that mitochondrial nitrative stress and perturbations in mitochondrial trafficking may be antecedents of neuronal cell death in animal models of PD and ALS .	1 14 5 5 5 1 1 9 7 6 9 13 13 9 14 16 14 18 16 23 22 22 23 18 25 23 14 28 33 31 31 28 33 33 35 33 39 39 39 35 41 39 41 39 46 46 39 48 46 48 33 60 56 56 56 56 51 58 56 58 60 60 60 73 69 69 69 69 69 63 71 69 71 73 73 73 77 89 81 81 81 77 81 81 81 86 84 89 89 89 89 95 93 91 93 102 95 99 99 96 99 99 102 106 106 106 102 106 110 110 107|110 110 110 110 110 110 102 119 119 121 121 129 121 121 121 129 129 129 129 130 130 133 133 130 130 154 154 146 139 146 143 143 143 139 146 146 154 146 150 150 154 152 150 152 154 156 154 154 161 161 161 173 161 164 161 166 164 161 161 171 171 173 173 173 173 180 180 180 179 177 180 182 180 180 180 186 184 190 190 190 186 180 193 194 194 197 197 194 201 201 201 194 194 205 205 206 206 206 211 211 211 207 206 206 215 213 219 219 219 215 221 219 224 224 213 206 228 228 229 229 232 230 229 232 236 236 233 236 242 242 239 239 237 229 254 244 244 250 250 250 244 244 244 254 254 259 259 259 259 254 254 266 265 265 265 261 266 268 266 268 271 273 273 268 268 268 278 278 280 280 266 282 280 285 285 282 266 288 289 289 289 293 293 289 289 296 297 297 309 301 301 309 301 301 306 306 303 309 309 297 313 313 313 309 316 316 309 318 316 318 318 297	0
25900096	23400	D028361	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and @DiseaseTgt$ . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and @DiseaseTgt$ in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 176|170 159 179 180 180 183 183 180 186 186 183 189 189 186 192 192 189 194 192 189 189 199 199 196 202 202 199 204 202 204 204 204 204|208 212 212 210 204 180 220 216 220 216 216 220 220 220	1
25900096	6622	C537177	False	4	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause @DiseaseTgt$ , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 39|40 40 44 44 40 44 47 44 49 47 49 55 55 55 53 50 57 55 57 61 61 57 57 57 57 30 68 68 78 70 68 70 70 70 75 68 78 78 78 78 81 82 82 84 82 88 87 88 84 91 91 88 88 95 95 88 97 95 101 101 101 95 101 105 105 102 82 108 116 111 111 108 114 114 111 116 116 119 119 116 124 124 124 124 119 127 127 124 129 127 129 132 129 135 135 129 139 139 139 129 141 129 144 144 141 116 147 158 149 147 151 147 151 151 147 158 158 158 158 158 163 163 163 158 166 166 163 166 169 167 169 172 169 169 169 176 169 158 179 180 180 183 183 180 186 186 183 189 189 186 192 192 189 194 192 189 189 199 199 196 202 202 199 204 202 204 204 204 209 204 213 213 211 204 180 221 217 221 217 217 221 221 221	0
25900096	6622	D028361	True	0	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and @DiseaseTgt$ . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and @DiseaseTgt$ in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 176|170 159 179 180 180 183 183 180 186 186 183 189 189 186 192 192 189 194 192 189 189 199 199 196 202 202 199 204 202 204 204 204 204|208 212 212 210 204 180 220 216 220 216 216 220 220 220	0
25900096	6622	D009128	False	4	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of @DiseaseTgt$ , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	23400	C537177	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause @DiseaseTgt$ , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 39|40 40 44 44 40 44 47 44 49 47 49 55 55 55 53 50 57 55 57 61 61 57 57 57 57 30 68 68 78 70 68 70 70 70 75 68 78 78 78 78 81 82 82 84 82 88 87 88 84 91 91 88 88 95 95 88 97 95 101 101 101 95 101 105 105 102 82 108 116 111 111 108 114 114 111 116 116 119 119 116 124 124 124 124 119 127 127 124 129 127 129 132 129 135 135 129 139 139 139 129 141 129 144 144 141 116 147 158 149 147 151 147 151 151 147 158 158 158 158 158 163 163 163 158 166 166 163 166 169 167 169 172 169 169 169 176 169 158 179 180 180 183 183 180 186 186 183 189 189 186 192 192 189 194 192 189 189 199 199 196 202 202 199 204 202 204 204 204 209 204 213 213 211 204 180 221 217 221 217 217 221 221 221	1
25900096	23400	D010302	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of @DiseaseTgt$ associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International @DiseaseTgt$ Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 219 218 218|219 219 219	0
25900096	6622	D010300	True	0	The role of ATP13A2 in @DiseaseTgt$ : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in @DiseaseTgt$ ( @DiseaseTgt$ ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic @DiseaseTgt$ is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of @DiseaseTgt$ and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in @DiseaseTgt$ . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 5 1|5 1 8 1 8 11 8 1 14 26 16 14 18 16 18 21 21|16 23 21 23 26 26 29 29 26 35 35 34 34 31 29 37 35 37 41 41 37 41 44 41 46 44 46 52 52 52 50 47 54 52 54 58 58 54 54 54 54 26 65 65 75 67 65 67 67 67 72 65 75 75 75 75 78 79 79 81 79 85 84 85 81 88 88 85 85 92 92 85 94 92 98 98 98 92 98 102 102 99 79 105 113 108 108 105 111 111 108 113 113 116 116 113 121 121 121 121 116 124 124 121 126 124 126 129 126 132 132 126 136 136 136 126 138 126 141 141 138 113 144 155 146 144 148 144 148 148 144 155 155 155 155 155 160 160 160 155 163 163 160 163 166 164 166 169 166 166 166 173 166 155 176 177 177 180 180 177 183 183 180 186 186 183 189 189 186 191 189 186 186 196 196 193 199 199 196 201 199 201 201 201 206 201 208 208|201 177 216 212 216 212 212 216 216 216	0
25900096	23400	D010243	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze @DiseaseTgt$ , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	23400	D003704	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and @DiseaseTgt$ . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	6622	D010243	False	4	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze @DiseaseTgt$ , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	6622	D003704	False	4	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and @DiseaseTgt$ . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	6622	D010302	False	1	The role of ATP13A2 in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of ATP13A2 ( PARK9 ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of @DiseaseTgt$ associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of ATP13A2 in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , @GeneSrc$ accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate @GeneSrc$ accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International @DiseaseTgt$ Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 219 218 218|219 219 219	0
25900096	23400	D009128	True	0	The role of @GeneSrc$ in Parkinson 's disease : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in Parkinson 's disease ( PD ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of @DiseaseTgt$ , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of PD and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson 's disease . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 7 7 7 1 1 10 1 10 13 10 1 16 30 18 16 20 18 20 25 25 25 18 27 25 27 30 30 33 33 30 39 39 38 38 35 33 41 39 41 45 45 41 45 48 45 50 48 50 56 56 56 54 51 58 56 58 62 62 58 58 58 58 30 69 69 79 71 69 71 71 71 76 69 79 79 79 79 82 83 83 85 83 89 88 89 85 92 92 89 89 96 96 89 98 96 102 102 102 96 102 106 106 103 83 109 117 112 112 109 115 115 112 117 117 120 120 117 125 125 125 125 120 128 128 125 130 128 130 133 130 136 136 130 140 140 140 130 142 130 145 145 142 117 148 159 150 148 152 148 152 152 148 159 159 159 159 159 164 164 164 159 167 167 164 167 170 168 170 173 170 170 170 177 170 159 180 181 181 184 184 181 187 187 184 190 190 187 193 193 190 195 193 190 190 200 200 197 203 203 200 205 203 205 205 205 210 205 214 214 212 205 181 222 218 222 218 218 222 222 222	0
25900096	23400	D010300	True	0	The role of @GeneSrc$ in @DiseaseTgt$ : Clinical phenotypes and molecular mechanisms . The importance of @GeneSrc$ ( @GeneSrc$ ) in @DiseaseTgt$ ( @DiseaseTgt$ ) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome , an autosomal recessive , juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity , supranuclear gaze palsy , and dementia . Eleven independent kindreds with homozygous or compound heterozygous @GeneSrc$ mutations have been identified . These reports make it clear that the condition exhibits considerable clinical heterogeneity , with a spectrum of disease even among family members carrying the same mutation . The relevance of the protein in sporadic @DiseaseTgt$ is demonstrated by the presence of single heterozygous @GeneSrc$ mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease . The involvement of @GeneSrc$ in Zn(2 + ) homeostasis has recently been demonstrated , with the molecular consequences of this disturbance causing lysosomal impairment , alpha-synuclein accumulation , and mitochondrial dysfunction . These discoveries provide a new understanding of the role that @GeneSrc$ plays in the development of @DiseaseTgt$ and identify a therapeutic target that may ameliorate alpha-synuclein accumulation and lysosomal and mitochondrial dysfunction in @DiseaseTgt$ . 2015 International Parkinson and Movement Disorder Society .	1 1 3 1 5 1|5 1 8 1 8 11 8 1 14 26 16 14 18 16 18 21 21|16 23 21 23 26 26 29 29 26 35 35 34 34 31 29 37 35 37 41 41 37 41 44 41 46 44 46 52 52 52 50 47 54 52 54 58 58 54 54 54 54 26 65 65 75 67 65 67 67 67 72 65 75 75 75 75 78 79 79 81 79 85 84 85 81 88 88 85 85 92 92 85 94 92 98 98 98 92 98 102 102 99 79 105 113 108 108 105 111 111 108 113 113 116 116 113 121 121 121 121 116 124 124 121 126 124 126 129 126 132 132 126 136 136 136 126 138 126 141 141 138 113 144 155 146 144 148 144 148 148 144 155 155 155 155 155 160 160 160 155 163 163 160 163 166 164 166 169 166 166 166 173 166 155 176 177 177 180 180 177 183 183 180 186 186 183 189 189 186 191 189 186 186 196 196 193 199 199 196 201 199 201 201 201 206 201 208 208|201 177 216 212 216 212 212 216 216 216	1
32603820	627	D003704	False	1	The role of CREB and @GeneSrc$ in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of @DiseaseTgt$ worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases @GeneSrc$ ( @GeneSrc$ ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of @GeneSrc$ appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 90|91 93 91 93 97 97 90 112 112 112 112 112 112 112 112 112 112 112 112 112 112 97 87 115 120 120 120 120 120 120 128 128 122 122 122 127 125 120 132 132 132 128 135 135 132 120 138 150 150 141 150 143 141 143 146 144 150 150 150 150 154 154 154 150 154 157 154 150 177 164 160 160 160 159 164 168 168 165 171 171 168 177 177 177 177 177 177 179 177 177 183 183 186 186 186 186 186 187 190 188 194 194 194 190 197 197 190 197 197 202 202 199 204 202 186 210 210 210 210 210 215 215 215 215 210 217 215 220 220 217 222 220 215 225 223 228 228 225 210	0
32603820	627	D064420	True	0	The role of CREB and @GeneSrc$ in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases @GeneSrc$ ( @GeneSrc$ ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of @GeneSrc$ appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of @DiseaseTgt$ in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 90|91 93 91 93 97 97 90 112 112 112 112 112 112 112 112 112 112 112 112 112 112 97 87 115 120 120 120 120 120 120 128 128 122 122 122 127 125 120 132 132 132 128 135 135 132 120 138 150 150 141 150 143 141 143 146 144 150 150 150 150 154 154 154 150 154 157 154 150 177 164 160 160 160 159 164 168 168 165 171 171 168 177 177 177 177 177 177 179 177 177 183 183 186 186 186 186 186 187 190 188 194 194 194 190 197 197 190 197 197 201 199|201 203 201 186 209 209 209 209 209 214 214 214 214 209 216 214 219 219 216 221 219 214 224 222 227 227 224 209	0
32603820	1385	D003072	True	0	The role of @GeneSrc$ and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and @DiseaseTgt$ in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( @GeneSrc$ ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by @GeneSrc$ has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in @DiseaseTgt$ and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of @DiseaseTgt$ in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 47|45 49 45 37 37 55 55 55 65 55 59 59 56 65 65 65 65 65 37 37 68 73 71 71 68 73 73 75 73 79 79 79 75 73 82 86 86 85 86 86 89 89 86 92 92 89 94 92 94 98 98 89 113 113 113 113 113 113 113 113 113 113 113 113 113 113 98 86 116 121 121 121 121 121 121 129 129 123 123 123 128 126 121 133 133 133 129 136 136 133 121 139 151 151 142 151 144 142 144 147 145 151 151 151 151 155 155 155 151 155 158 155 151 178 165 161 161 161 160 165 169 169 166 172 172 169 178 178 178 178 178 178 180 178 178 184 184 187 187 187 187 187 188 191 189 195 195 195 191 197 191|197 197 197 202 202 199 204 202 187 210 210 210 210 210 215 215 215 215 210 217 215 219 217|219 221 219 215 224 222 227 227 224 210	0
32603820	351	D003704	False	1	The role of CREB and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of @DiseaseTgt$ worldwide . @GeneSrc$ ( @GeneSrc$ ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that @GeneSrc$ decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of CREB-BDNF signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of CREB-BDNF signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of CREB-BDNF pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 30|36 32 30 32 36 36 36 41 41 41 41 36 44 44 41 44 47 44 49 44 36 36 55 55 55 65 55 59 59 56 65 65 65 65 65 36 36 68 73 71 71 68 73 73 75 73 79 79 79 75 73 82 86 86 85 86 86 89 89 86 92 92 89 94 92 94 98 98 89 113 113 113 113 113 113 113 113 113 113 113 113 113 113 98 86 116 121 121 121 121 121 121 129 129 123 123 123 128 126 121 133 133 133 129 136 136 133 121 139 151 151 142 151 144 142 144 147 145 151 151 151 151 155 155 155 151 155 158 155 151 178 165 161 161 161 160 165 169 169 166 172 172 169 178 178 178 178 178 178 180 178 178 184 184 187 187 187 187 187 188 191 189 195 195 195 191 198 198 191 198 198 203 203 200 205 203 187 211 211 211 211 211 216 216 216 216 211 218 216 221 221 218 223 221 216 226 224 229 229 226 211	0
32603820	627	D000544	True	0	The role of CREB and @GeneSrc$ in neurobiology and treatment of @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in @DiseaseTgt$ , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases @GeneSrc$ ( @GeneSrc$ ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of @GeneSrc$ appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and @DiseaseTgt$ development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for @DiseaseTgt$ . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in @DiseaseTgt$ . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in @DiseaseTgt$ based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 11 11|7 1 13|21 15 13 15 21 21 20 21 21 23 21 21 21 27 33 29 27 29 33 33 33 38 38 38 38 33 41 41 38 41 44 41 46 41 33 33 52 52 52 62 52 56 56 53 62 62 62 62 62 33 33 65 70 68 68 65 70 70 72 70 76 76 76 72 70 79 83 83 82 83 83 86 86 83 86|87 89 87 89 93 93 86 108 108 108 108 108 108 108 108 108 108 108 108 108 108 93 83 111 116 116 116 116 116 116 124 124 118 118 118 123 121 116 128 128 128 124 131 131 128 116 134 146 146 137 146 139 137 139 142 140 146 146 146 146 150 150 150 146 150 153 150 146 173 160 156 156 156 155 160 164 164 161 167 167 164 173 173 173 173 173 173 175 173 173 179 179 182 182 182 182 182 183 186 184 190 190 190 186 193 193 186 193 193 198 198 195 200 198 182 206 206 206 206 206 211 211 211 211 206 213 211 216 216 213 218 216 211 221 219 224 224 221 206	0
32603820	1385	D064420	True	0	The role of @GeneSrc$ and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( @GeneSrc$ ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by @GeneSrc$ has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of @DiseaseTgt$ in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 93 93 90 95 93 95 99 99 90 114 114 114 114 114 114 114 114 114 114 114 114 114 114 99 87 117 122 122 122 122 122 122 130 130 124 124 124 129 127 122 134 134 134 130 137 137 134 122 140 152 152 143 152 145 143 145 148 146 152 152 152 152 156 156 156 152 156 159 156 152 179 166 162 162 162 161 166 170 170 167 173 173 170 179 179 179 179 179 179 181 179 179 185 185 188 188 188 188 188 189 192 190 196 196 196 192 199 199 192 199 199 203 201|203 205 203 188 211 211 211 211 211 216 216 216 216 211 218 216 221 221 218 223 221 216 226 224 229 229 226 211	0
32603820	351	D064420	False	4	The role of CREB and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . @GeneSrc$ ( @GeneSrc$ ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that @GeneSrc$ decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of CREB-BDNF signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of CREB-BDNF signaling pathway in cognitive status and mediation of @DiseaseTgt$ in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of CREB-BDNF pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 30|36 32 30 32 36 36 36 41 41 41 41 36 44 44 41 44 47 44 49 44 36 36 55 55 55 65 55 59 59 56 65 65 65 65 65 36 36 68 73 71 71 68 73 73 75 73 79 79 79 75 73 82 86 86 85 86 86 89 89 86 92 92 89 94 92 94 98 98 89 113 113 113 113 113 113 113 113 113 113 113 113 113 113 98 86 116 121 121 121 121 121 121 129 129 123 123 123 128 126 121 133 133 133 129 136 136 133 121 139 151 151 142 151 144 142 144 147 145 151 151 151 151 155 155 155 151 155 158 155 151 178 165 161 161 161 160 165 169 169 166 172 172 169 178 178 178 178 178 178 180 178 178 184 184 187 187 187 187 187 188 191 189 195 195 195 191 198 198 191 198 198 202 200|202 204 202 187 210 210 210 210 210 215 215 215 215 210 217 215 220 220 217 222 220 215 225 223 228 228 225 210	0
32603820	1385	D003704	False	1	The role of @GeneSrc$ and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of @DiseaseTgt$ worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( @GeneSrc$ ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by @GeneSrc$ has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 93 93 90 95 93 95 99 99 90 114 114 114 114 114 114 114 114 114 114 114 114 114 114 99 87 117 122 122 122 122 122 122 130 130 124 124 124 129 127 122 134 134 134 130 137 137 134 122 140 152 152 143 152 145 143 145 148 146 152 152 152 152 156 156 156 152 156 159 156 152 179 166 162 162 162 161 166 170 170 167 173 173 170 179 179 179 179 179 179 181 179 179 185 185 188 188 188 188 188 189 192 190 196 196 196 192 199 199 192 199 199 204 204 201 206 204 188 212 212 212 212 212 217 217 217 217 212 219 217 222 222 219 224 222 217 227 225 230 230 227 212	0
32603820	351	D000544	True	0	The role of CREB and BDNF in neurobiology and treatment of @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common form of dementia worldwide . @GeneSrc$ ( @GeneSrc$ ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in @DiseaseTgt$ , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that @GeneSrc$ decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and @DiseaseTgt$ development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of CREB-BDNF signaling could be a promising treatment potential for @DiseaseTgt$ . In this review , we summarize data demonstrating the role of CREB-BDNF signaling pathway in cognitive status and mediation of Abeta toxicity in @DiseaseTgt$ . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in @DiseaseTgt$ based on targeting of CREB-BDNF pathway .	1 1 3 1 3 3 7 1 7 7 11 11|7 1 13|21 15 13 15 21 21 20 21 21 23 21 21 21 26|32 28 26 28 32 32 32 37 37 37 37 32 40 40 37 40 43 40 45 40 32 32 51 51 51 61 51 55 55 52 61 61 61 61 61 32 32 64 69 67 67 64 69 69 71 69 75 75 75 71 69 78 82 82 81 82 82 85 85 82 88 88 85 90 88 90 94 94 85 109 109 109 109 109 109 109 109 109 109 109 109 109 109 94 82 112 117 117 117 117 117 117 125 125 119 119 119 124 122 117 129 129 129 125 132 132 129 117 135 147 147 138 147 140 138 140 143 141 147 147 147 147 151 151 151 147 151 154 151 147 174 161 157 157 157 156 161 165 165 162 168 168 165 174 174 174 174 174 174 176 174 174 180 180 183 183 183 183 183 184 187 185 191 191 191 187 194 194 187 194 194 199 199 196 201 199 183 207 207 207 207 207 212 212 212 212 207 214 212 217 217 214 219 217 212 222 220 225 225 222 207	0
32603820	1385	D000544	True	0	The role of @GeneSrc$ and BDNF in neurobiology and treatment of @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in @DiseaseTgt$ , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( @GeneSrc$ ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by @GeneSrc$ has been widely analyzed in the memory process and @DiseaseTgt$ development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for @DiseaseTgt$ . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in @DiseaseTgt$ . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in @DiseaseTgt$ based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 11 11|7 1 13|21 15 13 15 21 21 20 21 21 23 21 21 21 27 33 29 27 29 33 33 33 38 38 38 38 33 41 41 38 41 44 41 46 41 33 33 52 52 52 62 52 56 56 53 62 62 62 62 62 33 33 65 70 68 68 65 70 70 72 70 76 76 76 72 70 79 83 83 82 83 83 86 86 83 89 89 86 91 89 91 95 95 86 110 110 110 110 110 110 110 110 110 110 110 110 110 110 95 83 113 118 118 118 118 118 118 126 126 120 120 120 125 123 118 130 130 130 126 133 133 130 118 136 148 148 139 148 141 139 141 144 142 148 148 148 148 152 152 152 148 152 155 152 148 175 162 158 158 158 157 162 166 166 163 169 169 166 175 175 175 175 175 175 177 175 175 181 181 184 184 184 184 184 185 188 186 192 192 192 188 195 195 188 195 195 200 200 197 202 200 184 208 208 208 208 208 213 213 213 213 208 215 213 218 218 215 220 218 213 223 221 226 226 223 208	0
32603820	351	D003072	True	0	The role of CREB and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . @GeneSrc$ ( @GeneSrc$ ) is currently assumed to be the main cause of synaptic dysfunction and @DiseaseTgt$ in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that @GeneSrc$ decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of CREB-BDNF signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of CREB-BDNF signaling pathway in @DiseaseTgt$ and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of @DiseaseTgt$ in AD based on targeting of CREB-BDNF pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 30|36 32 30 32 36 36 36 41 41 41 41 36 44 44 41 44 46|44 48 44 36 36 54 54 54 64 54 58 58 55 64 64 64 64 64 36 36 67 72 70 70 67 72 72 74 72 78 78 78 74 72 81 85 85 84 85 85 88 88 85 91 91 88 93 91 93 97 97 88 112 112 112 112 112 112 112 112 112 112 112 112 112 112 97 85 115 120 120 120 120 120 120 128 128 122 122 122 127 125 120 132 132 132 128 135 135 132 120 138 150 150 141 150 143 141 143 146 144 150 150 150 150 154 154 154 150 154 157 154 150 177 164 160 160 160 159 164 168 168 165 171 171 168 177 177 177 177 177 177 179 177 177 183 183 186 186 186 186 186 187 190 188 194 194 194 190 196 190|196 196 196 201 201 198 203 201 186 209 209 209 209 209 214 214 214 214 209 216 214 218 216|218 220 218 214 223 221 226 226 223 209	0
32603820	1385	D020258	False	2	The role of @GeneSrc$ and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its @DiseaseTgt$ consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( @GeneSrc$ ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by @GeneSrc$ has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 93 93 90 95 93 95 99 99 90 114 114 114 114 114 114 114 114 114 114 114 114 114 114 99 87 117 122 122 122 122 122 122 130 130 124 124 124 129 127 122 134 134 134 130 137 137 134 122 140 152 152 143 152 145 143 145 148 146 152 152 152 152 156 156 156 152 156 159 156 152 179 166 162 162 162 161 166 170 170 167 173 173 170 179 179 179 179 179 179 181 179 179 185 185 188 188 188 188 188 189 192 190 196 196 196 192 199 199 192 199 199 204 204 201 206 204 188 212 212 212 212 212 217 217 217 217 212 219 217 222 222 219 224 222 217 227 225 230 230 227 212	0
32603820	627	D003072	True	0	The role of CREB and @GeneSrc$ in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and @DiseaseTgt$ in AD , but the molecular signaling pathways underlying its neurotoxic consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases @GeneSrc$ ( @GeneSrc$ ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of @GeneSrc$ appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in @DiseaseTgt$ and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of @DiseaseTgt$ in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 47|45 49 45 37 37 55 55 55 65 55 59 59 56 65 65 65 65 65 37 37 68 73 71 71 68 73 73 75 73 79 79 79 75 73 82 86 86 85 86 86 89 89 86 89|90 92 90 92 96 96 89 111 111 111 111 111 111 111 111 111 111 111 111 111 111 96 86 114 119 119 119 119 119 119 127 127 121 121 121 126 124 119 131 131 131 127 134 134 131 119 137 149 149 140 149 142 140 142 145 143 149 149 149 149 153 153 153 149 153 156 153 149 176 163 159 159 159 158 163 167 167 164 170 170 167 176 176 176 176 176 176 178 176 176 182 182 185 185 185 185 185 186 189 187 193 193 193 189 195 189|195 195 195 200 200 197 202 200 185 208 208 208 208 208 213 213 213 213 208 215 213 217 215|217 219 217 213 222 220 225 225 222 208	0
32603820	351	D020258	True	0	The role of CREB and BDNF in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . @GeneSrc$ ( @GeneSrc$ ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its @DiseaseTgt$ consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that @GeneSrc$ decreases brain-derived neurotrophic factor ( BDNF ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of BDNF appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of CREB-BDNF signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of CREB-BDNF signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of CREB-BDNF pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 30|36 32 30 32 36 36 36 41 41 41 41 36 44 44 41 44 47 44 49 44 36 36 55 55 55 65 55 59 59 56 65 65 65 65 65 36 36 68 73 71 71 68 73 73 75 73 79 79 79 75 73 82 86 86 85 86 86 89 89 86 92 92 89 94 92 94 98 98 89 113 113 113 113 113 113 113 113 113 113 113 113 113 113 98 86 116 121 121 121 121 121 121 129 129 123 123 123 128 126 121 133 133 133 129 136 136 133 121 139 151 151 142 151 144 142 144 147 145 151 151 151 151 155 155 155 151 155 158 155 151 178 165 161 161 161 160 165 169 169 166 172 172 169 178 178 178 178 178 178 180 178 178 184 184 187 187 187 187 187 188 191 189 195 195 195 191 198 198 191 198 198 203 203 200 205 203 187 211 211 211 211 211 216 216 216 216 211 218 216 221 221 218 223 221 216 226 224 229 229 226 211	0
32603820	627	D020258	False	2	The role of CREB and @GeneSrc$ in neurobiology and treatment of Alzheimer 's disease . Alzheimer 's disease ( AD ) is the most common form of dementia worldwide . beta-amyloid peptide ( Abeta ) is currently assumed to be the main cause of synaptic dysfunction and cognitive impairments in AD , but the molecular signaling pathways underlying its @DiseaseTgt$ consequences have not yet been completely explored . Additional investigations regarding these pathways will contribute to development of new therapeutic targets . In context , developing evidence suggest that Abeta decreases @GeneSrc$ ( @GeneSrc$ ) mostly by lowering phosphorylated cyclic adenosine monophosphate ( cAMP ) response element binding protein ( CREB ) protein . In fact , it has been observed that brain or serum levels of @GeneSrc$ appear to be beneficial markers for cognitive condition . In addition , the participation of transcription mediated by CREB has been widely analyzed in the memory process and AD development . Designing pharmacologic or genetic therapeutic approaches based on the targeting of @GeneSrc$ signaling could be a promising treatment potential for AD . In this review , we summarize data demonstrating the role of @GeneSrc$ signaling pathway in cognitive status and mediation of Abeta toxicity in AD . Finally , we also focus on the developing intervention methods for improvement of cognitive decline in AD based on targeting of @GeneSrc$ pathway .	1 1 3 1 3 3 7 1 7 7 13 13 13 7 1 17 17 25 19 17 19 25 25 24 25 25 27 25 25 25 31 37 33 31 33 37 37 37 42 42 42 42 37 45 45 42 45 48 45 50 45 37 37 56 56 56 66 56 60 60 57 66 66 66 66 66 37 37 69 74 72 72 69 74 74 76 74 80 80 80 76 74 83 87 87 86 87 87 90 90 87 90|91 93 91 93 97 97 90 112 112 112 112 112 112 112 112 112 112 112 112 112 112 97 87 115 120 120 120 120 120 120 128 128 122 122 122 127 125 120 132 132 132 128 135 135 132 120 138 150 150 141 150 143 141 143 146 144 150 150 150 150 154 154 154 150 154 157 154 150 177 164 160 160 160 159 164 168 168 165 171 171 168 177 177 177 177 177 177 179 177 177 183 183 186 186 186 186 186 187 190 188 194 194 194 190 197 197 190 197 197 202 202 199 204 202 186 210 210 210 210 210 215 215 215 215 210 217 215 220 220 217 222 220 215 225 223 228 228 225 210	0
34440548	6622	D003072	True	0	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , @DiseaseTgt$ and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including @DiseaseTgt$ . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 77|75 77 77 63 84 84 84 89 86 84 89 89 89 89 92 89 95 95 92 97 95 97 102 102 102 89 89 111 106 104 106 111 111 111 111 113 111 111 111 117 111 117 117 111 122 120 111 136 128 128 128 124 130 128 130 136 136 136 134 136 138 136 141 141 136 136 149 149 149 145 148 146 149 151 149 153 157 153 153 153 149 157 160 160|157 149 164 164 167 167 167 167 167 167 173 172 170 167 173 177 177 174 173 181 181 188 184 184 181 188 187 188 188 188 192 192 194 194 194 196 194 198 196 198 201 198 201 201 201 206 194 210 210 210 206 212 210 194	0
34440548	6622	D009410	True	0	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are @DiseaseTgt$ and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate @DiseaseTgt$ . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 89 87 85 89 89 89 92 89 95 95 92 97 95 97 102 102 102 89 89 111 106 104 106 111 111 111 111 113 111 111 111 117 111 117 117 111 120|121 111 135 127 127 127 123 129 127 129 135 135 135 133 135 137 135 140 140 135 135 148 148 148 144 147 145 148 150 148 152 156 152 152 152 148 156 160 160 156 148 164 164 167 167 167 167 167 167 173 172 170 167 173 177 177 174 173 181 181 188 184 184 181 188 187 188 188 188 192 192 194 194 194 196 194 198 196 198 201 198 201 201 201 206 194 210 210 210 206 212 210 194	0
34440548	6622	D054969	False	2	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , cognitive decline and @DiseaseTgt$ . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
34440548	6622	D003248	False	2	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , @DiseaseTgt$ , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
34440548	6622	D000857	False	2	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include @DiseaseTgt$ , constipation , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
34440548	6622	D010300	True	0	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of @DiseaseTgt$ are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of @DiseaseTgt$ to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of @DiseaseTgt$ .	1 1 4 4 1 4 8 8 4 11 11 1 13 11|13 1 15|25 17 15 17 25 25 25 21 21 21 25 25 25 30 30 27 33 33 30 39 39 39 39 39 30 42 42 30 42 47 47 47 25 50 50 47 52 50 52 52 52 25 58 59 59 59 60 60 60 60 60 60 59 59 71 71 59 71 74 71 74 74 59 81 81 81 86 83 81 86 86 86 86 89 86 92 92 89 94 92 94 99 99 99 86 86 108 103 101 103 108 108 108 108 110 108 108 108 114 108 114 114 108 119 117 108 133 125 125 125 121 127 125 127 133 133 133 131 133 135 133 138 138 133 133 146 146 146 142 145 143 146 148 146 150 154 150 150 150 146 154 158 158 154 146 162 162 165 165 165 165 165 165 171 170 168 165 171 175 175 172 171 179 179 186 182 182 179 186 185 186 186 186 190 190 192 192 192 194 192 196 194 196 199 196 199 199 199 204 192 208 208 208 204 210 208 192	1
34440548	6622	D019636	False	1	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive @DiseaseTgt$ , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 28 21 19 21 28 28 28 25 25 25|28 28 28 33 33 30 36 36 33 42 42 42 42 42 33 45 45 33 45 50 50 50 28 53 53 50 55 53 55 55 55 28 61 62 62 62 63 63 63 63 63 63 62 62 74 74 62 74 77 74 77 77 62 84 84 84 89 86 84 89 89 89 89 92 89 95 95 92 97 95 97 102 102 102 89 89 111 106 104 106 111 111 111 111 113 111 111 111 117 111 117 117 111 122 120 111 136 128 128 128 124 130 128 130 136 136 136 134 136 138 136 141 141 136 136 149 149 149 145 148 146 149 151 149 153 157 153 153 153 149 157 161 161 157 149 165 165 168 168 168 168 168 168 174 173 171 168 174 178 178 175 174 182 182 189 185 185 182 189 188 189 189 189 193 193 195 195 195 197 195 199 197 199 202 199 202 202 202 207 195 211 211 211 207 213 211 195	0
34440548	6622	D010146	False	2	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , @DiseaseTgt$ and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
34440548	6622	D000275	False	2	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , @DiseaseTgt$ , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset parkinsonism with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
34440548	6622	D010302	True	0	The Impact of @GeneSrc$ Variations and Its Product @GeneSrc$ on Non-Motor Features of Parkinson 's Disease . Parkinson 's disease ( PD ) is a common and progressive neurodegenerative disease , caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain , which is clinically characterized by a constellation of motor and non-motor manifestations . The latter include hyposmia , constipation , depression , pain and , in later stages , cognitive decline and dysautonomia . The main pathological features of PD are neuronal loss and consequent accumulation of Lewy bodies ( LB ) in the surviving neurons . @GeneSrc$ ( @GeneSrc$ ) is the main component of LB , and @GeneSrc$ aggregation and accumulation perpetuate neuronal degeneration . Mutations in the @GeneSrc$ gene ( @GeneSrc$ ) were the first genetic cause of PD to be identified . Generally , patients carrying @GeneSrc$ mutations present early-onset @DiseaseTgt$ with severe and early non-motor symptoms , including cognitive decline . Several @GeneSrc$ polymorphisms were also identified , and some of them showed association with non-motor manifestations . The functional role of these polymorphisms is only partially understood . In this review we explore the contribution of @GeneSrc$ and its product , @GeneSrc$ , in predisposing to the non-motor manifestations of PD .	1 1 4 4 1 4 8 8 4 11 11 1 15 15 13 11 1 19 19 29 21 19 21 29 29 29 25 25 25 29 29 29 34 34 31 37 37 34 43 43 43 43 43 34 46 46 34 46 51 51 51 29 54 54 51 56 54 56 56 56 29 62 63 63 63 64 64 64 64 64 64 63 63 75 75 63 75 78 75 78 78 63 85 85 85 90 87 85 90 90 90 90 93 90 96 96 93 98 96 98 103 103 103 90 90 112 107 105 107 112 112 112 112 114 112 112 112 118 112 118 118 112 123 121 112 137 129 129 129 125 131 129 131 137 137 137 135 137 139 137 142 142 137 137 150 150 150 146 149 147 150 152 150 154 158 154 154 154 150 158 162 162 158 150 166 166 169 169 169 169 169 169 175 174 172 169 175 179 179 176 175 183 183 190 186 186 183 190 189 190 190 190 194 194 196 196 196 198 196 200 198 200 203 200 203 203 203 208 196 212 212 212 208 214 212 196	0
33599827	4853	D000544	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with @DiseaseTgt$ , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 92 90|92 92 95 92 92 99 97 92 92 103 103 92 103 106 92 106 109 106 92 92 113 92 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D019636	False	2	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a @DiseaseTgt$ . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual @DiseaseTgt$ that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 22 22 19|22 16 27 24 27 41 30 30 27 30 34 34 41 37 37 34 41 41 41 41 41 48 48 48 48 48 48 65 53 53 53 65 57 57 57 53 61 61 61 57 65 65 65 48 67 65 48 72 72 72 89 75 75 72 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 168 168 168 168 167|176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D010300	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , @DiseaseTgt$ , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 94|99 94 103 103 94 103 106 94 106 109 106 94 94 113 94 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D003704	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal @DiseaseTgt$ , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D017825	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of @DiseaseTgt$ , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 75 73|75 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	4853	D010523	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , @DiseaseTgt$ , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 76 76 73 76 78|76 76 76 82 76 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D014202	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential @DiseaseTgt$ , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D009135	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal @DiseaseTgt$ . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D056784	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult @DiseaseTgt$ , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D000544	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with @DiseaseTgt$ , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 92 90|92 92 95 92 92 99 97 92 92 103 103 92 103 106 92 106 109 106 92 92 113 92 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D014202	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential @DiseaseTgt$ , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	C537395	True	0	@DiseaseTgt$ : recognition and update . @DiseaseTgt$ ( @DiseaseTgt$ ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of @DiseaseTgt$ . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable @DiseaseTgt$ phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	0 0 0 2 2 0 6|10 8 6 8 10 13 13 10 17 17 17 13 10 22 19 22 36 25 25 22 25 29 29 36 32 32 29 36 36 36 36 36 43 43 43 43 43 43 60 48 48 48 60 52 52 52 48 56 56 56 52 60 60 60 43 62 60 43 67 67 67 84 70 70 67 70 73 70 70 70 77 70 84 81 81 84 84 84 84 88 88 88 84 88 91 88 88 95 93 88 88 99 99 88 99 102 88 102 105 102 88 88 109 88 84 115 115 115 115 115 117 115 119 117 126 124 124 124 126 126 119 132 131 131 131 132 126 115 135 135 138 138 135 138 141 138 141 144 141 138 148 148 138 150 138 153 153 150 153 153 157 153 135 164 164 164 164 162 172 167 167 164 169 167 167 172 172 175 175 172 172 181 181 181 181 181 185 185 185 181 190 190 190 190 185 192 190 192 192 192 192 192 192 198 198 204 204 204 192 206 204 206 206 206 211 206 211 211 206 206 206 181 219 230 230 223 223 230 225 223 225 225 230 230 230 250 235 235 235 250 239 239 239 235 241 239 241 246 246 246 239 250 250 250 230 252 250 252 256 254 250 256 259 250 262 262 259 262 259 259 250 266 266 266 271 273 273 266 273 273 273 273 266 266 279 279 279 284 285 279 285 285 279 279 279 279 291 291 279 296 279 296 296 279 266 266 266 302 302 302 309 309 309 302 312 312 309 302 302 266 230 318 328 328 321 328 325 325 325 321 328 328 328 328 328 332 341 338 337 337 337 338 332 341 341 328 343 341 343 343 343 348 343 348 348 343 343 343 341 359 359 358 359 370 363 363 363 359 367 367 367 363 370 370 370 373 373 370 375 373 375 379 379 370 383 383 383 379 370 391 387 391 391 391 391 370 395 395 395 391 397 395 370 400 398 402 404 404 370 370 409 409 409 370 409 409 370 414 417 417 417 423 420 420 417 423 423 423 425 423 428 428 425 430 428 432 425 435 435 432 435 439 439 436 442 442 439 425 425 446 444 449 449 444 449 449 449 454 449 423	1
33599827	4853	D001284	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system @DiseaseTgt$ , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D017825	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of @DiseaseTgt$ , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 75 73|75 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D003704	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal @DiseaseTgt$ , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D019636	False	2	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a @DiseaseTgt$ . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual @DiseaseTgt$ that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 22 22 19|22 16 27 24 27 41 30 30 27 30 34 34 41 37 37 34 41 41 41 41 41 48 48 48 48 48 48 65 53 53 53 65 57 57 57 53 61 61 61 57 65 65 65 48 67 65 48 72 72 72 89 75 75 72 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 168 168 168 168 167|176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D010300	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , @DiseaseTgt$ , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 94|99 94 103 103 94 103 106 94 106 109 106 94 94 113 94 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D010523	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , @DiseaseTgt$ , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 76 76 73 76 78|76 76 76 82 76 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D009135	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal @DiseaseTgt$ . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	C537395	True	0	@DiseaseTgt$ : recognition and update . @DiseaseTgt$ ( @DiseaseTgt$ ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of @DiseaseTgt$ . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable @DiseaseTgt$ phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	0 0 0 2 2 0 6|10 8 6 8 10 13 13 10 17 17 17 13 10 22 19 22 36 25 25 22 25 29 29 36 32 32 29 36 36 36 36 36 43 43 43 43 43 43 60 48 48 48 60 52 52 52 48 56 56 56 52 60 60 60 43 62 60 43 67 67 67 84 70 70 67 70 73 70 70 70 77 70 84 81 81 84 84 84 84 88 88 88 84 88 91 88 88 95 93 88 88 99 99 88 99 102 88 102 105 102 88 88 109 88 84 115 115 115 115 115 117 115 119 117 126 124 124 124 126 126 119 132 131 131 131 132 126 115 135 135 138 138 135 138 141 138 141 144 141 138 148 148 138 150 138 153 153 150 153 153 157 153 135 164 164 164 164 162 172 167 167 164 169 167 167 172 172 175 175 172 172 181 181 181 181 181 185 185 185 181 190 190 190 190 185 192 190 192 192 192 192 192 192 198 198 204 204 204 192 206 204 206 206 206 211 206 211 211 206 206 206 181 219 230 230 223 223 230 225 223 225 225 230 230 230 250 235 235 235 250 239 239 239 235 241 239 241 246 246 246 239 250 250 250 230 252 250 252 256 254 250 256 259 250 262 262 259 262 259 259 250 266 266 266 271 273 273 266 273 273 273 273 266 266 279 279 279 284 285 279 285 285 279 279 279 279 291 291 279 296 279 296 296 279 266 266 266 302 302 302 309 309 309 302 312 312 309 302 302 266 230 318 328 328 321 328 325 325 325 321 328 328 328 328 328 332 341 338 337 337 337 338 332 341 341 328 343 341 343 343 343 348 343 348 348 343 343 343 341 359 359 358 359 370 363 363 363 359 367 367 367 363 370 370 370 373 373 370 375 373 375 379 379 370 383 383 383 379 370 391 387 391 391 391 391 370 395 395 395 391 397 395 370 400 398 402 404 404 370 370 409 409 409 370 409 409 370 414 417 417 417 423 420 420 417 423 423 423 425 423 428 428 425 430 428 432 425 435 435 432 435 439 439 436 442 442 439 425 425 446 444 449 449 444 449 449 449 454 449 423	0
33599827	79017	D056784	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult @DiseaseTgt$ , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D001284	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system @DiseaseTgt$ , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
31178126	4853	D000544	True	0	Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large GGC repeat expansion within human-specific NOTCH2NLC . Expanded GGC repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the GGC repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , GGC repeat expansion was observed in two @DiseaseTgt$ @DiseaseTgt$ families and three parkinsonism-affected families , implicating that the GGC repeat expansions in @GeneSrc$ could also contribute to the pathogenesis of both @DiseaseTgt$ and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded GGC repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 169 167 167|168 169 164 169 173 173 169 164 164 185 180 179 180 185 182 180 185 185 175 188 188 185 191 191 188 191 191 164 198 198 198 198 198 201 203 203 199 205 203 205 203 210 210 203 210 211 214 211 216 211 211 222 222 222 222 217 225 225 217 198	0
31178126	79017	D019636	True	0	Expansion of Human-Specific @GeneSrc$ Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing @DiseaseTgt$ characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large @GeneSrc$ repeat expansion within human-specific NOTCH2NLC . Expanded @GeneSrc$ repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the @GeneSrc$ repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , @GeneSrc$ repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the @GeneSrc$ repeat expansions in NOTCH2NLC could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related @DiseaseTgt$ caused by the expanded @GeneSrc$ repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 23 17 15 17 23 23 22 23 23 23 28 28 28 24 32 32 32 28 32 36 36 32 23 40 40 43 42 40 43 43 43 43 48 54 48 48 48 54 54 43 54 59 59 59 59 62 62 59 59 59 67 67 64 69 64 59 75 75 74 75 59 79 79 79 75 59 83 83 83 86 86 83 83 83 93 93 93 93 88 96 96 88 83 100 100 108 103 103 100 105 103 108 108 108 114 114 114 114 114 108 114 115 115 122 122 122 122 114 108 134 134 129 129 129 134 131 129 134 134 134 136 134 140 140 140 136 143 143 136 146 146 134 149 149 146 154 154 154 154 146 154 134 163 163 161 161 163 163 163 169 167 167 168 169 163 169 173 173 169 163 163 185 180 179 180 185 182 180 185 185 175 188 188 185 191 191 188 191 191 163 198 198 198 198 198 201 203 203 199 205 203 205 203 210 210 203 210 211 214 211 211|215 211 221 221 221 221 216 224 224 216 198	0
31178126	4853	D010302	True	0	Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large GGC repeat expansion within human-specific NOTCH2NLC . Expanded GGC repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the GGC repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , GGC repeat expansion was observed in two Alzheimer disease (AD)-affected families and three @DiseaseTgt$ families , implicating that the GGC repeat expansions in @GeneSrc$ could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded GGC repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 170 168 168 169 170 164 170 174 174 170 164 164 186 181 180 181 186 183 181 186 186 176 189 189 186 192 192 189 192 192 164 199 199 199 199 199 202 204 204 200 206 204 206 204 211 211 204 211 212 215 212 217 212 212 223 223 223 223 218 226 226 218 199	0
31178126	79017	D010300	True	0	Expansion of Human-Specific @GeneSrc$ Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large @GeneSrc$ repeat expansion within human-specific NOTCH2NLC . Expanded @GeneSrc$ repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the @GeneSrc$ repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , @GeneSrc$ repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the @GeneSrc$ repeat expansions in NOTCH2NLC could also contribute to the pathogenesis of both AD and @DiseaseTgt$ . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded @GeneSrc$ repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 170 168 168 169 170 164 170 174 174 170 164 164 186 181 180 181 186 183 181 186 186 176 189 189 186 192 192 189 192 192 164 199 199 199 199 199 202 204 204 200 206 204 206 204 211 211 204 211 212 215 212 217 212 212 223 223 223 223 218 226 226 218 199	0
31178126	4853	D019636	False	1	Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing @DiseaseTgt$ characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large GGC repeat expansion within human-specific NOTCH2NLC . Expanded GGC repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the GGC repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , GGC repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the GGC repeat expansions in @GeneSrc$ could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related @DiseaseTgt$ caused by the expanded GGC repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 23 17 15 17 23 23 22 23 23 23 28 28 28 24 32 32 32 28 32 36 36 32 23 40 40 43 42 40 43 43 43 43 48 54 48 48 48 54 54 43 54 59 59 59 59 62 62 59 59 59 67 67 64 69 64 59 75 75 74 75 59 79 79 79 75 59 83 83 83 86 86 83 83 83 93 93 93 93 88 96 96 88 83 100 100 108 103 103 100 105 103 108 108 108 114 114 114 114 114 108 114 115 115 122 122 122 122 114 108 134 134 129 129 129 134 131 129 134 134 134 136 134 140 140 140 136 143 143 136 146 146 134 149 149 146 154 154 154 154 146 154 134 163 163 161 161 163 163 163 169 167 167 168 169 163 169 173 173 169 163 163 185 180 179 180 185 182 180 185 185 175 188 188 185 191 191 188 191 191 163 198 198 198 198 198 201 203 203 199 205 203 205 203 210 210 203 210 211 214 211 211|215 211 221 221 221 221 216 224 224 216 198	0
31178126	4853	D010300	True	0	Expansion of Human-Specific GGC Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large GGC repeat expansion within human-specific NOTCH2NLC . Expanded GGC repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the GGC repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , GGC repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the GGC repeat expansions in @GeneSrc$ could also contribute to the pathogenesis of both AD and @DiseaseTgt$ . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded GGC repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 170 168 168 169 170 164 170 174 174 170 164 164 186 181 180 181 186 183 181 186 186 176 189 189 186 192 192 189 192 192 164 199 199 199 199 199 202 204 204 200 206 204 206 204 211 211 204 211 212 215 212 217 212 212 223 223 223 223 218 226 226 218 199	0
31178126	79017	D010302	True	0	Expansion of Human-Specific @GeneSrc$ Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large @GeneSrc$ repeat expansion within human-specific NOTCH2NLC . Expanded @GeneSrc$ repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the @GeneSrc$ repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , @GeneSrc$ repeat expansion was observed in two Alzheimer disease (AD)-affected families and three @DiseaseTgt$ families , implicating that the @GeneSrc$ repeat expansions in NOTCH2NLC could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded @GeneSrc$ repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 170 168 168 169 170 164 170 174 174 170 164 164 186 181 180 181 186 183 181 186 186 176 189 189 186 192 192 189 192 192 164 199 199 199 199 199 202 204 204 200 206 204 206 204 211 211 204 211 212 215 212 217 212 212 223 223 223 223 218 226 226 218 199	0
31178126	4853	C537395	False	7	Expansion of Human-Specific GGC Repeat in @DiseaseTgt$ . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large GGC repeat expansion within human-specific NOTCH2NLC . Expanded GGC repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the GGC repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , GGC repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the GGC repeat expansions in @GeneSrc$ could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded GGC repeat within human-specific NOTCH2NLC .	0 4 4 4 0 6 0|6 0 11 11 11 20 13 11 13 20 20 18 20 20 20 20 25 25 25 21 29 29 29 25 29 33 33 29 20 37 37 40 39 37 40 40 40 40 45 51 45 45 45 51 51 40 51 56 56 56 56 59 59 56 56 56 64 64 61 66 61 56 72 72 71 72 56 76 76 76 72 56 80 80 80 83 83 80 80 80 90 90 90 90 85 93 93 85 80 97 97 105 100 100 97 102 100 105 105 105 111 111 111 111 111 105 111 112 112 119 119 119 119 111 105 131 131 126 126 126 131 128 126 131 131 131 133 131 137 137 137 133 140 140 133 143 143 131 146 146 143 151 151 151 151 143 151 131 160 160 158 158 160 160 160 166 164 164 165 166 160 166 170 170 166 160 160 182 177 176 177 182 179 177 182 182 172 185 185 182 188 188 185 188 188 160 195 195 195 195 195 198 200 200 196 202 200 202 200 207 207 200 207 208 211 208 213 208 208 219 219 219 219 214 222 222 214 195	1
31178126	79017	C537395	True	0	Expansion of Human-Specific @GeneSrc$ Repeat in @DiseaseTgt$ . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large @GeneSrc$ repeat expansion within human-specific NOTCH2NLC . Expanded @GeneSrc$ repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the @GeneSrc$ repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , @GeneSrc$ repeat expansion was observed in two Alzheimer disease (AD)-affected families and three parkinsonism-affected families , implicating that the @GeneSrc$ repeat expansions in NOTCH2NLC could also contribute to the pathogenesis of both AD and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded @GeneSrc$ repeat within human-specific NOTCH2NLC .	0 4 4 4 0 6 0|6 0 11 11 11 20 13 11 13 20 20 18 20 20 20 20 25 25 25 21 29 29 29 25 29 33 33 29 20 37 37 40 39 37 40 40 40 40 45 51 45 45 45 51 51 40 51 56 56 56 56 59 59 56 56 56 64 64 61 66 61 56 72 72 71 72 56 76 76 76 72 56 80 80 80 83 83 80 80 80 90 90 90 90 85 93 93 85 80 97 97 105 100 100 97 102 100 105 105 105 111 111 111 111 111 105 111 112 112 119 119 119 119 111 105 131 131 126 126 126 131 128 126 131 131 131 133 131 137 137 137 133 140 140 133 143 143 131 146 146 143 151 151 151 151 143 151 131 160 160 158 158 160 160 160 166 164 164 165 166 160 166 170 170 166 160 160 182 177 176 177 182 179 177 182 182 172 185 185 182 188 188 185 188 188 160 195 195 195 195 195 198 200 200 196 202 200 202 200 207 207 200 207 208 211 208 213 208 208 219 219 219 219 214 222 222 214 195	0
31178126	79017	D000544	True	0	Expansion of Human-Specific @GeneSrc$ Repeat in Neuronal Intranuclear Inclusion Disease-Related Disorders . Neuronal intranuclear inclusion disease ( NIID ) is a slowly progressing neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous system and multiple visceral organs . The clinical manifestation of NIID varies widely , and both familial and sporadic cases have been reported . Here we have performed genetic linkage analysis and mapped the disease locus to 1p13.3-q23.1 ; however , whole-exome sequencing revealed no potential disease-causing mutations . We then performed long-read genome sequencing and identified a large @GeneSrc$ repeat expansion within human-specific NOTCH2NLC . Expanded @GeneSrc$ repeats as the cause of NIID was further confirmed in an additional three NIID-affected families as well as five sporadic NIID-affected case subjects . Moreover , given the clinical heterogeneity of NIID , we examined the size of the @GeneSrc$ repeat among 456 families with a variety of neurological conditions with the known pathogenic genes excluded . Surprisingly , @GeneSrc$ repeat expansion was observed in two @DiseaseTgt$ @DiseaseTgt$ families and three parkinsonism-affected families , implicating that the @GeneSrc$ repeat expansions in NOTCH2NLC could also contribute to the pathogenesis of both @DiseaseTgt$ and PD . Therefore , we suggest defining a term NIID-related disorders ( NIIDRD ) , which will include NIID and other related neurodegenerative diseases caused by the expanded @GeneSrc$ repeat within human-specific NOTCH2NLC .	0 4 4 4 0 10 10 10 9 10 0 0 15 15 15 24 17 15 17 24 24 22 24 24 24 24 29 29 29 25 33 33 33 29 33 37 37 33 24 41 41 44 43 41 44 44 44 44 49 55 49 49 49 55 55 44 55 60 60 60 60 63 63 60 60 60 68 68 65 70 65 60 76 76 75 76 60 80 80 80 76 60 84 84 84 87 87 84 84 84 94 94 94 94 89 97 97 89 84 101 101 109 104 104 101 106 104 109 109 109 115 115 115 115 115 109 115 116 116 123 123 123 123 115 109 135 135 130 130 130 135 132 130 135 135 135 137 135 141 141 141 137 144 144 137 147 147 135 150 150 147 155 155 155 155 147 155 135 164 164 162 162 164 164 164 169 167 167|168 169 164 169 173 173 169 164 164 185 180 179 180 185 182 180 185 185 175 188 188 185 191 191 188 191 191 164 198 198 198 198 198 201 203 203 199 205 203 205 203 210 210 203 210 211 214 211 216 211 211 222 222 222 222 217 225 225 217 198	0
33599827	4853	D000544	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with @DiseaseTgt$ , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 92 90|92 92 95 92 92 99 97 92 92 103 103 92 103 106 92 106 109 106 92 92 113 92 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D019636	False	2	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a @DiseaseTgt$ . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual @DiseaseTgt$ that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 22 22 19|22 16 27 24 27 41 30 30 27 30 34 34 41 37 37 34 41 41 41 41 41 48 48 48 48 48 48 65 53 53 53 65 57 57 57 53 61 61 61 57 65 65 65 48 67 65 48 72 72 72 89 75 75 72 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 168 168 168 168 167|176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D010300	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , @DiseaseTgt$ , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 94|99 94 103 103 94 103 106 94 106 109 106 94 94 113 94 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D003704	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal @DiseaseTgt$ , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D017825	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of @DiseaseTgt$ , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 75 73|75 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	4853	D010523	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , @DiseaseTgt$ , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 76 76 73 76 78|76 76 76 82 76 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D014202	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential @DiseaseTgt$ , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D009135	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal @DiseaseTgt$ . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D056784	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult @DiseaseTgt$ , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D000544	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with @DiseaseTgt$ , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 92 90|92 92 95 92 92 99 97 92 92 103 103 92 103 106 92 106 109 106 92 92 113 92 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D014202	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential @DiseaseTgt$ , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	C537395	True	0	@DiseaseTgt$ : recognition and update . @DiseaseTgt$ ( @DiseaseTgt$ ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of @DiseaseTgt$ . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable @DiseaseTgt$ phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	0 0 0 2 2 0 6|10 8 6 8 10 13 13 10 17 17 17 13 10 22 19 22 36 25 25 22 25 29 29 36 32 32 29 36 36 36 36 36 43 43 43 43 43 43 60 48 48 48 60 52 52 52 48 56 56 56 52 60 60 60 43 62 60 43 67 67 67 84 70 70 67 70 73 70 70 70 77 70 84 81 81 84 84 84 84 88 88 88 84 88 91 88 88 95 93 88 88 99 99 88 99 102 88 102 105 102 88 88 109 88 84 115 115 115 115 115 117 115 119 117 126 124 124 124 126 126 119 132 131 131 131 132 126 115 135 135 138 138 135 138 141 138 141 144 141 138 148 148 138 150 138 153 153 150 153 153 157 153 135 164 164 164 164 162 172 167 167 164 169 167 167 172 172 175 175 172 172 181 181 181 181 181 185 185 185 181 190 190 190 190 185 192 190 192 192 192 192 192 192 198 198 204 204 204 192 206 204 206 206 206 211 206 211 211 206 206 206 181 219 230 230 223 223 230 225 223 225 225 230 230 230 250 235 235 235 250 239 239 239 235 241 239 241 246 246 246 239 250 250 250 230 252 250 252 256 254 250 256 259 250 262 262 259 262 259 259 250 266 266 266 271 273 273 266 273 273 273 273 266 266 279 279 279 284 285 279 285 285 279 279 279 279 291 291 279 296 279 296 296 279 266 266 266 302 302 302 309 309 309 302 312 312 309 302 302 266 230 318 328 328 321 328 325 325 325 321 328 328 328 328 328 332 341 338 337 337 337 338 332 341 341 328 343 341 343 343 343 348 343 348 348 343 343 343 341 359 359 358 359 370 363 363 363 359 367 367 367 363 370 370 370 373 373 370 375 373 375 379 379 370 383 383 383 379 370 391 387 391 391 391 391 370 395 395 395 391 397 395 370 400 398 402 404 404 370 370 409 409 409 370 409 409 370 414 417 417 417 423 420 420 417 423 423 423 425 423 428 428 425 430 428 432 425 435 435 432 435 439 439 436 442 442 439 425 425 446 444 449 449 444 449 449 449 454 449 423	1
33599827	4853	D001284	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system @DiseaseTgt$ , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D017825	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of @DiseaseTgt$ , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 75 73|75 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D003704	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal @DiseaseTgt$ , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	4853	D019636	False	2	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a @DiseaseTgt$ . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual @DiseaseTgt$ that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 22 22 19|22 16 27 24 27 41 30 30 27 30 34 34 41 37 37 34 41 41 41 41 41 48 48 48 48 48 48 65 53 53 53 65 57 57 57 53 61 61 61 57 65 65 65 48 67 65 48 72 72 72 89 75 75 72 75 78 75 75 75 82 75 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 168 168 168 168 167|176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	4853	D010300	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the GGC repeat expansion in the 5'-untranslated region of the @GeneSrc$ gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , @DiseaseTgt$ , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into @GeneSrc$ repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the GGC repeat expansion in the 5'-untranslated region ( 5'UTR ) of the @GeneSrc$ gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of @GeneSrc$ repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with GGC repeat expansion of the @GeneSrc$ gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 94|99 94 103 103 94 103 106 94 106 109 106 94 94 113 94 90 119 119 119 119 119 121 119 123 121 130 128 128 128 130 130 123 136 135 135 135 136 130 119 139 139 142 142 139 142 145 142 145 148 145 142 152 152 142 154 142 157 157 154 157 157 161 157 139 168 168 168 168 166 176 171 171 168 173 171 171 176 176 179 179 176 176 185 185 185 185 185 189 189 189 185 194 194 194 194 189 196 194 196 196 196 196 196 196 202 202 208 208 208 196 210 208 210 210 210 215 210 215 215 210 210 210 185 223 234 234 227 227 234 229 227 229 229 234 234 234 254 239 239 239 254 243 243 243 239 245 243 245 250 250 250 243 254 254 254 234 256 254 256 260 258 254 260 263 254 266 266 263 266 263 263 254 270 270 270 275 277 277 270 277 277 277 277 270 270 283 283 283 288 289 283 289 289 283 283 283 283 295 295 283 300 283 300 300 283 270 270 270 306 306 306 313 313 313 306 316 316 313 306 306 270 234 322 332 332 325 332 329 329 329 325 332 332 332 332 332 336 345 342 341 341 341 342 336 345 345 332 347 345 347 347 347 352 347 352 352 347 347 347 345 363 363 362 363 374 367 367 367 363 371 371 371 367 374 374 374 377 377 374 379 377 379 383 383 374 387 387 387 383 374 395 391 395 395 395 395 374 399 399 399 395 401 399 374 404 402 406 408 408 374 374 413 413 413 374 413 413 374 418 421 421 421 427 424 424 421 427 427 427 429 427 432 432 429 434 432 436 429 439 439 436 439 443 443 440 446 446 443 429 429 450 448 453 453 448 453 453 453 458 453 427	0
33599827	79017	D010523	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , @DiseaseTgt$ , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 89 76 76 73 76 78|76 76 76 82 76 89 86 86 89 89 89 89 93 93 93 89 93 96 93 93 100 98 93 93 104 104 93 104 107 93 107 110 107 93 93 114 93 89 120 120 120 120 120 122 120 124 122 131 129 129 129 131 131 124 137 136 136 136 137 131 120 140 140 143 143 140 143 146 143 146 149 146 143 153 153 143 155 143 158 158 155 158 158 162 158 140 169 169 169 169 167 177 172 172 169 174 172 172 177 177 180 180 177 177 186 186 186 186 186 190 190 190 186 195 195 195 195 190 197 195 197 197 197 197 197 197 203 203 209 209 209 197 211 209 211 211 211 216 211 216 216 211 211 211 186 224 235 235 228 228 235 230 228 230 230 235 235 235 255 240 240 240 255 244 244 244 240 246 244 246 251 251 251 244 255 255 255 235 257 255 257 261 259 255 261 264 255 267 267 264 267 264 264 255 271 271 271 276 278 278 271 278 278 278 278 271 271 284 284 284 289 290 284 290 290 284 284 284 284 296 296 284 301 284 301 301 284 271 271 271 307 307 307 314 314 314 307 317 317 314 307 307 271 235 323 333 333 326 333 330 330 330 326 333 333 333 333 333 337 346 343 342 342 342 343 337 346 346 333 348 346 348 348 348 353 348 353 353 348 348 348 346 364 364 363 364 375 368 368 368 364 372 372 372 368 375 375 375 378 378 375 380 378 380 384 384 375 388 388 388 384 375 396 392 396 396 396 396 375 400 400 400 396 402 400 375 405 403 407 409 409 375 375 414 414 414 375 414 414 375 419 422 422 422 428 425 425 422 428 428 428 430 428 433 433 430 435 433 437 430 440 440 437 440 444 444 441 447 447 444 430 430 451 449 454 454 449 454 454 454 459 454 428	0
33599827	79017	D009135	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal @DiseaseTgt$ . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	C537395	True	0	@DiseaseTgt$ : recognition and update . @DiseaseTgt$ ( @DiseaseTgt$ ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of @DiseaseTgt$ . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable @DiseaseTgt$ phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	0 0 0 2 2 0 6|10 8 6 8 10 13 13 10 17 17 17 13 10 22 19 22 36 25 25 22 25 29 29 36 32 32 29 36 36 36 36 36 43 43 43 43 43 43 60 48 48 48 60 52 52 52 48 56 56 56 52 60 60 60 43 62 60 43 67 67 67 84 70 70 67 70 73 70 70 70 77 70 84 81 81 84 84 84 84 88 88 88 84 88 91 88 88 95 93 88 88 99 99 88 99 102 88 102 105 102 88 88 109 88 84 115 115 115 115 115 117 115 119 117 126 124 124 124 126 126 119 132 131 131 131 132 126 115 135 135 138 138 135 138 141 138 141 144 141 138 148 148 138 150 138 153 153 150 153 153 157 153 135 164 164 164 164 162 172 167 167 164 169 167 167 172 172 175 175 172 172 181 181 181 181 181 185 185 185 181 190 190 190 190 185 192 190 192 192 192 192 192 192 198 198 204 204 204 192 206 204 206 206 206 211 206 211 211 206 206 206 181 219 230 230 223 223 230 225 223 225 225 230 230 230 250 235 235 235 250 239 239 239 235 241 239 241 246 246 246 239 250 250 250 230 252 250 252 256 254 250 256 259 250 262 262 259 262 259 259 250 266 266 266 271 273 273 266 273 273 273 273 266 266 279 279 279 284 285 279 285 285 279 279 279 279 291 291 279 296 279 296 296 279 266 266 266 302 302 302 309 309 309 302 312 312 309 302 302 266 230 318 328 328 321 328 325 325 325 321 328 328 328 328 328 332 341 338 337 337 337 338 332 341 341 328 343 341 343 343 343 348 343 348 348 343 343 343 341 359 359 358 359 370 363 363 363 359 367 367 367 363 370 370 370 373 373 370 375 373 375 379 379 370 383 383 383 379 370 391 387 391 391 391 391 370 395 395 395 391 397 395 370 400 398 402 404 404 370 370 409 409 409 370 409 409 370 414 417 417 417 423 420 420 417 423 423 423 425 423 428 428 425 430 428 432 425 435 435 432 435 439 439 436 442 442 439 425 425 446 444 449 449 444 449 449 449 454 449 423	0
33599827	79017	D056784	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system atrophy , essential tremor , adult @DiseaseTgt$ , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
33599827	79017	D001284	False	1	Neuronal intranuclear inclusion disease : recognition and update . Neuronal intranuclear inclusion disease ( NIID ) used to be considered as a neurodegenerative disease . Due to the availability of skin biopsy , the diagnostic efficiency of the disease has been greatly improved . Recently , researchers have successfully identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region of the NOTCH2NLC gene is the causative mutation of NIID . Besides the typical phenotype of brain degeneration , peripheral neuropathy , and autonomic disturbance , the gene mutation is also associated with Alzheimer 's disease , frontotemporal dementia , Parkinson 's disease , multiple system @DiseaseTgt$ , essential tremor , adult leukoencephalopathy , and oculopharyngodistal myopathy . However , it still needs more studies to elucidate whether those variable NIID phenotypes can categorize into NOTCH2NLC repeat expansion related disorders . We update the discovery milestone , clinical phenotype , laboratory examinations , as well as new insight into the diagnosis and treatment of NIID . NIID is an unusual degenerative disease that can involve multiple systems , especially involves the nervous system . Originally , it is named after the pathological characteristics with extensive intranuclear eosinophilic inclusions in central and peripheral nervous tissues , as well as in multiple other organs ( Sone et al. , Brain 139:3170 - 3186 , 2016 ) . In 2019 , several research teams from China and Japan have simultaneously identified that the @GeneSrc$ repeat expansion in the 5'-untranslated region ( 5'UTR ) of the NOTCH2NLC gene is the pathogenic mutation of NIID ( Ishiura et al. , Nat Genet 51:1222 - 1232 , 2019 ; Deng et al. , J Med Genet 56:758 - 764 , 2019 ; Sone et al. , Nat Genet 51:1215 - 1221 , 2019 ; Sun et al. , Brain 143:222 - 233 , 2020 ; Tian et al. , Am J Hum Genet 105:166 - 176 , 2019 ) . Since then , the number of reported NIID cases is rapidly increasing , and the spectrum of NOTCH2NLC repeat expansion related disorders is significantly broadening ( Westenberger and Klein , Brain 143:5 - 8 , 2020 ) . However , the NIID associated with @GeneSrc$ repeat expansion of the NOTCH2NLC gene might be account for a part of patients , probably more frequently in the Asian population , because this expansion has not been identified in an European series with postmortem confirmed NIID cases ( Chen et al. , Ann Clin Transl Neurol 2020 ) . In order to better understand of the disease , we need to revisit the current state of NIID in combination with the findings based on our experiences in recent years and update the concepts about the clinical and pathogenic progression of NIID .	3 3 3 3 3 3 5 5 3 12 12 12 16 14 12 14 16 19 19 16 23 23 23 19 16 28 25 28 42 31 31 28 31 35 35 42 38 38 35 42 42 42 42 42 49 49 49 49 49 49 66 54 54 54 66 58 58 58 54 62 62 62 58 66 66 66 49 68 66 49 73 73 73 90 76 76 73 76 79 76 76 76 83 76 90 87 87 90 90 90 90 94 94 94 90 94 97 94 94 101 99 94 94 105 105 94 105 108 94 108 111 108 94 94 115 94 90 121 121 121 121 121 123 121 125 123 132 130 130 130 132 132 125 138 137 137 137 138 132 121 141 141 144 144 141 144 147 144 147 150 147 144 154 154 144 156 144 159 159 156 159 159 163 159 141 170 170 170 170 168 178 173 173 170 175 173 173 178 178 181 181 178 178 187 187 187 187 187 191 191 191 187 196 196 196 196 191 198 196 198 198 198 198 198 198 204 204 210 210 210 198 212 210 212 212 212 217 212 217 217 212 212 212 187 225 236 236 229 229 236 231 229 231 231 236 236 236 256 241 241 241 256 245 245 245 241 247 245 247 252 252 252 245 256 256 256 236 258 256 258 262 260 256 262 265 256 268 268 265 268 265 265 256 272 272 272 277 279 279 272 279 279 279 279 272 272 285 285 285 290 291 285 291 291 285 285 285 285 297 297 285 302 285 302 302 285 272 272 272 308 308 308 315 315 315 308 318 318 315 308 308 272 236 324 334 334 327 334 331 331 331 327 334 334 334 334 334 338 347 344 343 343 343 344 338 347 347 334 349 347 349 349 349 354 349 354 354 349 349 349 347 365 365 364 365 376 369 369 369 365 373 373 373 369 376 376 376 379 379 376 381 379 381 385 385 376 389 389 389 385 376 397 393 397 397 397 397 376 401 401 401 397 403 401 376 406 404 408 410 410 376 376 415 415 415 376 415 415 376 420 423 423 423 429 426 426 423 429 429 429 431 429 434 434 431 436 434 438 431 441 441 438 441 445 445 442 448 448 445 431 431 452 450 455 455 450 455 455 455 460 455 429	0
28781905	6622	D010300	True	0	Genetic Variants in @GeneSrc$ and the Risk of @DiseaseTgt$ and Clinical Outcomes : A Review . There is increasing evidence of the contribution of genetic susceptibility to the etiology of @DiseaseTgt$ ( @DiseaseTgt$ ) . Genetic variations in the @GeneSrc$ gene are well established by linkage and genome-wide association studies . Positive associations of single nucleotide polymorphisms ( SNPs ) in @GeneSrc$ and increased risk for @DiseaseTgt$ were found . However , the role of @GeneSrc$ variants in individual traits or phenotypes of @DiseaseTgt$ is unknown . Here , we reviewed the current literature and identified 57 studies , performed in fourteen different countries , that investigated @GeneSrc$ variants and susceptibility to @DiseaseTgt$ . We discussed the findings based on environmental factors , history of @DiseaseTgt$ , clinical outcomes , and ethnicity . In conclusion , SNPs within the @GeneSrc$ gene can modify the susceptibility to @DiseaseTgt$ , leading to increased or decreased risk . The risk associations of some SNPs varied among samples . Of notice , no studies in South American or African populations were found . There is little information about the effects of these variants on particular clinical aspects of @DiseaseTgt$ , such as motor and nonmotor symptoms . Similarly , evidence of possible interactions between @GeneSrc$ SNPs and environmental factors or disease progression is scarce . There is a need to expand the clinical applicability of these data as well as to investigate the role of @GeneSrc$ SNPs in populations with different ethnic backgrounds .	1 1 3 1 3 6 3 8 8|6 8 8 1 1 14 1 1 17 17 19 17 22 22 19 25 25 22 28 28 25 30 28|30 32 30 32 17 36 43 40 40 40 36 43 43 43 45 43 45 45 49 45 43 52 68 56 56 56 52 58 56 58 61 56 52 52 63 66 64 68 68 68 85 85 73 85 76 76 73 79 79 73 79 79 83 81 85 85 85 90 90 90 90 93 93 90 90 90 97 95 97 97 103 103 103 99 97 106 97 108 106 108 108 112 110 90 115 115 117 115 117 121 121 118 121 121 125 123 125 128 123 128 123 123 115 134 142 142 142 140 140 140 136 142 142 144 142 146 144 142 142 150 148 150 150 150 142 157 157 161 160 160 157 161 163 161 161 166 177 166 169 177 172 172 169 172 172 172 177 177 177 180 180 182 180 185 185 182 188 188 185 192 192 190 182 194 192 194 198 196 192 198 198 198 180 219 219 219 208 208 205 211 211 208 211 214 211 211 217 211 219 219 219 222 222 224 222 226 224 229 229 226 232 232 229 229 233 233 237 226 239 237 242 242 239 244 239 248 248 248 244 222	1
24768741	6622	D019636	False	1	Genetic variants and animal models in @GeneSrc$ and Parkinson disease . Parkinson disease ( PD ; MIM 168600 ) is the second most common @DiseaseTgt$ characterized by a variety of motor and non-motor features . To date , at least 20 loci and 15 disease-causing genes for parkinsonism have been identified . Among them , the @GeneSrc$ ( @GeneSrc$ ) gene was associated with @GeneSrc$ . Point mutations , duplications and triplications in the @GeneSrc$ gene cause a rare dominant form of PD in familial and sporadic PD cases . The @GeneSrc$ protein , a member of the synuclein family , is abundantly expressed in the brain . The protein is the major component of Lewy bodies and Lewy neurites in dopaminergic neurons in PD . Further understanding of its role in the pathogenesis of PD through various genetic techniques and animal models will likely provide new insights into our understanding , therapy and prevention of PD .	1 1 1 4 1 6 1 6 9 6 1 12 24 14 12 14 14 16 14 24 24 24 23 24 23|24 24 28 28 25 30 28 30 30 30 24 36 50 50 39 40 41 50 41 45 45 41 47 45 50 50 50 50 53 62 62 60 60 58 56 58 62 62 62 64 62 62 67 76 67 67 69 69 75 75 75 69 76 80 80 78 76 82 80 84 80 84 84 88 84 76 92 92 103 92 95 92 99 99 99 95 92 103 103 103 106 106 103 103 109 113 113 113 113 113 116 116 113 116 119 116 122 122 113 124 122 113 127 145 130 130 127 133 133 127 135 133 139 139 139 127 139 142 139 145 145 145 147 145 150 150 147 150 150 150 150 156 154 145	0
24768741	6622	D010300	True	0	Genetic variants and animal models in @GeneSrc$ and @DiseaseTgt$ . @DiseaseTgt$ ( @DiseaseTgt$ ; MIM 168600 ) is the second most common progressive neurodegenerative disorder characterized by a variety of motor and non-motor features . To date , at least 20 loci and 15 disease-causing genes for parkinsonism have been identified . Among them , the @GeneSrc$ ( @GeneSrc$ ) gene was associated with @GeneSrc$ . Point mutations , duplications and triplications in the @GeneSrc$ gene cause a rare dominant form of @DiseaseTgt$ in familial and sporadic @DiseaseTgt$ cases . The @GeneSrc$ protein , a member of the synuclein family , is abundantly expressed in the brain . The protein is the major component of Lewy bodies and Lewy neurites in dopaminergic neurons in @DiseaseTgt$ . Further understanding of its role in the pathogenesis of @DiseaseTgt$ through various genetic techniques and animal models will likely provide new insights into our understanding , therapy and prevention of @DiseaseTgt$ .	1 1 1 4 1 6 1 6 8|6 1 10|24 12 10 12 12 14 12 24 24 24 21 24 21 24 24 24 28 28 25 30 28 30 30 30 24 36 50 50 39 40 41 50 41 45 45 41 47 45 50 50 50 50 53 62 62 60 60 58 56 58 62 62 62 64 62 62 67 76 67 67 69 69 75 75 75 69 76 80 80 78 76 82 80 84 80 84 84 88 84 76 92 92 103 92 95 92 99 99 99 95 92 103 103 103 106 106 103 103 109 113 113 113 113 113 116 116 113 116 119 116 122 122 113 124 122 113 127 145 130 130 127 133 133 127 135 133 139 139 139 127 139 142 139 145 145 145 147 145 150 150 147 150 150 150 150 156 154 145	1
24768741	6622	D010302	False	1	Genetic variants and animal models in @GeneSrc$ and Parkinson disease . Parkinson disease ( PD ; MIM 168600 ) is the second most common progressive neurodegenerative disorder characterized by a variety of motor and non-motor features . To date , at least 20 loci and 15 disease-causing genes for @DiseaseTgt$ have been identified . Among them , the @GeneSrc$ ( @GeneSrc$ ) gene was associated with @GeneSrc$ . Point mutations , duplications and triplications in the @GeneSrc$ gene cause a rare dominant form of PD in familial and sporadic PD cases . The @GeneSrc$ protein , a member of the synuclein family , is abundantly expressed in the brain . The protein is the major component of Lewy bodies and Lewy neurites in dopaminergic neurons in PD . Further understanding of its role in the pathogenesis of PD through various genetic techniques and animal models will likely provide new insights into our understanding , therapy and prevention of PD .	1 1 1 4 1 6 1 6 9 6 1 12 26 14 12 14 14 16 14 26 26 26 23 26 23 26 26 26 30 30 27 32 30 32 32 32 26 38 52 52 41 42 43 52 43 47 47 43 49 47 52 52 52 52 55 64 64 62 62 60 58 60 64 64 64 66 64 64 69 78 69 69 71 71 77 77 77 71 78 82 82 80 78 84 82 86 82 86 86 90 86 78 94 94 105 94 97 94 101 101 101 97 94 105 105 105 108 108 105 105 111 115 115 115 115 115 118 118 115 118 121 118 124 124 115 126 124 115 129 147 132 132 129 135 135 129 137 135 141 141 141 129 141 144 141 147 147 147 149 147 152 152 149 152 152 152 152 158 156 147	0
36348357	348	D000544	True	0	@GeneSrc$ in @DiseaseTgt$ : pathophysiology and therapeutic strategies . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common cause of dementia worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the @GeneSrc$ ( @GeneSrc$ ) gene remains the strongest and most prevalent , impacting more than half of all @DiseaseTgt$ cases . While the epsilon4 allele of the @GeneSrc$ gene significantly increases @DiseaseTgt$ risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three @GeneSrc$ protein isoforms that differ at two amino acid positions . The primary physiological function of @GeneSrc$ is to mediate lipid transport in the brain and periphery ; however , additional functions of @GeneSrc$ in diverse biological functions have been recognized . Pathogenically , @GeneSrc$ seeds amyloid-beta ( Abeta ) plaques in the brain with @GeneSrc$ driving earlier and more abundant amyloids . @GeneSrc$ isoforms also have differential effects on multiple Abeta-related or Abeta-independent pathways . The complexity of @GeneSrc$ biology and pathobiology presents challenges to designing effective @GeneSrc$ therapeutic strategies . This review examines the key pathobiological pathways of @GeneSrc$ and related targeting strategies with a specific focus on the latest technological advances and tools .	0 2 0|2 0 0 4 7 4 0 9|17 11 9 11 17 17 16 17 17 19 17 17 17 17 24 27 27 27 17 31 28 31 27 27 36 36 36 49 40 40 40 36 40 49 48 48 48 48 48 49 49 51 49 51 54 51 51 49 59 59 56 63 63 63 59 49 74 68 68 74 72 72 72 68 74 82 76 74 82 80 80 82 82 82 82 88 88 88 86 83 82 92 92 93 93 97 97 97 93 99 97 104 104 104 104 99 93 109 108 109 112 111 109 112 114 112 116 114 119 119 116 119 119 114 135 135 126 135 128 126 132 132 132 126 135 135 114 112 156 156 140 156 140 143 141 143 140 148 148 140 150 148 150 151 152 155 152 156 156 159 161 161 161 163 161 166 166 161 166 166 166 161 172 178 175 175 172 175 175 178 178 181 178 185 182 182 181 178 188 189 189 193 193 193 189 195 193 195 195 195 195 203 203 203 189 208 208 208 208 203 208 208 189	0
36348357	348	D003704	False	1	@GeneSrc$ in Alzheimer 's disease : pathophysiology and therapeutic strategies . Alzheimer 's disease ( AD ) is the most common cause of @DiseaseTgt$ worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the @GeneSrc$ ( @GeneSrc$ ) gene remains the strongest and most prevalent , impacting more than half of all AD cases . While the epsilon4 allele of the @GeneSrc$ gene significantly increases AD risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three @GeneSrc$ protein isoforms that differ at two amino acid positions . The primary physiological function of @GeneSrc$ is to mediate lipid transport in the brain and periphery ; however , additional functions of @GeneSrc$ in diverse biological functions have been recognized . Pathogenically , @GeneSrc$ seeds amyloid-beta ( Abeta ) plaques in the brain with @GeneSrc$ driving earlier and more abundant amyloids . @GeneSrc$ isoforms also have differential effects on multiple Abeta-related or Abeta-independent pathways . The complexity of @GeneSrc$ biology and pathobiology presents challenges to designing effective @GeneSrc$ therapeutic strategies . This review examines the key pathobiological pathways of @GeneSrc$ and related targeting strategies with a specific focus on the latest technological advances and tools .	0 4 4 4 0 0 0 6 9 6 0 13 13 21 15 13 15 21 21 20 21 21 23 21 21 21 21 28 31 31 31 21 35 32 35 31 31 40 40 40 53 44 44 44 40 44 53 52 52 52 52 52 53 53 55 53 55 58 55 55 53 63 63 60 67 67 67 63 53 78 72 72 78 76 76 76 72 78 86 80 78 86 84 84 86 86 86 86 92 92 92 90 87 86 96 96 97 97 101 101 101 97 103 101 108 108 108 108 103 97 113 112 113 116 115 113 116 118 116 120 118 123 123 120 123 123 118 139 139 130 139 132 130 136 136 136 130 139 139 118 116 160 160 144 160 144 147 145 147 144 152 152 144 154 152 154 155 156 159 156 160 160 163 165 165 165 167 165 170 170 165 170 170 170 165 176 182 179 179 176 179 179 182 182 185 182 189 186 186 185 182 192 193 193 197 197 197 193 199 197 199 199 199 199 207 207 207 193 212 212 212 212 207 212 212 193	0
36348357	351	D000544	False	3	ApoE in @DiseaseTgt$ : pathophysiology and therapeutic strategies . @DiseaseTgt$ ( @DiseaseTgt$ ) is the most common cause of dementia worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the apolipoprotein E ( APOE ) gene remains the strongest and most prevalent , impacting more than half of all @DiseaseTgt$ cases . While the epsilon4 allele of the APOE gene significantly increases @DiseaseTgt$ risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three apoE protein isoforms that differ at two amino acid positions . The primary physiological function of apoE is to mediate lipid transport in the brain and periphery ; however , additional functions of apoE in diverse biological functions have been recognized . Pathogenically , apoE seeds @GeneSrc$ ( @GeneSrc$ ) plaques in the brain with apoE4 driving earlier and more abundant amyloids . ApoE isoforms also have differential effects on multiple @GeneSrc$ or @GeneSrc$ pathways . The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies . This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools .	0 2 0|2 0 0 4 7 4 0 9|17 11 9 11 17 17 16 17 17 19 17 17 17 17 24 27 27 27 17 31 28 31 27 27 36 36 36 50 40 40 40 36 40 50 49 49 49 49 49 49 50 50 52 50 52 55 52 52 50 60 60 57 64 64 64 60 50 75 69 69 75 73 73 73 69 75 83 77 75 83 81 81 83 83 83 83 89 89 89 87 84 83 93 93 94 94 98 98 98 94 100 98 105 105 105 105 100 94 110 109 110 113 112 110 113 115 113 117 115 120 120 117 120 120 115 136 136 127 136 129 127 133 133 133 127 136 136 115 113 157 157 141 157 141 144 142 144 141 149 149 141 151 149 151 152 153 156 153 157 157 160 162 162 162 164 162 167 167 162 167 167 167 162 173 179 176 176 173 176 176 179 179 182 179 186 183 183 182 179 189 190 190 194 194 194 190 196 194 196 196 196 196 204 204 204 190 209 209 209 209 204 209 209 190	0
36348357	351	D003704	False	5	ApoE in Alzheimer 's disease : pathophysiology and therapeutic strategies . Alzheimer 's disease ( AD ) is the most common cause of @DiseaseTgt$ worldwide , and its prevalence is rapidly increasing due to extended lifespans . Among the increasing number of genetic risk factors identified , the apolipoprotein E ( APOE ) gene remains the strongest and most prevalent , impacting more than half of all AD cases . While the epsilon4 allele of the APOE gene significantly increases AD risk , the epsilon2 allele is protective relative to the common epsilon3 allele . These gene alleles encode three apoE protein isoforms that differ at two amino acid positions . The primary physiological function of apoE is to mediate lipid transport in the brain and periphery ; however , additional functions of apoE in diverse biological functions have been recognized . Pathogenically , apoE seeds @GeneSrc$ ( @GeneSrc$ ) plaques in the brain with apoE4 driving earlier and more abundant amyloids . ApoE isoforms also have differential effects on multiple @GeneSrc$ or @GeneSrc$ pathways . The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies . This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools .	0 4 4 4 0 0 0 6 9 6 0 13 13 21 15 13 15 21 21 20 21 21 23 21 21 21 21 28 31 31 31 21 35 32 35 31 31 40 40 40 54 44 44 44 40 44 54 53 53 53 53 53 53 54 54 56 54 56 59 56 56 54 64 64 61 68 68 68 64 54 79 73 73 79 77 77 77 73 79 87 81 79 87 85 85 87 87 87 87 93 93 93 91 88 87 97 97 98 98 102 102 102 98 104 102 109 109 109 109 104 98 114 113 114 117 116 114 117 119 117 121 119 124 124 121 124 124 119 140 140 131 140 133 131 137 137 137 131 140 140 119 117 161 161 145 161 145 148 146 148 145 153 153 145 155 153 155 156 157 160 157 161 161 164 166 166 166 168 166 171 171 166 171 171 171 166 177 183 180 180 177 180 180 183 183 186 183 190 187 187 186 183 193 194 194 198 198 198 194 200 198 200 200 200 200 208 208 208 194 213 213 213 213 208 213 213 194	0
30958695	11816	D000544	True	0	@GeneSrc$ genotype influences the gut microbiome structure and function in humans and mice : relevance for @DiseaseTgt$ pathophysiology . @GeneSrc$ ( @GeneSrc$ ) genotype is the strongest prevalent genetic risk factor for @DiseaseTgt$ ( @DiseaseTgt$ ) . Numerous studies have provided insights into the pathologic mechanisms . However , a comprehensive understanding of the impact of @GeneSrc$ genotype on microflora speciation and metabolism is completely lacking . In this study , we investigated the association between @GeneSrc$ genotype and the gut microbiome composition in human and APOE-targeted replacement ( TR ) transgenic mice . Fecal microbiota amplicon sequencing from matched individuals with different APOE genotypes revealed no significant differences in overall microbiota diversity in group-aggregated human APOE genotypes . However , several bacterial taxa showed significantly different relative abundance between APOE genotypes . Notably , we detected an association of Prevotellaceae and Ruminococcaceae and several butyrate-producing genera abundances with APOE genotypes . These findings were confirmed by comparing the gut microbiota of APOE-TR mice . Furthermore , metabolomic analysis of murine fecal water detected significant differences in microbe-associated amino acids and short-chain fatty acids between @GeneSrc$ genotypes . Together , these findings indicate that @GeneSrc$ genotype is associated with specific gut microbiome profiles in both humans and APOE-TR mice . This suggests that the gut microbiome is worth further investigation as a potential target to mitigate the deleterious impact of the APOE4 allele on cognitive decline and the prevention of @DiseaseTgt$ , T. T. T. , Corsini , S. , Kellingray , L. , Hegarty , C. , Le Gall , G. , Narbad , A. , Muller , M. , Tejera , N. , O'Toole , P. W. , Minihane , A.-M. , Vauzour , D. @GeneSrc$ genotype influences the gut microbiome structure and function in humans and mice : relevance for @DiseaseTgt$ pathophysiology .	1 2 2 6 6 6 2 6 6 10 6 10 10 2 2 17 16|17 14 2 23 23 23 23 30 30 30 27 30 30 30 30 32 30|32 34 32 34 30 38 40 40 40 40 45 45 45 41 40 65 65 51 51 65 54 54 51 57 57 54 60 60 54 60 60 65 65 65 65 69 69 72 72 72 72 74 72 77 77 74 77 82 82 82 77 92 87 84 84 92 89 87 89 92 74 72 96 96 97 105 100 100 97 104 104 104 97 105 108 108 105 112 112 112 108 117 117 117 117 112 105 124 124 123 123 124 124 126 128 128 124 131 131 128 124 136 136 136 136 138 136 140 138 140 140 142 145 147 147 138 150 150 147 136 153 155 155 155 157 155 160 160 157 163 163 160 155 173 173 168 173 172 172 172 168 173 175 173 179 179 179 175 179 183 183 179 186 186 175 173 192 192 191 192 192 197 195 197 197 192 202 202 202 202 197 205 205 197 205 208 205 192 211 211 217 215 215 217 217 211 219 217 223 223 223 217 225 217 228 228 225 232 232 232 228 235 235 228 235 238 235 240 238 211 244 244 289 244 244 246 244 244 252 252 244 244 256 256 244 244 259 244 261 259 261 259 263 259 265 269 267 259 269 273 273 269 273 273 278 278 259 278 244 280 280 280 280 280 288 288 289 211 293 293 293 289 293 293 297 293 297 297 211 211 304 303|304 301 211	0
30958695	348	D000544	False	3	APOE genotype influences the gut microbiome structure and function in humans and mice : relevance for @DiseaseTgt$ pathophysiology . Apolipoprotein E ( APOE ) genotype is the strongest prevalent genetic risk factor for @DiseaseTgt$ ( @DiseaseTgt$ ) . Numerous studies have provided insights into the pathologic mechanisms . However , a comprehensive understanding of the impact of APOE genotype on microflora speciation and metabolism is completely lacking . In this study , we investigated the association between APOE genotype and the gut microbiome composition in human and @GeneSrc$ replacement ( TR ) transgenic mice . Fecal microbiota amplicon sequencing from matched individuals with different @GeneSrc$ genotypes revealed no significant differences in overall microbiota diversity in group-aggregated human @GeneSrc$ genotypes . However , several bacterial taxa showed significantly different relative abundance between @GeneSrc$ genotypes . Notably , we detected an association of Prevotellaceae and Ruminococcaceae and several butyrate-producing genera abundances with @GeneSrc$ genotypes . These findings were confirmed by comparing the gut microbiota of APOE-TR mice . Furthermore , metabolomic analysis of murine fecal water detected significant differences in microbe-associated amino acids and short-chain fatty acids between APOE genotypes . Together , these findings indicate that APOE genotype is associated with specific gut microbiome profiles in both humans and APOE-TR mice . This suggests that the gut microbiome is worth further investigation as a potential target to mitigate the deleterious impact of the APOE4 allele on cognitive decline and the prevention of @DiseaseTgt$ , T. T. T. , Corsini , S. , Kellingray , L. , Hegarty , C. , Le Gall , G. , Narbad , A. , Muller , M. , Tejera , N. , O'Toole , P. W. , Minihane , A.-M. , Vauzour , D. APOE genotype influences the gut microbiome structure and function in humans and mice : relevance for @DiseaseTgt$ pathophysiology .	1 2 2 6 6 6 2 6 6 10 6 10 10 2 2 17 16|17 14 2 24 24 24 24 24 31 31 31 28 31 31 31 31 33 31|33 35 33 35 31 39 41 41 41 41 46 46 46 42 41 66 66 52 52 66 55 55 52 58 58 55 61 61 55 61 61 66 66 66 66 70 70 73 73 73 73 75 73 78 78 75 78 83 83 83 78 93 88 85 85 93 90 88 90 93 75 73 97 97 98 106 101 101 98 105 105 105 98 106 109 109 106 113 113 113 109 118 118 118 118 113 106 125 125 124 124 125 125 127 129 129 125 132 132 129 125 137 137 137 137 139 137 141 139 141 141 143 146 148 148 139 151 151 148 137 154 156 156 156 158 156 161 161 158 164 164 161 156 174 174 169 174 173 173 173 169 174 176 174 180 180 180 176 180 184 184 180 187 187 176 174 193 193 192 193 193 198 196 198 198 193 203 203 203 203 198 206 206 198 206 209 206 193 212 212 218 216 216 218 218 212 220 218 224 224 224 218 226 218 229 229 226 233 233 233 229 236 236 229 236 239 236 241 239 212 245 245 290 245 245 247 245 245 253 253 245 245 257 257 245 245 260 245 262 260 262 260 264 260 266 270 268 260 270 274 274 270 274 274 279 279 260 279 245 281 281 281 281 281 289 289 290 212 294 294 294 290 294 294 298 294 298 298 212 212 305 304|305 302 212	0
33712570	64231	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , @GeneSrc$ , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	9179	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , @GeneSrc$ , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	7791	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and @GeneSrc$ ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	10307	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , @GeneSrc$ , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	6688	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , @GeneSrc$ , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	9135	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , @GeneSrc$ , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	51338	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , @GeneSrc$ , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	23431	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including @GeneSrc$ , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	94241	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , @GeneSrc$ , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	29992	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , BIN1 , MS4A4A , MS4A6A , @GeneSrc$ , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
33712570	274	D000544	True	0	Integration of @DiseaseTgt$ genetics and myeloid genomics identifies disease risk regulatory elements and genes . Genome-wide association studies ( GWAS ) have identified more than 40 loci associated with @DiseaseTgt$ ( @DiseaseTgt$ ) , but the causal variants , regulatory elements , genes and pathways remain largely unknown , impeding a mechanistic understanding of @DiseaseTgt$ pathogenesis . Previously , we showed that @DiseaseTgt$ risk alleles are enriched in myeloid-specific epigenomic annotations . Here , we show that they are specifically enriched in active enhancers of monocytes , macrophages and microglia . We integrated @DiseaseTgt$ GWAS with myeloid epigenomic and transcriptomic datasets using analytical approaches to link myeloid enhancer activity to target gene expression regulation and @DiseaseTgt$ risk modification . We identify @DiseaseTgt$ risk enhancers and nominate candidate causal genes among their likely targets ( including AP4E1 , AP4M1 , APBB3 , @GeneSrc$ , MS4A4A , MS4A6A , PILRA , RABEP1 , SPI1 , TP53INP1 , and ZYX ) in twenty loci . Fine-mapping of these enhancers nominates candidate functional variants that likely modify @DiseaseTgt$ risk by regulating gene expression in myeloid cells . In the MS4A locus we identified a single candidate functional variant and validated it in human induced pluripotent stem cell (hiPSC)-derived microglia and brain . Taken together , this study integrates @DiseaseTgt$ GWAS with multiple myeloid genomic datasets to investigate the mechanisms of @DiseaseTgt$ risk alleles and nominates candidate functional variants , regulatory elements and genes that likely modulate disease susceptibility .	7 3 2|3 0 3 6 3 7 11 11 11 7 11 11 7 17 17 22 19 17 19 22 22 25 25 26 22 26 29 27|29 31 29 31 22 22 37 37 45 37 40 37 40 40 37 37 22 47 45 45 45 52 52 49 55 55 52 22 60 60 60 60 66 64 64 66 66 60 70 70 70 66 60 75 75 75 75 80 80 80 80 75 83 83 80 85 83 85 85 85 85 75 92 92 94 92 97 97 92 97 97 92 100 103 101 105 103 108 108 105 110 92 113 113 110 113 110 117 92 92 120 120 123 123 120 120 120 127 128 125 132 132 132 125 135 135 132 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 135 160 160 132 120 166 165 165 162 166 169 169 166 172 172 169 174 172 176 172 178 176 181 181 176 166 186 186 186 188 188 188 193 193 193 193 188 188 188 195 204 199 204 204 202 204 204 195 204 204 188 213 208 213 212 213 213 215 213 220 220 219 220 213 222 213 224 222 228 228 228 224 222 222 233 233 230 233 236 233 236 236 241 241 236 243 241 213	1
36504281	4319	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , @GeneSrc$ in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , @GeneSrc$ , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	0
36504281	8751	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and @GeneSrc$ in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	1
36504281	8751	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and @GeneSrc$ in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	0
36504281	945	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , @GeneSrc$ , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	1
36504281	27180	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , @GeneSrc$ in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	945	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , @GeneSrc$ , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	0
36504281	8751	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , GPNMB , and @GeneSrc$ in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	10457	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , @GeneSrc$ , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and @GeneSrc$ were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	10457	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , @GeneSrc$ , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and @GeneSrc$ were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	2896	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and @GeneSrc$ in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of @GeneSrc$ , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	2896	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and @GeneSrc$ in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of @GeneSrc$ , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	952	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and @GeneSrc$ , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	1
36504281	4319	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in @DiseaseTgt$ , @GeneSrc$ in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , @GeneSrc$ , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	0
36504281	10457	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , @GeneSrc$ , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and @GeneSrc$ were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	0
36504281	348	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , @GeneSrc$ , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	10457	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , @GeneSrc$ , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and @GeneSrc$ were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	1
36504281	27180	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , @GeneSrc$ in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	0
36504281	945	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , @GeneSrc$ , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	952	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and @GeneSrc$ , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	0
36504281	4319	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , @GeneSrc$ in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , @GeneSrc$ , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	952	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and @GeneSrc$ , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	2896	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and @GeneSrc$ in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of @GeneSrc$ , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	0
36504281	348	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , @GeneSrc$ , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	2896	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and @GeneSrc$ in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of @GeneSrc$ , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	1
36504281	27180	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , @GeneSrc$ in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	0
36504281	348	D000544	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , @GeneSrc$ , CD33 , and GRN in @DiseaseTgt$ , MMP-10 in preclinical @DiseaseTgt$ , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in @DiseaseTgt$ , preclinical @DiseaseTgt$ , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 139 137|139 137 124 144 144 144|141 144 124 150 150 150 124 150 150 150 153 153 153 150 150 162 162 160 150 122 165 174 167 165 167 167 167 167 167 174 174 176 174|176 176 179 176|179 176 174 184 182 174 184 184 174 189 190 190 192 190 195 195 190 198 198 195 190 202 202 202 206 205 206 202 208 206 208 211 209 214 214 211 218 218 218 214 222 222 222 218 202	1
36504281	8751	D020271	False	5	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of @DiseaseTgt$ . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and @GeneSrc$ in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 28 26|28 23 31 35 33 31 35 35 38 38 35 42 42 42 38 35 47 47 47 52 49 47 49 52 52 54 52 57 57 54 57 57 54 63 63 54 67 67 67 63 78 78 69 72 69 69 73 69 75 78 67 67 81 67 67 52 85 96 87 85 92 92 92 92 87 92 96 96 96 99 99 96 96 109 103 101 103 103 103 109 109 109 109 109 113 116 116 116 109 116 120 120 121 121 123 121 126 126 123 126 129 123 129 130 131 131 131 131 130 140 140 140 136 136 123 147 147 147 147 142 147 123 153 153 153 123 153 153 153 156 156 156 153 153 165 165 163 153 121 168 177 170 168 170 170 170 170 170 177 177 181 181 181 177 181 186 186 186 181 181 177 191 189 177 191 191 177 196 197 197 199 197 202 202 197 205 205 202 197 209 209 209 213 212 213 209 215 213 215 218 216 221 221 218 225 225 225 221 229 229 229 225 209	0
36504281	4319	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , @GeneSrc$ in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , @GeneSrc$ , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	952	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and @GeneSrc$ , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	27180	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , @GeneSrc$ in @DiseaseTgt$ , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	1
36504281	945	D000690	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , ApoE , @GeneSrc$ , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in @DiseaseTgt$ , and CD38 , GPNMB , and ADAM15 in Parkinson 's disease . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and Parkinson 's disease , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 152 152|124 152 152 152 155 155 155 152 152 164 164 162 152 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 190 188 176 190 190 176 195 196 196 198 196 201 201 196 204 204 201 196 208 208 208 212 211 212 208 214 212 214 217 215 220 220 217 224 224 224 220 228 228 228 224 208	0
36504281	348	D010300	True	0	The genetic regulation of protein expression in cerebrospinal fluid . Studies of the genetic regulation of cerebrospinal fluid ( CSF ) proteins may reveal pathways for treatment of neurological diseases . 398 proteins in CSF were measured in 1,591 participants from the BioFINDER study . Protein quantitative trait loci ( pQTL ) were identified as associations between genetic variants and proteins , with 176 pQTLs for 145 CSF proteins ( P < 1.25 x 10 - 10 , 117 cis-pQTLs and 59 trans-pQTLs ) . Ventricular volume ( measured with brain magnetic resonance imaging ) was a confounder for several pQTLs . pQTLs for CSF and plasma proteins were overall correlated , but CSF-specific pQTLs were also observed . Mendelian randomization analyses suggested causal roles for several proteins , for example , @GeneSrc$ , CD33 , and GRN in Alzheimer 's disease , MMP-10 in preclinical Alzheimer 's disease , SIGLEC9 in amyotrophic lateral sclerosis , and CD38 , GPNMB , and ADAM15 in @DiseaseTgt$ . CSF levels of GRN , MMP-10 , and GPNMB were altered in Alzheimer 's disease , preclinical Alzheimer 's disease , and @DiseaseTgt$ , respectively . These findings point to pathways to be explored for novel therapies . The novel finding that ventricular volume confounded pQTLs has implications for design of future studies of the genetic regulation of the CSF proteome .	2 2 2 5 5 2 8 8 2 2 23 14 14 14 10 21 17 21 19 21 21 14 23 23 23 26 24 29 29 26 23 32 36 34 32 36 36 39 39 36 43 43 43 39 36 48 48 48 53 50 48 50 53 53 55 53 58 58 55 58 58 55 64 64 55 68 68 68 64 79 79 70 73 70 70 74 70 76 79 68 68 82 68 68 53 86 97 88 86 93 93 93 93 88 93 97 97 97 100 100 97 97 110 104 102 104 104 104 110 110 110 110 110 114 117 117 117 110 117 121 121 122 122 124 122 127 127 124 127 130 124 130 131 132 132 132 132 131 141 141 141 137 137 124 148 148 148 148 143 148 124 154 154 154 124 154 154 154 157 157 157 154 154 164 154|164 122 167 176 169 167 169 169 169 169 169 176 176 180 180 180 176 180 185 185 185 180 180 176 176|188 188 188 176 193 194 194 196 194 199 199 194 202 202 199 194 206 206 206 210 209 210 206 212 210 212 215 213 218 218 215 222 222 222 218 226 226 226 222 206	0
33543479	7337	D017204	True	0	@GeneSrc$ reinstatement as a disease-modifying therapy for @DiseaseTgt$ . Half a century ago , Harry Angelman reported three patients with overlapping clinical features , now well known as @DiseaseTgt$ . @DiseaseTgt$ is caused by mutations affecting the maternally inherited @GeneSrc$ gene , which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development . Emerging evidence indicates that @GeneSrc$ plays a particularly important role in the nucleus . However , the critical substrates that are controlled by @GeneSrc$ remain elusive , which hinders the search for effective treatments . Moreover , given the multitude of signalling mechanisms that are derailed , it is unlikely that targeting a single pathway is going to be very effective . Therefore , expectations are very high for approaches that aim to restore @GeneSrc$ protein levels . A particular promising strategy is an antisense oligonucleotide approach , which activates the silenced paternal @GeneSrc$ gene . When successful , such treatments potentially offer a disease-modifying therapy for @DiseaseTgt$ and several other neurodevelopmental disorders . What this paper adds Loss of @GeneSrc$ affects multiple signalling pathways in the brain . Emerging evidence suggests that @GeneSrc$ plays a critical role in the cell nucleus . Trials using antisense oligonucleotides to restore @GeneSrc$ levels are continuing .	1 1 5 5 5 1 7 5|7 1 11 11 12 16 16 15 16 16 18 16 22 22 22 18 16 26 26 16 28 26|28 16 30|32 32 32 34 32 34 40 38 40 40 35 40 43 40 46 46 43 49 49 46 54 54 54 54 49 32 57 58 58 61 61 58 65 64 65 61 68 68 61 58 80 80 74 74 80 77 77 74 79 77 80 80 81 84 80 86 84 89 89 86 80 95 95 95 95 95 98 98 95 101 101 98 104 104 105 112 112 112 110 110 107 112 95 116 116 116 112 95 123 123 123 123 123 123 125 123 127 125 129 127 132 132 129 123 137 137 135 142 142 142 142 142 142 142 145 142 150 150 150 150 145 142 153 158 158 156 158 158 158 161 161 158 163 161|163 163 168 168 168 163 158 173 172 173 173 173 176 174 173 180 180 177 183 183 177 173 186 187 187 190 190 187 193 193 190 197 197 197 190 187 208 199 202 200 204 200 206 204 208 208 208	1
33543479	7337	D002658	False	1	@GeneSrc$ reinstatement as a disease-modifying therapy for Angelman syndrome . Half a century ago , Harry Angelman reported three patients with overlapping clinical features , now well known as Angelman syndrome . Angelman syndrome is caused by mutations affecting the maternally inherited @GeneSrc$ gene , which encodes an E3-ubiquitin ligase that is critical for typical postnatal brain development . Emerging evidence indicates that @GeneSrc$ plays a particularly important role in the nucleus . However , the critical substrates that are controlled by @GeneSrc$ remain elusive , which hinders the search for effective treatments . Moreover , given the multitude of signalling mechanisms that are derailed , it is unlikely that targeting a single pathway is going to be very effective . Therefore , expectations are very high for approaches that aim to restore @GeneSrc$ protein levels . A particular promising strategy is an antisense oligonucleotide approach , which activates the silenced paternal @GeneSrc$ gene . When successful , such treatments potentially offer a disease-modifying therapy for Angelman syndrome and several other @DiseaseTgt$ . What this paper adds Loss of @GeneSrc$ affects multiple signalling pathways in the brain . Emerging evidence suggests that @GeneSrc$ plays a critical role in the cell nucleus . Trials using antisense oligonucleotides to restore @GeneSrc$ levels are continuing .	1 1 5 5 5 1 8 8 5 1 12 12 13 17 17 16 17 17 19 17 23 23 23 19 17 27 27 17 30 30 27 17 33 35 35 35 37 35 37 43 41 43 43 38 43 46 43 49 49 46 52 52 49 57 57 57 57 52 35 60 61 61 64 64 61 68 67 68 64 71 71 64 61 83 83 77 77 83 80 80 77 82 80 83 83 84 87 83 89 87 92 92 89 83 98 98 98 98 98 101 101 98 104 104 101 107 107 108 115 115 115 113 113 110 115 98 119 119 119 115 98 126 126 126 126 126 126 128 126 130 128 132 130 135 135 132 126 140 140 138 145 145 145 145 145 145 145 148 145 153 153 153 153 148 145 156 161 161 159 161 161 161 164 164 161 167 167 164 167 171 171 171|167 161 176 175 176 176 176 179 177 176 183 183 180 186 186 180 176 189 190 190 193 193 190 196 196 193 200 200 200 193 190 211 202 205 203 207 203 209 207 211 211 211	0
34403652	14810	D000544	True	0	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and @GeneSrc$ protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in @GeneSrc$ protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	17709	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , @GeneSrc$ , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	14810	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and @GeneSrc$ protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in @GeneSrc$ protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	18669	D007239	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The @GeneSrc$ , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter @GeneSrc$ and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	17709	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , @GeneSrc$ , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	239273	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , @GeneSrc$ , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	23945	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as @GeneSrc$ , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	17250	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , @GeneSrc$ , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	20539	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and @GeneSrc$ did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	26357	D000544	True	0	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , @GeneSrc$ and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and @GeneSrc$ protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	1
34403652	23945	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as @GeneSrc$ , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	20539	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and @GeneSrc$ did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	20539	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and @GeneSrc$ did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	26357	D007249	True	0	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , @GeneSrc$ and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and @GeneSrc$ protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	20525	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , @GeneSrc$ and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	14810	D007239	True	0	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and @GeneSrc$ protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in @GeneSrc$ protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	18669	D007249	True	0	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The @GeneSrc$ , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter @GeneSrc$ and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	17250	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , @GeneSrc$ , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	20525	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , @GeneSrc$ and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	239273	D007249	False	1	Systemic @DiseaseTgt$ Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , @GeneSrc$ , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic @DiseaseTgt$ can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral infection in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	20525	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , @GeneSrc$ and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	18669	D000544	True	0	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The @GeneSrc$ , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter @GeneSrc$ and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	1
34403652	17709	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , @GeneSrc$ , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	17250	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , @GeneSrc$ , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	239273	D000544	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of @DiseaseTgt$ Mouse Model . @DiseaseTgt$ ( @DiseaseTgt$ ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential @DiseaseTgt$ drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial @DiseaseTgt$ mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , @GeneSrc$ , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in @DiseaseTgt$ , which can affect intra-brain drug distribution and play a role in @DiseaseTgt$ development . Moreover , the inflammatory insult caused by peripheral infection in @DiseaseTgt$ may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in @DiseaseTgt$ drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 23 21|23 23 19 2 25|32 27 25 27 32 32 32 32 32 36 36 32 36 39 36 41 39 41 45 45 42 32 49 49 52 52 52 52 57 53 57 57 52 59 57 61 59 66 66 66 66 61 66 66 68 66 66 74 74 61 76 74 80 80 80 52 80 84 84 80 86 84 86 92 88 88 92 52 94 52 102 102 102 102 100 98 100 94 52 105 115 105 105 105 105 111 112 105 114 112 122 115 116 116 120 116 122 122 126 125 126 122 129 129 126 126 122 122 135 135 122 135 136 139 136 136 135 145 145 145 135 145 145 149 145 145 135 135 122 157 157 157 178 160 160 157 163 161 160 163 163 163 163 163 163 163 163 163 163 163 163 178 178 178 182 182 182 178 178 188 188 187 188 188 193 191 193 193 188 193 194 197 198 194 200 194 202 194 202 206 206 194 209 209 206 206 206 213 211 216 216 211 188 234 234 222 222 234 222 226 226 223 228 226 234 234 232 234 234 234 238 238 238 234 234 244 244 243 244 244 247 247 244 251 248 251 247 253 251 244 257 257 264 260 260 257 263 263 260 264 266 264 266 270 270 266 274 274 274 270 278 278 278 274 282 282 282 274 282 285 282 288 288 285 290 285 264	0
34403652	26357	D007239	False	1	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , @GeneSrc$ and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as MGLL , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and @GeneSrc$ protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0
34403652	23945	D007239	False	2	Systemic Inflammation Induced Changes in Protein Expression of ABC Transporters and Ionotropic Glutamate Receptor Subunit 1 in the Cerebral Cortex of Familial Alzheimer`s Disease Mouse Model . Alzheimer 's disease ( AD ) is an incurable disease , with complex pathophysiology and a myriad of proteins involved in its development . In this study , we applied quantitative targeted absolute proteomic analysis for investigation of changes in potential AD drug targets , biomarkers , and transporters in cerebral cortices of lipopolysaccharide (LPS)-induced neuroinflammation mouse model , familial AD mice ( APdE9 ) with and without LPS treatment as compared to age-matched wild type ( WT ) mice . The ABCB1 , ABCG2 and GluN1 protein expression ratios between LPS treated APdE9 and WT control mice were 0.58 ( 95 % CI 0.44 - 0.72 ) , 0.65 ( 95 % CI 0.53 - 0.77 ) and 0.61 ( 95 % CI 0.52 - 0.69 ) , respectively . The protein expression levels of other proteins such as @GeneSrc$ , COX-2 , CytC , ABCC1 , ABCC4 , SLC2A1 and SLC7A5 did not differ between the study groups . Overall , the study revealed that systemic inflammation can alter ABCB1 and ABCG2 protein expression in brain in AD , which can affect intra-brain drug distribution and play a role in AD development . Moreover , the inflammatory insult caused by peripheral @DiseaseTgt$ in AD may be important factor triggering changes in GluN1 protein expression . However , more studies need to be performed in order to confirm these findings . The quantitative information about the expression of selected proteins provides important knowledge , which may help in the optimal use of the mouse models in AD drug development and better translation of preclinical data to humans .	1 2 2 2 6 6 3 9 9 6 9 14 14 14 9 14 19 19 19 2 25 23 23 25 25 19 2 29 29 36 31 29 31 36 36 36 36 36 40 40 36 40 43 40 45 43 45 49 49 46 36 53 53 56 56 56 56 61 57 61 61 56 63 61 65 63 70 70 70 70 65 70 70 72 70 70 78 78 65 80 78 84 84 84 56 84 88 88 84 90 88 90 96 92 92 96 56 98 56 106 106 106 106 104 102 104 98 56 109 119 109 109 109 109 115 116 109 118 116 126 119 120 120 124 120 126 126 130 129 130 126 133 133 130 130 126 126 139 139 126 139 140 143 140 140 139 149 149 149 139 149 149 153 149 149 139 139 126 161 161 161 182 164 164 161 167 165 164 167 167 167 167 167 167 167 167 167 167 167 167 182 182 182 186 186 186 182 182 192 192 191 192 192 197 195 197 197 192 197 198 201 202 198 204 198 206 198 206 210 210 198 213 213 210 210 210 217 215 220 220 215 192 238 238 226 226 238 226 230 230 227 232 230 238 238 236 238 238 238 242 242 242 238 238 248 248 247 248 248 251 251 248 255 252 255 251 257 255 248 261 261 268 264 264 261 267 267 264 268 270 268 270 274 274 270 278 278 278 274 282 282 282 278 286 286 286 278 286 289 286 292 292 289 294 289 268	0